PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME

Abstract

A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a composition for muscle relaxation containing the phenyl alkyl carbamate derivative compounds and/or pharmaceutically acceptable salt thereof as an active ingredient, and a method of muscle relaxation comprising administering a pharmaceutically effective amount of the phenyl alkyl carbamate derivative compound and/or a pharmaceutically acceptable salt thereof to a subject in need of to a subject in need of, are provided.

Description

BACKGROUND OF THE INVENTION

(a) Field of the Invention

A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the present invention relates to phenyl alkyl carbamate derivative compounds and a pharmaceutically acceptable salt thereof, which have a considerably high muscle relaxation effect and low toxicity, and compositions for muscle relaxation containing the compounds and/or pharmaceutically acceptable salt thereof as an active ingredient.

(b) Description of the Related Art

The central nervous system(CNS) disorders nowadays concern large sections of the population. In particular on account of the increase in elderly people, the numbers of patients are increasing continuously.

Myotony, or spasm, is one of skeletal muscle dysfunction diseases due to increase of muscle tone, and caused by central nervous system damage due to various causes such as external injury, and the like. The muscle tension is caused by various causes, for example, fatigue, age-related spine deformity, and the like, and causes spasticity in skeletal muscles of the neck, shoulders, arms, waist, and back; spastic paralysis causing disability of voluntary movement due to muscle hypertonia of hands and feet by disorder of central nervous system and a combination thereof, thereby resulting in serious hindrances to normal life.

In particular, spastic paralysis is a serious disorder with accompanying symptoms including muscle tension and/or muscle stiffness of hands and feet, difficulty in walking, and the like, thererby causing serious hindrances to normal life. Centrally acting muscle relaxants relieve muscle tension by blocking receptors associated with stimulating muscular function or stimulating receptors associated with inhibiting muscular function, or reducing excessively activated reflex function.

Such centrally acting muscle relaxants may include Methocarbaamol, Chlormezanon, Carisoprodol, Eperisone, Phenprobamide, and the like. However, these drugs act on interneuron of the spinal cord, thereby inhibiting monosynaptic and polysynaptic reflexes, and thus, may cause side effects, such as central nervous inhibition, muscle weakness, and the like.

U.S. Pat. No. 3,313,692 discloses a racemic carbamate compound useful as a therapeutic agent for the central nervous system with decreased side effects compared to cholinergic agent. U.S. Pat. Nos. 2,884,444, 2,937,119, and 3,265,727 suggest dicarbamate compounds useful as therapeutic agents for central nervous system disorders, and U.S. Pat. No. 2,937,119 discloses a N-isopropyl-2-methyl-2-propyl-1,3-propanediol dicarbamate, which was released with the trademark of Soma as a muscle relaxant.

Muscle relaxants are used for improving various symptoms, such as vascular disorders of the spinal cord, spastic spinal paralysis, cervical spondylosis, cerebral palsy, sequelae of injuries (spinal cord injuries, head injuries), spinocerebellar degeneration, and the like, which are associated with muscle spasm involved in musculoskeletal diseases, and also used as an adjuvant to anesthestic agent.

Considering the various and valuable uses of muscle relaxants as aforementioned, development of more effective muscel relaxant is needed.

SUMMARY OF THE INVENTION

An embodiment of the present invention provides a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof:

wherein,

X is a halogen, for example, chlorine, fluorine, iodine, or bromine, n, that means the number of substituent X, is an integer from 1 to 5, for example, 1 or 2,

R1 is a hydrogen or C1-C4 linear or branched alkyl group, for example, methyl group, ethyl group, isopropyl group, or butyl group,

A is selected from the group consisting of hydrogen, a C1-C4 linear or branched alkyl group (such as a methyl group, etc.), a C2-C4 alkoxy alky ether group (such as a methoxy methyl group (MOM), etc.), and a carbamoyl derivative represented by

B is selected from the group consisting of hydrogen, a C1-C4 linear or branched alkyl group (such as a methyl group, etc.), a C2-C4 alkoxy alky ether group (such as a methoxy methyl group (MOM), etc.), and a carbamoyl derivative represented by

and

R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.

In a concrete embodiment, when one of A and B is hydrogen, the other is neither hydrogen nor the carbamoyl derivative.

Another embodiment provides a pharmaceutical composition containing a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient.

Another embodiment provides a pharmaceutical composition for muscle relaxation, or treating and/or preventing a muscle spasm associated disease, containing a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient.

Another embodiment provides a method of muscle relaxation, or treating and/or preventing a muscle spasm associated disease, comprising administering a therapeutically effective amount of a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, to a subject in need of muscle relaxation.

Another embodiment provides a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, a for use in muscle relaxation.

Another embodiment provides a use of phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, in muscle relaxation or in preparing a muscle relaxant.

DETAILED DESCRIPTION OF THE EMBODIMENTS

Upon attempting to discover a muscle relaxant with more excellent efficacy and decreased side effects, the present inventors found that substituted phenyl alkyl carbamate derivative compounds represented by the following Chemical Formula 1 exhibit a considerably excellent activity of muscle relaxation with very low toxicity, to complete the present invention.

Therefore, an embodiment provides a phenyl alkyl carbamate derivative compound represented by the following Chemical Formula 1:

wherein,

X is a halogen, for example, chlorine, fluorine, iodine, or bromine, n, that means the number of substituent X, is an integer from 1 to 5, for example, 1 or 2,

R1 is a hydrogen or C1-C4 linear or branched alkyl group, for example, methyl group, ethyl group, isopropyl group, or butyl group,

A is selected from the group consisting of hydrogen, a C1-C4 linear or branched alkyl group (such as a methyl group, etc.), a C2-C4 alkoxy alky ether group (such as a methoxy methyl group (MOM), etc.), and a carbamoyl derivative represented by

B is selected from the group consisting of hydrogen, a C1-C4 linear or branched alkyl group (such as a methyl group, etc.), a C2-C4 alkoxy alky ether group (such as a methoxy methyl group (MOM), etc.), and a carbamoyl derivative represented by

and

R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R2 and R3 may be the same as or different from each other, and independently selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.

In a concrete embodiment, when one of A and B is hydrogen, the other is neither hydrogen nor the carbamoyl derivative.

In a concrete embodiment, at least one of A and B may be a carbamoyl derivative represented by

When one of A and B is the carbamoyl derivative, the other is not hydrogen.

Since the compound has two chiral carbons at the 1^st and 2^nd positions from the X substituted phenyl alkyl carbamate derivative group, they may be in the form of a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers.

In a concrete embodiment, the compound may be selected from the group consisting of:

• 1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-carbamate,
• 1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-N-methylcarbamate,
• 1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-N-propylcarbamate
• 1-(2-chlorophenyl)-2-carbamoyloxybutyl-1-carbamate,
• 1-(2-chlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,
• 1-(2-chlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,
• 1-(2-iodophenyl)-2-carbamoyloxypropyl-1-carbamate,
• 1-(2-iodophenyl)-2-carbamoyloxybutyl-1-carbamate,
• 1-(2-iodophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,
• 1-(2-iodophenyl)-2-carbamoyloxyhexyl-1-carbamate,
• 1-(2-fluorophenyl)-2-carbamoyloxypropyl-1-carbamate,
• 1-(2-fluorophenyl)-2-carbamoyloxybutyl-1-carbamate,
• 1-(2-fluorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,
• 1-(2-fluorophenyl)-2-carbamoyloxyhexyl-1-carbamate,
• 1-(2,4-dichlorophenyl)-2-carbamoyloxypropyl-1-carbamate,
• 1-(2,4-dichlorophenyl)-2-carbamoyloxybutyl-1-carbamate,
• 1-(2,4-dichlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,
• 1-(2,4-dichlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,
• 1-(2,6-dichlorophenyl)-2-carbamoyloxypropyl-1-carbamate,
• 1-(2,6-dichlorophenyl)-2-carbamoyloxybutyl-1-carbamate,
• 1-(2,6-dichlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,
• 1-(2,6-dichlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-ethyl-2-carbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-ethyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxy)-ethyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxy)-propyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate
• 1-(2-iodophenyl)-1-(methoxy)-butyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-methylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-propylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-isopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-cyclopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-cyclohexylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-benzylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-methylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-propylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-isopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-cyclopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-cyclohexylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-benzylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-hexyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-methylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-propylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-isopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-cyclopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-cyclohexylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-benzylcarbamate,
• 1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-bicyclo[2,2,1]heptanecarbamate,
• 1-(3-iodophenyl)-1-(methoxy)-propyl-2-carbamate,
• 1-(3-iodophenyl)-1-(methoxy)-butyl-2-carbamate,
• 1-(3-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,
• 1-(3-iodophenyl)-1-(methoxy)-hexyl-2-carbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-propyl-2-carbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate
• 1-(2-fluorophenyl)-1-(methoxy)-butyl-2-carbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,
• 1-(2-fluorophenyl)-1-(methoxy)-hexyl-2-carbamate,
• 1-(4-fluorophenyl)-1-(methoxy)-proyl-2-carbamate,
• 1-(4-fluorophenyl)-1-(methoxy)-butyl-2-carbamate,
• 1-(4-fluorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,
• 1-(4-fluorophenyl)-1-(methoxy)-hexyl-2-carbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-propyl-2-carbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate
• 1-(2-chlorophenyl)-1-(methoxy)-butyl-2-carbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,
• 1-(2-chlorophenyl)-1-(methoxy)-hexyl-2-carbamate,
• 1-(2,3-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,
• 1-(2,4-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,
• 1-(2,4-dichlorophenyl)-1-(methoxy)-butyl-2-carbamate,
• 1-(2,4-dichlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,
• 1-(2,4-dichlorophenyl)-1-(methoxy)-hexyl-2-carbamate,
• 1-(2,6-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,
• 1-(2,6-dichlorophenyl)-1-(methoxy)-butyl-2-carbamate,
• 1-(2,6-dichlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,
• 1-(2,6-dichlorophenyl)-1-(methoxy)-hexyl-2-carbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,
• 1-(2-chlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,
• 1-(2,3-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,
• 1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,
• 1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,
• 1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,
• 1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,
• 1-(2,5-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,
• 1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,
• 1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,
• 1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,
• 1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,
• 1-(2-fluorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,
• 1-(4-fluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,
• 1-(4-fluorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,
• 1-(4-fluorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,
• 1-(4-fluorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,
• 1-(2,6-difluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate
• 1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-methylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-propylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-isopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-cyclopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-cyclohexylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-benzylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-bicyclo[2,2,1]heptanecarbamate
• 1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-methylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-prop ylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-isopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-cyclopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-cyclohexylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-benzylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-methylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-propylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-isopropylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-cyclopropylcarbamate,
• 1-(2-iodophenyl-1-(methoxymethoxy)-hexyl-2-N-cyclohexylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-benzylcarbamate,
• 1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-bicyclo[2,2,1]heptanecarbamate
• 1-(3-iodophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,
• 1-(3-iodophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,
• 1-(3-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,
• 1-(3-iodophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,
• 1-(2-chlorophenyl)-2-(methoxymethoxy)-propyl-1-carbamate,
• 1-(2-chlorophenyl)-2-(methoxy)-propyl-1-carbamate, and

a racemate of the compound, an enantiomer of the compound, a diastereomer of the compound, a mixture of enantiomers of the compound, or a mixture of diastereomers of the compound.

Alternatively, the compound may be in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salt may include an additional salt of acid or base, and its stereochemical isomer. For example, the compound may be in the form of an additional salt of an organic or inorganic acid. The salt may not be specially limited, and include any salts that maintain the activities of their parent compounds, with no undesirable effects, in the subject, when they are administered to the subject. Such salts may include inorganic and organic salts, such as salts of acetic acid, nitric acid, aspartic acid, sulfonic acid, sulfuric acid, maleic acid, glutamic acid, formic acid, succinic acid, phosphoric acid, phthalic acid, tannic acid, tartaric acid, hydrobromic acid, propionic acid, benzene sulfonic acid, benzoic acid, stearic acid, lactic acid, bicarbonic acid, bisulfuric acid, bitartaric acid, oxalic acid, butyric acid, calcium edetate, carbonic acid, chlorobezoic acid, citric acid, edetic acid, toluenesulfonic acid, fumaric acid, gluceptic acid, esilic acid, pamoic acid, gluconic acid, methyl nitric acid, malonic acid, hydrochloric acid, hydroiodic, hydroxynaphtholic acid, isethionic acid, lactobionic acid, mandelic acid, mucic acid, naphthylic acid, muconic acid, p-nitromethanesulfonic acid, hexamic acid, pantothenic acid, monohydrogen phosphoric acid, dihydrogen phosphoric acid, salicylic acid, sulfamic acid, sulfanilic acid, methane sulfonic acid, and the like. The additional salts of base may include salts of akali metal or alkaline earth metal, such as salts of ammonium, lithium, sodium, potassium, magnesium, calcium, and the like; salts having an organic base, such as benzathine, N-methyl-D-glucamine, hydrabamine, and the like; and salts having an amino acid such as arginine, lysine, and the like. In addition, these salts may be converted to a released form by treating with a proper base or acid.

Another embodiment provides a pharmaceutical composition containing a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient.

As demonstrated in the following experimental examples, the compound of Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or pharmaceutically acceptable salt thereof exhibits an excellent effect on muscle relaxation. Thus, the pharmaceutical composition may be a pharmaceutical composition for muscle relaxation (muscle relaxant).

Therefore, another embodiment provides a pharmaceutical composition for muscle relaxation containing a compound of Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient.

In addition, since a muscle relaxant can be used for improving (alleviating) and/or treating symptoms of diseases associated with muscle spasm, the pharmaceutical composition capable of acting as muscle relaxant may also be used as a pharmaceutical composition for preventing and/or treating a muscle spasm associated disease, for example, vascular disorders of the spinal cord, spastic spinal paralysis, cervical spondylosis, cerebral palsy, sequelae of injuries (spinal cord injuries, head injuries), spinocerebellar degeneration, and the like. Therefore, another embodiment provides a pharmaceutical composition for preventing and/or treating a muscle spasm associated disease containing a compound of Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, as an active ingredient.

A muscle spasm associated disease is a sudden, involuntary contraction of a muscle. It is generally known to the relevant art that muscle spasm associated diseases are not associated with abnormal or excessive neuronal activity in the brain, such as seizure. Therefore, in the present invention, the muscle spasm associated disease is not a disease associated with abnormal or excessive neuronal activity in the brain, such as seizure.

The pharmaceutical composition may be formulated in various forms for oral or parenteral administration. For example, the pharmaceutical composition may be formulated in the oral administration form, such as a tablet, pill, soft or hard capsule, liquid, suspension, emulsion, syrup, granules, elixirs, and the like. In addition to the active ingredient, the oral administration form may further include pharmaceutically acceptable and conventional components, for example, a diluent such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, and the like; a lubricant such as silica, talc, stearic acid, magnesium or calcium salt thereof, polyethyleneglycol, and the like.

In the case that the oral administration form is a tablet, it may further include a binder such as magnesium aluminium silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, polyvinylpirrolidine, and the like; and optionally include one or more additives selected from the group consisting of a disintegrant such as starch, agar, arginic acid or sodium salt thereof, an absorbent, a colorant, a flavoring, a sweetener, and the like.

Alternatively, the pharmaceutical composition may also be formulated in a parenteral administration form, which can be administered by subcutaneous injection, intravenous injection, intramuscular injection, injection into thoracic cavity, and the like. In order to formulate the parenteral administration form, the pharmaceutical composition may be prepared as a solution or suspension wherein the active ingredient is dissolved in water together with a stabilizer and/or a buffering agent, and such solution or suspension formulation may be prepared as a dosage form in ample or vial.

The pharmaceutical composition may be sterilized, and/or include further additives such as a preservative, a stabilizer, a hydrating agent, an emulsification accelerator, a salt and/or buffering agent for osmoregulation, and the like, and/or further therapeutically effective ingredients. The pharmaceutical composition may be formulated by any conventional method for mixing, granulating, coating, and the like.

The pharmaceutical composition may be administered to a mammal including human, in the therapeutically effective amount of 0.01 to 750 mg/kg(body weight), preferably 0.1 to 500 mg/kg(body weight) per one day, based on the active ingredient. The term “therapeutically effective amount” may refer to an amount of the active gradient capable of exhibiting the effect of alleviating and/or treating pain. The therapeutically effective amount may be administered through oral or parenteral pathway, one or two or more times per one day.

The therapeutically effective amount and the administration pathway of the present pharmaceutical composition may be properly adjusted by a person skilled in the relevant field considering the conditions of the subject (patient), desired effects, and the like.

Another embodiment provides a method of muscle relaxation comprising administering a therapeutically effective amount of a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, to a subject in need of muscle relaxation. The method of muscle relaxation may further include the step of identifying the subject in need of muscle relaxation, prior to the step of administration.

Another embodiment provides a method of treating and/or preventing a muscle spasm associated disease, comprising administering a therapeutically effective amount of a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, to a subject in need of treating and/or preventing a muscle spasm associated disease. The method of treating and/or preventing a muscle spasm associated disease may further include the step of identifying the subject in need of treating and/or preventing a muscle spasm associated disease, prior to the step of administration.

The administration may be conducted by oral or parenteral administration such as subcutaneous injection, intravenous injection, intramuscular injection, injection into thoracic cavity, and the like.

The subject may be a mammal including human or cells and/or tissues separated therefrom.

Another embodiment provides a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, a for use in muscle relaxation.

Another embodiment provides a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, for use in treating and/or preventing a muscle spasm associated disease.

Another embodiment provides a use of phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, in muscle relaxation or in preparing a muscle relaxant.

Another embodiment provides a use of a phenyl alkyl carbamate derivative compound represented by Chemical Formula 1; a racemate, an enantiomer, a diastereomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof, in treating and/or preventing a muscle spasm associated disease or in preparing a pharmaceutical composition for treating and/or preventing a muscle spasm associated disease.

The carbamate compound of the present invention may prepared by the following reaction formula.

A diol compound used in the synthesis of the carbamate compound may be synthesized by dihydroxylation of a trans-olefin compound. A diol compound having optical activity may be synthesized using a sharpless asymmetric dihydroxylation catalyst.

As indicated in the Reaction Formula II, the optically active substance of diol may also be synthesized using a reduction reagent after synthesizing a hydroxy-ketone compound using Haloro-Mandelic acid. In the Reaction Formula II, PG may be Trialkyl Silyl group (TMS, TES, TIPS, TBDMS, TBDPS), Ether group[NOM(Mothoxymethyl ether), MEM(2-Methoxyethoxymethyl ether), BOM(Benzyloxymethyl ether). MTM(Methylthiomethyl ether), SEM(2-(Trimethylsilyl)ethoxymethyl ether), PMBM(p-Methoxybenzyl ether), THP(Tetrahydropyranyl ether), Allyl ether, Trityl ether, Ester group[Ac(acetate), Bz(Benzoate), Pv(Pivaloate), Cbz(Benzyl carbonate), BOC(t-Butyl carbonate), Fmoc(9-Fulorenylmethyl)carbaonate, Alloc(Allyl Carbonate), Troc(Trichloroethyl carbonate), or p-Methoxybenzoate, Methyl carbonate, and so on.

As a highly selectivity form of regioisomer of single carbamate of diol having halogen substituent at phenyl ring.

Two substances in the form of regioisomers of a single carbamate of diol having halogen substituent at phenyl ring may be separated by flash column chromatography to obtain two kinds of single carbamate compounds.

A and B is alkyl or alkoxy alky ether such as methoxy methyl ether(MOM) or a carbamoyl derivative represented by

and R2 may be selected from the group consisting of hydrogen, a linear or branched alkyl group of C1-C4, for example C1-C3, a cycloalkyl group of C3-C8, for example C3-C7, and benzyl group, and more specifically, R2 may be selected from the group consisting of hydrogen, methyl group, propyl group, isopropyl group, cyclopropyl group, cyclohexyl group, bicycloheptane group, and benzyl group.

EXAMPLE

The present invention is further explained in more detail with reference to the following examples. These examples, however, should not be interpreted as limiting the scope of the present invention in any manner.

Preparation Example 1

Synthesis of 1-(2-chlorophenyl)-trans-1-propene

48 ml of 2-chlorobenzenaldehyde (0.42 mol) and 49.7 ml of 3-pentanone (0.47 mol) were dissolved in 600 mL of hexane in flask, and then stirred with raising the temperature. 53.6 ml of Boron trifluoride etherate (BF₃OEt₂, 0.42 mol) was added to the resultant under reflux conditions. When the reaction was completed, water was added thereto. After layer separation, the obtained organic layer was washed twice with 1M sodium hydroxide solution (1M NaOH), and then the separated organic layer was washed with water. The separated organic layer was dehydrated with anhydrous magnesium sulfate (MgSO₄) and concentrated. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (38 g, yield 58%).

¹H NMR (400 MHz, CDCl₃) δ1.94 (d, J=4.8 Hz, 3H), 6.24 (m, 1H), 6.78 (d, J=14 Hz, 1H), 7.11˜7.51 (m, 4H)

Preparation Example 2

Synthesis of 1-(2-chlorophenyl)-trans-1-butene

The substantially same method as described in Preparation Example 1 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (2.9 g, yield 83%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (d, J=7.6 Hz, 3H), 2.29˜2.33 (m, 2H), 6.28 (dt, J=16 Hz, 6.4 Hz, 1H), 6.78 (d, J=15.6 Hz, 1H), 7.13˜7.54 (m, 4H)

Preparation Example 3

Synthesis of 1-(2-chlorophenyl)-3-methyl-trans-1-butene

The substantially same method as described in Preparation Example 1 was conducted, except that 2,6-dimethyl-heptan-4-one was used instead of 3-pentanone, to obtain the title compound (8.0 g, yield 50˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (d, J=6.8 Hz, 6H), 2.25˜2.57 (m, 1H), 6.20 (dd, J=16 Hz, 7.2 Hz, 1H), 7.64 (d, J=16 Hz, 1H), 7.12˜7.54 (m, 4H)

Preparation Example 4

Synthesis of 1-(2-chlorophenyl)-trans-1-hexene

The substantially same method as described in Preparation Example 1 was conducted, except that 6-undecanone was used instead of 3-pentanone, to obtain the title compound (10 g, yield 85%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=7.2 Hz, 3H), 1.33˜1.56 (m, 4H), 2.26˜2.32 (m, 4H), 6.24 (dt, J=15.6 Hz, 7 Hz, 1H), 6.78 (d, J=16 Hz, 1H), 7.13˜7.54 (m, 4H)

Preparation Example 5

Synthesis of 1-(2,4-dichlorophenyl)-trans-1-propene

The substantially same method as described in Preparation Example 1 was conducted, except that 2,4-dichlorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (2.4 g, yield 57%).

¹H NMR (400 MHz, CDCl₃) δ1.95 (dd, J=6.8 Hz, 1.6 Hz, 3H), 6.24 (m, 1H), 6.72 (d, J=15.6 Hz, 1H), 7.18˜7.44 (m, 3H)

Preparation Example 6

Synthesis of 1-(2,4-dichlorophenyl)-trans-1-butene

The substantially same method as described in Preparation Example 5 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (2.1 g, yield 90%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (d, J=7.6 Hz, 3H), 2.20˜2.33 (m, 2H), 6.26 (dt, J=16 Hz, 6.8 Hz, 1H), 6.70 (d, J=15.6 Hz, 1H), 7.18˜7.46 (m, 3H)

Preparation Example 7

Synthesis of 1-(2,6-dichlorophenyl)-3-methyl-trans-1-butene

The substantially same method as described in Preparation Example 5 was conducted, except that 2,6-dimethyl-heptan-4-one was used instead of 3-pentanone, to obtain the title compound (0.23 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.8 Hz, 6H), 2.53˜2.58 (m, 1H), 6.19 (dd, J=16.4 Hz, 6.8 Hz, 1H), 6.31 (d, J=16.4 Hz, 1H), 7.18˜7.46 (m, 3H)

Preparation Example 8

Synthesis of 1-(2,4-dichlorophenyl)-trans-1-hexene

The substantially same method as described in Preparation Example 5 was conducted, except that 6-undecanone was used instead of 3-pentanone, to obtain the title compound (3.2 g, yield 40˜80%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=7.2 Hz, 3H), 1.38˜1.52 (m, 4H), 2.25˜2.31 (m, 2H), 6.22 (dt, J=15.6 Hz, 6.8 Hz, 1H), 6.70 (d, J=15.6 Hz, 1H), 7.18˜7.46 (m, 3H)

Preparation Example 9

Synthesis of 1-(2,6-dichlorophenyl)-trans-1-propene

The substantially same method as described in Preparation Example 1 was conducted, except that 2,6-dichlorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (0.4 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.98 (d, J=8 Hz, 3H), 6.23˜6.31 (m, 1H), 6.40 (d, J=16 Hz, 1H), 7.05˜7.32 (m, 3H)

Preparation Example 10

Synthesis of 1-(2,6-dichlorophenyl)-trans-1-butene

The substantially same method as described in Preparation Example 9 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (1.2 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.17 (t, J=7.6 Hz, 3H), 2.30˜2.37 (m, 2H), 6.29 (dt, J=16.4 Hz, 6 Hz, 1H), 6.37 (d, J=16.4 Hz, 1H), 7.05˜7.32 (m, 3H)

Preparation Example 11

Synthesis of 1-(2,6-dichlorophenyl)-3-methyl-trans-1-butene

The substantially same method as described in Preparation Example 9 was conducted, except that 2,6-dimethyl-heptan-4-one was used instead of 3-pentanone, to obtain the title compound (0.23 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.8 Hz, 6H), 2.53˜2.58 (m, 1H), 6.19 (dd, J=16.4 Hz, 6.8 Hz, 1H), 6.31 (d, J=16.4 Hz, 1H), 7.05˜7.32 (m, 3H)

Preparation Example 12

Synthesis of 1-(2,6-dichlorophenyl)-trans-1-hexene

The substantially same method as described in Preparation Example 9 was conducted, except that 6-undecanone was used instead of 3-pentanone, to obtain the title compound (0.2 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ0.99 (t, J=7.2 Hz, 3H), 1.14˜1.59 (m, 4H), 2.30˜2.36 (m, 2H), 6.24 (dt, J=16 Hz, 6.6 Hz, 1H), 6.38 (d, J=16.4 Hz, 1H), 7.05˜7.33 (m, 3H)

Preparation Example 13

Synthesis of 1-(2,3-dichlorophenyl)-trans-1-propene

The substantially same method as described in Preparation Example 1 was conducted, except that 2,3-dichlorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (0.2 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.94 (d, J=4.8 Hz, 3H), 6.24 (m, 1H), 6.78 (d, J=14 Hz, 1H), 7.11˜7.51 (m, 3H)

Preparation Example 14

Synthesis of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol

1-(2-chlorophenyl)-trans-1-propene (1.5 g, Preparation Example 1) was dissolved in 30 mL of the mixture of t-BuOH/H₂O (1:1(V/V)). At 0° C., AD-mix-α (Aldrich, U.S.A.) (13.7 g) and methane sulfone amide (CH₃SO₂NH₂, 0.76 g, 0.0080 mol) were added thereto and stirred for overnight. When the reaction was completed, the obtained product was washed with an aqueous solution of sodium sulfite (Na₂SO₃) and ethylacetate (EA). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgSO₄), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (1.65 g, yield 90%).

¹H NMR (400 MHz, CDCl₃) δ1.20 (d, J=6.4 Hz, 3H), 2.48 (d, J=4.0 Hz 1H), 2.92 (d, J=4.4 Hz, 1H), 3.93˜3.97 (m, 1H), 4.97 (t, J=4.8 Hz, 1H), 7.22˜7.51 (m, 4H)

¹³CNMR (100 MHz, CDCl₃) M8.8, 71.5, 74.4, 127.1, 128.1, 128.9, 129.5, 132.6, 138.9

Preparation Example 15

Synthesis of 1-(2-chlorophenyl)-(R,R)-1,2-propanediol

1-(2-chlorophenyl)-trans-1-propene (2.5 g, Preparation Example 1) was dissolved in 50 mL of the mixture of t-BuOH/H₂O (1:1(V/V)). At 0° C., AD-mix-α (Aldrich, U.S.A.) (23.5 g) and methane sulfone amide (CH₃SO₂NH₂, 1.27 g, 0.013 mol) were added thereto and stirred for overnight. When the reaction was completed, the obtained product was washed with an aqueous solution of sodium sulfite (Na₂SO₃) and ethylacetate (EA). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgSO₄), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (2.96 g, yield 90%).

¹H NMR (400 MHz, CDCl₃) δ1.20 (d, J=6.4 Hz, 3H), 2.48 (d, J=4.0 Hz, 1H), 2.92 (d, J=4.4 Hz, 1H), 3.93˜3.97 (m, 1H), 4.97 (t, J=4.8 Hz, 1H), 7.22˜7.51 (m, 4H)

Preparation Example 16

Synthesis of the Mixture of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol and 1-(2-chlorophenyl)-(R,R)-1,2-propanediol

1-(2-chlorophenyl)-trans-1-propene (6.53 g, Preparation Example 1) was dissolved in 45 mL of the mixture of acetone/t-BuOH/H₂O (5:1:1 V/V). At the room temperature, N-methylmorpholine-N-oxide (7.51 g) and OsO₄ (0.54 g) were added thereto and stirred for 2-3 hours. When the reaction was completed, the obtained product was washed with water and methylenechloride (MC). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgSO₄), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (6.42 g, yield 80%).

¹H NMR (400 MHz, CDCl₃) δ1.20 (d, J=6.4 Hz, 3H), 2.48 (d, J=4.0 Hz, 1H), 2.92 (d, J=4.4 Hz, 1H), 3.93˜3.97 (m, 1H), 4.97 (t, J=4.8 Hz, 1H), 7.22˜7.51 (m, 4H)

Preparation Example 17

Synthesis of 1-(2-chlorophenyl)-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-chlorophenyl)-trans-1-butene (Preparation Example 2) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.36 g, yield 95%).

¹H NMR (400 MHz, CDCl₃) δ1.01 (t, J=7.4 Hz, 3H), 1.52˜1.65 (m, 2H), 2.01 (d, J=4.4 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.69˜3.75 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.23˜7.54 (m, 4H)

Preparation Example 18

Synthesis of 1-(2-chlorophenyl)-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-chlorophenyl)-trans-1-butene (Preparation Example 2) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.84 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ1.01 (t, J=7.4 Hz, 3H), 1.52˜1.65 (m, 2H), 2.01 (d, J=4.4 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.69˜3.75 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.23˜7.54 (m, 4H)

Preparation Example 19

Synthesis of the Mixture of 1-(2-chlorophenyl)-(S,S)-1,2-butanediol and 1-(2-chlorophenyl)-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2-chlorophenyl)-trans-1-butene (Preparation Example 2) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (5.1 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.01 (t, J=7.4 Hz, 3H), 1.52˜1.65 (m, 2H), 2.01 (d, J=4.4 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.69˜3.75 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.23˜7.54 (m, 4H)

Preparation Example 20

Synthesis of 1-(2-chlorophenyl)-3-methyl-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-chlorophenyl)-3-methyl-trans-1-butene (Preparation Example 3) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.96 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.2 Hz, 6H), 1.83˜1.89 (m, 1H), 1.92 (d, J=5.6 Hz, 1H), 2.69 (d, J=6.4 Hz, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 7.23˜7.55 (m, 4H)

Preparation Example 21

Synthesis of 1-(2-chlorophenyl)-3-methyl-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-chlorophenyl)-3-methyl-trans-1-butene (Preparation Example 3) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (4.2 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.2 Hz, 6H), 1.82˜1.90 (m, 1H), 1.93 (d, J=5.6 Hz, 1H), 2.79 (d, J=6 Hz, 1H), 3.53˜3.57 (m, 1H), 5.23˜5.25 (m, 1H), 7.23˜7.54 (m, 4H)

Preparation Example 22

Synthesis of the Mixture of 1-(2-chlorophenyl)-3-methyl-(S,S)-1,2-butanediol and 1-(2-chlorophenyl)-3-methyl-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2-chlorophenyl)-3-methyl-trans-1-butene (Preparation Example 3) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.8 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.2 Hz, 6H), 1.83˜1.90 (m, 1H), 1.92 (d, J=5.6 Hz, 1H), 2.69 (d, J=6.4 Hz, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 7.23˜7.55 (m, 4H)

Preparation Example 23

Synthesis of 1-(2-chlorophenyl)-(S,S)-1,2-hexanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-chlorophenyl)-trans-1-hexene (Preparation Example 4) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.37 g, yield 90%).

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 2.08 (d, J=4.4 Hz, 1H), 2.71 (d, J=5.2 Hz, 1H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 7.23˜7.53 (m, 4H)

Preparation Example 24

Synthesis of 1-(2-chlorophenyl)-(R,R)-1,2-hexanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-chlorophenyl)-trans-1-hexene (Preparation Example 4) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (4.2 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ0.91 (t, J=6.6 Hz, 3H), 1.35˜1.65 (m, 6H), 2.08 (d, J=4.8 Hz, 1H), 2.70 (d, J=5.2 Hz, 1H), 3.80˜3.83 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.24˜7.56 (m, 4H)

Preparation Example 25

Synthesis of the Mixture of 1-(2-chlorophenyl)-(S,S)-1,2-hexanediol and 1-(2-chlorophenyl)-(R,R)-1,2-hexanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2-chlorophenyl)-trans-1-hexene (Preparation Example 4) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (7.9 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.2 Hz, 3H), 1.26˜1.55 (m, 6H), 2.08 (d, J=4.4 Hz, 1H), 2.71 (d, J=5.6 Hz, 1H), 3.78˜3.84 (m, 1H), 5.04 (t, J=3.2 Hz, 1H), 7.24˜7.55 (m, 4H)

Preparation Example 26

Synthesis of 1-(2,4-dichlorophenyl)-(S,S)-1,2-propanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 5) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.33 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ1.22 (d, J=6.4 Hz, 3H), 2.10 (d, J=4.4 Hz, 1H), 2.71 (d, J=4.8 Hz, 1H), 3.90˜3.95 (m, 1H), 4.94 (t, J=5.0 Hz, 1H), 7.31 (dd, J=2.0 Hz, J=8.0 Hz, 1H), 7.40 (d, J=2.0 Hz, 1H), 7.49 (d, J=8.4 Hz, 1H)

Preparation Example 27

Synthesis of 1-(2,4-dichlorophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 5) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.45 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ1.22 (d, J=6.4 Hz, 3H), 2.10 (d, J=4.4 Hz, 1H), 2.71 (d, J=4.8 Hz, 1H), 3.90˜3.95 (m, 1H), 4.94 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)

Preparation Example 28

Synthesis of the Mixture of 1-(2,4-dichlorophenyl)-(S,S)-1,2-propanediol and 1-(2,4-dichlorophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 5) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.45 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ1.22 (d, J=6.4 Hz, 3H), 2.10 (d, J=4.4 Hz, 1H), 2.71 (d, J=4.8 Hz, 1H), 3.90˜3.95 (m, 1H), 4.94 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)

Preparation Example 29

Synthesis of 1-(2,4-dichlorophenyl)-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-butene (Preparation Example 6) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.32 g, yield 90%).

¹H NMR (400 MHz, CDCl₃) δ1.02 (t, J=7.4 Hz, 3H), 1.54˜1.61 (m, 2H), 2.07 (d, J=4.8 Hz, 1H), 2.74 (d, J=4.8 Hz, 1H), 3.65˜3.68 (m, 1H), 5.01 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)

Preparation Example 30

Synthesis of 1-(2,4-dichlorophenyl)-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-butene (Preparation Example 6) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.43 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.02 (t, J=7.4 Hz, 3H), 1.54˜1.61 (m, 2H), 2.07 (d, J=4.8 Hz, 1H), 2.74 (d, J=4.8 Hz, 1H), 3.65˜3.68 (m, 1H), 5.01 (t, J=5.0 Hz, 1H), 7.31˜7.49 (m, 3H)

Preparation Example 31

Synthesis of the Mixture of 1-(2,4-dichlorophenyl)-(S,S)-1,2-butanediol and 1-(2,4-dichlorophenyl)-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-butene (Preparation Example 6) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.33 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.02 (t, J=7.4 Hz, 3H), 1.54˜1.61 (m, 2H), 2.07 (d, J=4.8 Hz, 1H), 2.74 (d, J=4.8 Hz, 1H), 3.65˜3.68 (m, 1H), 5.01 (t, J=5.0 Hz, 1H), 77.31˜7.49 (m, 3H)

Preparation Example 32

Synthesis of 1-(2,4-dichlorophenyl)-3-methyl-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 7) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.25 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 33

Synthesis of 1-(2,4-dichlorophenyl)-3-methyl-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 7) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.36 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 34

Synthesis of the Mixture of 1-(2,4-dichlorophenyl)-3-methyl-(S,S)-1,2-butanediol and 1-(2,4-dichlorophenyl)-3-methyl-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 7) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.26 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 35

Synthesis of 1-(2,4-dichlorophenyl)-(S,S)-1,2-hexanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 8) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (1.1 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ0.89˜0.93 (m, 3H), 1.30˜1.39 (m, 2H), 1.49˜1.52 (m, 2H), 1.56˜1.62 (m, 2H), 2.05 (d, J=5.2 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.72˜3.77 (m, 1H), 4.98 (t, J=4.8 Hz, 1H), 7.28˜7.50 (m, 3H)

Preparation Example 36

Synthesis of 1-(2,4-dichlorophenyl)-(R,R)-1,2-hexanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 8) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (1.2 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ0.89˜0.93 (m, 3H), 1.30˜1.39 (m, 2H), 1.49˜1.52 (m, 2H), 1.56˜1.62 (m, 2H), 2.05 (d, J=5.2 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.72˜3.77 (m, 1H), 4.98 (t, J=4.8 Hz, 1H), 7.28˜7.50 (m, 3H)

Preparation Example 37

Synthesis of the Mixture of 1-(2,4-dichlorophenyl)-(S,S)-1,2-hexanediol and 1-(2,4-dichlorophenyl)-(R,R)-1,2-hexanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,4-dichlorophenyl)-trans-1-propene (Preparation Example 8) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.67 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ0.89˜0.93 (m, 3H), 1.30˜1.39 (m, 2H), 1.49˜1.52 (m, 2H), 1.56˜1.62 (m, 2H), 2.05 (d, J=5.2 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.72˜3.77 (m, 1H), 4.98 (t, J=4.8 Hz, 1H), 7.28˜7.50 (m, 3H)

Preparation Example 38

Synthesis of 1-(2,6-dichlorophenyl)-(S,S)-1,2-propanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-propene (Preparation Example 9) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.9 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.36 (m, 3H)

Preparation Example 39

Synthesis of 1-(2,6-dichlorophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-propene (Preparation Example 9) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.84 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.36 (m, 3H)

Preparation Example 40

Synthesis of the Mixture of 1-(2,6-dichlorophenyl)-(S,S)-1,2-propanediol and 1-(2,6-dichlorophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-propene (Preparation Example 9) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.91 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.36 (m, 3H)

Preparation Example 41

Synthesis of 1-(2,6-dichlorophenyl)-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-butene (Preparation Example 10) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (1.23 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (t, J=7.6 Hz, 3H), 1.26˜1.53 (m, 2H), 2.64 (dd, J=0.8 Hz, J=4.0 Hz, 1H), 3.14 (d, J=8.4 Hz, 1H), 4.22˜4.26 (m, 1H), 5.26 (t, J=8.4 Hz, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 42

Synthesis of 1-(2,6-dichlorophenyl)-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-butene (Preparation Example 10) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.96 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (t, J=7.6 Hz, 3H), 1.26˜1.53 (m, 2H), 2.64 (dd, J=0.8 Hz, J=4.0 Hz, 1H), 3.14 (d, J=8.4 Hz, 1H), 4.22˜4.26 (m, 1H), 5.26 (t, J=8.4 Hz, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 43

Synthesis of the Mixture of 1-(2,6-dichlorophenyl)-(S,S)-1,2-butanediol and 1-(2,6-dichlorophenyl)-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-butene (Preparation Example 10) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.86 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (t, J=7.6 Hz, 3H), 1.26˜1.53 (m, 2H), 2.64 (dd, J=0.8 Hz, J=4.0 Hz, 1H), 3.14 (d, J=8.4 Hz, 1H), 4.22˜4.26 (m, 1H), 5.26 (t, J=8.4 Hz, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 44

Synthesis of 1-(2,6-dichlorophenyl)-3-methyl-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 11) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.25 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 45

Synthesis of 1-(2,6-dichlorophenyl)-3-methyl-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 11) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.37 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 46

Synthesis of the Mixture of 1-(2,6-dichlorophenyl)-3-methyl-(S,S)-1,2-butanediol and 1-(2,6-dichlorophenyl)-3-methyl-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-trans-1-butene (Preparation Example 11) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.47 g, yield 60˜95%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (d, J=6.8 Hz, 6H), 1.60˜1.65 (m, 1H), 2.35 (d, J=4.0 Hz, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.13˜4.18 (m, 1H), 5.36 (t, J=7.6 Hz, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 47

Synthesis of 1-(2,6-dichlorophenyl)-(S,S)-1,2-hexanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-hexene (Preparation Example 12) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.36 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ0.85 (t, J=6.8 Hz, 3H), 1.20˜1.31 (m, 4H), 1.45˜1.53 (m, 2H), 2.61˜2.62 (m, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.28˜4.33 (m, 1H), 5.25 (t, J=8.4 Hz, 1H), 7.18˜7.35 (m, 3H)

Preparation Example 48

Synthesis of 1-(2,6-dichlorophenyl)-(R,R)-1,2-hexanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-hexene (Preparation Example 12) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.58 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ0.85 (t, J=6.8 Hz, 3H), 1.20˜1.31 (m, 4H), 1.45˜1.53 (m, 2H), 2.61˜2.62 (m, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.28˜4.33 (m, 1H), 5.25 (t, J=8.4 Hz, 1H), 7.18˜7.35 (m, 3H)

Preparation Example 49

Synthesis of the Mixture of 1-(2,6-dichlorophenyl)-(S,S)-1,2-hexanediol and 1-(2,6-dichlorophenyl)-(R,R)-1,2-hexanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,6-dichlorophenyl)-trans-1-hexene (Preparation Example 12) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.62 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ0.85 (t, J=6.8 Hz, 3H), 1.20˜1.31 (m, 4H), 1.45˜1.53 (m, 2H), 2.61˜2.62 (m, 1H), 3.12 (d, J=8.4 Hz, 1H), 4.28˜4.33 (m, 1H), 5.25 (t, J=8.4 Hz, 1H), 7.18˜7.35 (m, 3H)

Preparation Example 50

Synthesis of methyl 2-(2-chlorophenyl)-(R)-2-hydroxyacetate

15 g of (R)-2-chloromandelic acid was mixed with methanol (CH₃OH, 150 ml) and phosphorus chloride oxide (POCl₃, 0.76 ml) in a flask by stiffing using a magnetic stirrer at the room temperature for 6 hours. When the reaction was completed, the obtained product was washed with an aqueous solution of sodium sulfite (Na₂SO₃) and ethylacetate (EA). Then, the organic layer was dehydrated with anhydrous magnesium sulfate (MgSO₄), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (15.64 g, yield 95%).

¹H NMR (400 MHz, CDCl₃) δ 3.59 (d, J=5.2, 1H), 3.79 (t, J=6.0, 3H), 5.59 (d, J=5.2, 1H), 7.28˜7.43 (m, 4H)

Preparation Example 51

Synthesis of 2-(2-chlorophenyl)-(R)-2-hydroxy-N-methoxy-N-methylacetamide

N,O-dimethylhydroxylamine hydrochloride (N,O-dimethylhydroxylamine.HCl, 15.2 g) was dissolved in dichloromethane (DCM, 150 ml), and cooled to 0° C. using an ice-bath. Then, 77.7 ml of 2.0M trimethylaluminium in hexane was slowly added thereto in drop-wise manner for 30 minutes. Thereafter, the ice-bath was removed, and the obtained product was stirred at the room temperature for 2 hours. Methyl-2-(2-chlorophenyl)-(R)-2-hydroxyacetate (15.64 g) dissolved in dichloromethane (DCM, 150 ml) was added in drop-wise manner thereto at the room temperature for 30 minutes, and subjected to reflux for 12 hours. When the reaction was completed, the obtained product was cooled to 0° C., and washed by a slow drop-wise addition of hydrochloric acid (HCl, 200 ml). The obtained organic layer was washed with distilled water and brine, dehydrated with anhydrous magnesium sulfate (MgSO₄), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (14.68 g, yield 82%).

¹H NMR (400 MHz, CDCl₃) δ3.23 (s, 3H), 3.28 (s, 3H), 4.33 (d, J=6.0 Hz, 1H), 5.81 (d, J=5.6 Hz, 1H), 7.23˜7.42 (m, 4H)

Preparation Example 52

Synthesis of 2-(2-chlorophenyl)-N-methoxy-(R)-2-(methoxymethoxy)-N-methylacetamide

2-(2-chlorophenyl)-(R)-2-hydroxy-N-methoxy-N-methylacetamide (14.68 g) obtained in Preparation Example 51 was dissolved in dichloromethane (DCM, 140 ml), and cooled to 0° C. Diisopropylethylamine (55.67 ml) was slowly added thereto in drop-wise manner, and stirred for 10 minutes. Chloro methyl methyl ether (25.25 ml) was slowly added thereto in drop-wise manner for 30 minutes. After 30 minutes, the ice-bath was removed and the obtained product was stirred for 30 at room temperature. When the reaction was completed, the obtained product was cooled to 0° C. And then, to the obtained product, 1M sodium hydroxide solution (1M NaOH, 20 ml) was added in drop-wise manner, and dichloromethane(DMC) was injected. Then the obtained product was washed with water. The obtained organic layer was dehydrated with anhydrous magnesium sulfate (MgSO₄), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (15.57 g, yield 89%).

¹H NMR (400 MHz, CDCl₃) δ3.19 (s, 3H), 3.42 (s, 3H), 3.47 (s, 3H), 4.75 (d, J=6.8, 1H), 4.81 (d, J=6.8, 1H), 6.07 (s, 1H), 7.27˜7.58 (m, 4H)

Preparation Example 53

Synthesis of 1-(2-chlorophenyl)-(R)-1-(methoxymethoxy)propane-2-on

2-(2-chlorophenyl)-N-methoxy-(R)-2-(methoxymethoxy)-N-methylacetamide (15.57 g) obtained in Preparation Example 52 was dissolved in tetrahydrofuran(THF, 150 ml), and cooled to 0° C. 3.0M methyl magnesium bromide (MeMgBr) solution in ether was added thereto in drop-wise manner for 30 minutes, and the obtained product was stirred for 1 hour at 0° C. When the reaction was completed, diethylether (100 ml) was added thereto. The obtained product was washed with 10% (w/v) potassium hydrogen sulfate (KHSO₄,100 ml) and then, washed again with brine. The obtained organic layer was dehydrated with anhydrous magnesium sulfate (MgSO₄), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (11.83 g, yield 90%).

¹H NMR (400 MHz, CDCl₃) δ2.18 (s, 3H), 3.39 (s, 3H), 4.65 (d, J=6.8, 1H), 4.74 (d, J=6.8, 1H), 5.63 (s, 1H), 7.30˜7.45 (m, 4H)

Preparation Example 54

Synthesis of 1-(2-chlorophenyl)-(R)-1-(methoxymethoxy)-(S)-2-propanol

1-(2-chlorophenyl)-(R)-1-(methoxymethoxy)propane-2-on (11.83 g) obtained in Preparation Example 53 was dissolved in toluene (110 ml), and cooled to −40° C. Sodium bis(2-methoxyethoxy)aluminumhydride solution (15.7 ml) in toluene was slowly added thereto for 30 minutes, and then, the obtained product was stirred for 1 hour. When the reaction was completed, the obtained product was washed by slow drop-wise addition of sodium potassium tartrate (100 ml). The obtained organic layer was dehydrated with anhydrous magnesium sulfate (MgSO₄), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (10.38 g, yield 87%).

¹H NMR (400 MHz, CDCl₃) δ1.13 (d, J=6.4, 3H), 2.33 (d, J=7.2, 1H), 3.44 (s, 3H), 4.10˜4.18 (m, 1H), 4.61 (d, J=6.4, 1H), 4.69 (d, J=6.8, 1H), 5.14 (d, J=3.6, 1H), 7.22˜7.55 (m, 4H)

Preparation Example 55

Synthesis of 1-(2-chlorophenyl)-(R,S)-1,2-propanediol

1-(2-chlorophenyl)-(R)-1-(methoxymethoxy)-(S)-2-propanol (10.38 g) obtained in Preparation Example 54 was dissolved in methanol (CH₃OH, 100 ml), and then, cooled to 0° C. 8M hydrochloric acid(HCl, 56.2 ml) was slowly added in drop-wise manner to the obtained product, and then, the obtained product was warmed to the room temperature, and stirred for 15 hours. When the reaction was completed, the obtained product was cooled to 0° C. 5N sodium hydroxide (NaOH, 30 ml) was slowly added thereto, and the obtained product was subjected to vacuum concentration. The obtained product was diluted with ethylacetate. The obtained organic layer was washed with distilled water, dehydrated with anhydrous magnesium sulfate (MgSO₄), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography to produce the title compound (7.05 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.07 (d, J=6.8, 3H), 2.01 (d, J=5.6, 1H), 2.61 (s, 1H), 4.21˜4.27 (m, 1H), 5.24 (d, J=3.6, 1H), 7.22˜7.64 (m, 4H)

Preparation Example 56

Synthesis of 1-(2-chlorophenyl)-(S,R)-1,2-propanediol

The substantially same method as described in Preparation Example 50˜55 was conducted, except that (S)-2-chloromandelic acid was used instead of (R)-2-chloromandelic acid, to obtain the title compound (5.04 g, yield 84%).

¹H NMR (400 MHz, CDCl₃) δ1.07 (d, J=6.8, 3H), 2.00 (d, J=5.6, 1H), 2.54 (d, J=3.6, 1H), 4.22˜4.26 (m, 1H), 5.25 (t, J=3.2, 1H), 7.22˜7.65 (m, 4H)

Preparation Example 57

Synthesis of 1-(2,3-dichlorophenyl)-(S,S)-1,2-propanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,3-dichlorophenyl)-trans-1-propene (Preparation Example 13) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.9 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜ (m, 3H)

Preparation Example 58

Synthesis of 1-(2,3-dichlorophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,3-dichlorophenyl)-trans-1-propene (Preparation Example 13) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.84 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜ (m, 3H)

Preparation Example 59

Synthesis of the Mixture of 1-(2,3-dichlorophenyl)-(S,S)-1,2-propanediol and 1-(2,3-dichlorophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 16 was conducted, except that 1-(2,3-dichlorophenyl)-trans-1-propene (Preparation Example 13) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.91 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜ (m, 3H)

Preparation Example 60

Synthesis of 1-(2-fluorophenyl)-trans-1-propene

The substantially same method as described in Preparation Example 1 was conducted, except that 2-fluorobenzenaldehyde was used instead of 2-chlorobenzenealdehyde, to obtain the title compound (6.67 g, yield 61%).

¹H NMR (400 MHz, CDCl₃) δ1.94 (d, J=6.8 Hz, 3H), 6.30˜6.38 (m, 1H), 6.57 (d, J=16 Hz, 1H), 7.00˜7.41 (m, 4H)

Preparation Example 61

Synthesis of 1-(2-fluorophenyl)-(S,S)-1,2-propanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-fluorophenyl)-trans-1-propene (Preparation Example 60) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (6.46 g, yield 78%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 2.43 (d, J=3.6 Hz, 1H), 2.69 (d, J=4.8 Hz, 1H), 3.90˜3.98 (m, 1H), 4.78 (dd, J=4.4, 7.2 Hz, 1H), 7.04˜7.50 (m, 4H)

Preparation Example 62

Synthesis of 1-(2-fluorophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-fluorophenyl)-trans-1-propene (Preparation Example 60) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (3.29 g, yield 79%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 2.43 (d, J=3.6 Hz, 1H), 2.69 (d, J=4.8 Hz, 1H), 3.90˜3.98 (m, 1H), 4.78 (dd, J=4.4, 7.2 Hz, 1H), 7.04˜7.50 (m, 4H)

Preparation Example 63

Synthesis of 2-iodobenzenealdehyde

In a flask, 2-iodobenzyl alcohol (4 g, 17.09 mmol) was dissolved in dichloromethane (MC, 85 ml), and then, manganese oxide (MnO₂, 14.86 g, 170.92 mmol) was added thereto. The obtained reaction product was stirred under the reflux condition. When the reaction was completed, the obtained reaction product was cooled to the room temperature, and then, fiteated and concentrated using celite, to obtain the title compound (3.6 g, yield 91%).

¹H NMR (400 MHz, CDCl₃) δ7.30˜7.99 (m, 4H), 10.10 (s, 1H)

Preparation Example 64

Synthesis of 1-(2-iodophenyl)-trans-1-propene

The substantially same method as described in Preparation Example 1 was conducted, except that 2-iodobenzenealdehyde (Preparation Example 63) was used instead of 2-chlorobenzenealdehyde, to obtain the title compound (3.4 g, yield 65%).

¹H NMR (400 MHz, CDCl₃) δ1.95 (dd, J=6.8 Hz, 1.6 Hz, 3H), 6.09˜6.18 (m, 1H), 6.60 (dd, J=15.66 Hz, 1.8 Hz, 1H), 6.89˜7.84 (m, 4H)

Preparation Example 65

Synthesis of 1-(2-iodophenyl)-trans-1-butene

The substantially same method as described in Preparation Example 64 was conducted, except that 3-heptanone was used instead of 3-pentanone, to obtain the title compound (8.5 g, yield 75%).

¹H NMR (400 MHz, CDCl₃) δ1.46 (t, J=7.6 Hz, 3H), 2.26˜2.34 (m, 2H), 6.17 (dt, J=15.6 Hz, 6.6 Hz 1H), 6.57 (d, J=15.6 Hz, 1H), 6.89˜7.85 (m, 4H)

Preparation Example 66

Synthesis of 1-(2-iodophenyl)-(S,S)-1,2-propanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-iodophenyl)-trans-1-propene (Preparation Example 64) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (3.4 g, yield 88%).

¹H NMR (400 MHz, CDCl₃) δ1.27 (d, J=6.4 Hz, 3H), 2.26 (br s, 1H), 2.74 (br s, 1H), 3.99 (t, J=6.0 Hz, 1H), 4.81 (d, J=4.0 Hz, 1H), 7.01˜7.87 (m, 4H)

Preparation Example 67

Synthesis of 1-(2-iodorophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 15 was conducted was conducted, except that 1-(2-iodophenyl)-trans-1-propene (Preparation Example 64) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (7.4 g, yield 84%).

¹H NMR (400 MHz, CDCl₃) δ1.26 (d, J=6.4 Hz, 3H), 2.35 (br s, 1H), 2.85 (br d, J=4.0 Hz, 1H), 3.98 (t, J=6.2 Hz, 1H), 4.80 (dd, J=5.0, 4.4 Hz, 1H), 7.00˜7.87 (m, 4H)

Preparation Example 68

Synthesis of 1-(2-iodophenyl)-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 14 was conducted was conducted, except that 1-(2-iodophenyl)-trans-1-butene (Preparation Example 65) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (9.5 g, yield 84%).

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.07 (br s, 1H), 2.74 (br s, 1H), 3.71˜3.76 (m, 1H), 4.87 (d, J=4.8 Hz, 1H), 7.01˜7.87 (m, 4H)

Preparation Example 69

Synthesis of 1-(2-iodophenyl)-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-iodophenyl)-trans-1-butene (Preparation Example 65) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (1.9 g, yield 70˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.01 (t, J=7.4 Hz, 3H), 1.52˜1.65 (m, 2H), 2.01 (d, J=4.4 Hz, 1H), 2.74 (d, J=5.2 Hz, 1H), 3.69˜3.75 (m, 1H), 5.05 (t, J=5.0 Hz, 1H), 7.03˜7.84 (m, 4H)

Preparation Example 70

Synthesis of 1-(2-iodophenyl)-3-methyl-trans-1-butene

The substantially same method as described in Preparation Example 3 was conducted, except that 2-iodobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (0.37 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (d, J=6.8 Hz, 6H), 2.25˜2.57 (m, 1H), 6.20 (dd, J=16 Hz, 7.2 Hz, 1H), 7.64 (d, J=16 Hz, 1H), 7.04˜7.82 (m, 4H)

Preparation Example 71

Synthesis of 1-(2-iodophenyl)-trans-1-hexene

The substantially same method as described in Preparation Example 4 was conducted, except that 2-iodobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (1.21 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=7.2 Hz, 3H), 1.33˜1.56 (m, 4H), 2.26˜2.32 (m, 4H), 6.24 (dt, J=15.6 Hz, 7 Hz, 1H), 6.78 (d, J=16 Hz, 1H), 7.12˜7.51 (m, 4H)

Preparation Example 72

Synthesis of 1-(2-fluorophenyl)-trans-1-butene

The substantially same method as described in Preparation Example 2 was conducted, except that 2-fluorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (0.72 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (d, J=7.6 Hz, 3H), 2.29˜2.33 (m, 2H), 6.28 (dt, J=16 Hz, 6.4 Hz, 1H), 6.78 (d, J=15.6 Hz, 1H), 7.15˜7.55 (m, 4H)

Preparation Example 73

Synthesis of 1-(2-fluorophenyl)-3-methyl-trans-1-butene

The substantially same method as described in Preparation Example 3 was conducted, except that 2-fluorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (1.31 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (d, J=6.8 Hz, 6H), 2.25˜2.57 (m, 1H), 6.20 (dd, J=16 Hz, 7.2 Hz, 1H), 7.64 (d, J=16 Hz, 1H), 7.11˜7.55 (m, 4H)

Preparation Example 74

Synthesis of 1-(2-fluorophenyl)-trans-1-hexene

The substantially same method as described in Preparation Example 4 was conducted, except that 2-fluorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (1.02 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=7.2 Hz, 3H), 1.33˜1.56 (m, 4H), 2.26˜2.32 (m, 4H), 6.24 (dt, J=15.6 Hz, 7 Hz, 1H), 6.78 (d, J=16 Hz, 1H), 7.14˜7.52 (m, 4H)

Preparation Example 75

Synthesis of 1-(3-iodophenyl)-trans-1-propene

The substantially same method as described in Preparation Example 64 was conducted, except that 3-iodobenzenaldehyde was used instead of 2-iodobenzenaldehyde, to obtain the title compound (1.22 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.95 (dd, J=6.8 Hz, 1.6 Hz, 3H), 6.09˜6.18 (m, 1H), 6.60 (dd, J=15.66 Hz, 1.8 Hz, 1H), 6.87˜7.80 (m, 4H)

Preparation Example 76

Synthesis of 1-(3-iodophenyl)-trans-1-butene

The substantially same method as described in Preparation Example 65 was conducted, except that 3-iodobenzenaldehyde was used instead of 2-iodobenzenaldehyde, to obtain the title compound (1.12 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.46 (t, J=7.6 Hz, 3H), 2.26˜2.34 (m, 2H), 6.17 (dt, J=15.6 Hz, 6.6 Hz 1H), 6.57 (d, J=15.6 Hz, 1H), 6.86˜7.81 (m, 4H)

Preparation Example 77

Synthesis of 1-(3-iodophenyl)-3-methyl-trans-1-butene

The substantially same method as described in Preparation Example 70 was conducted, except that 3-iodobenzenaldehyde was used instead of 2-iodobenzenaldehyde, to obtain the title compound (0.62 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (d, J=6.8 Hz, 6H), 2.25˜2.57 (m, 1H), 6.20 (dd, J=16 Hz, 7.2 Hz, 1H), 7.64 (d, J=16 Hz, 1H), 6.88˜7.64 (m, 4H)

Preparation Example 78

Synthesis of 1-(3-iodophenyl)-trans-1-hexene

The substantially same method as described in Preparation Example 71 was conducted, except that 3-iodobenzenaldehyde was used instead of 2-iodobenzenaldehyde, to obtain the title compound (0.42 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=7.2 Hz, 3H), 1.33˜1.56 (m, 4H), 2.26˜2.32 (m, 4H), 6.24 (dt, J=15.6 Hz, 7 Hz, 1H), 6.78 (d, J=16 Hz, 1H), 6.88˜7.59 (m, 4H)

Preparation Example 79

Synthesis of 1-(4-fluorophenyl)-trans-1-propene

The substantially same method as described in Preparation Example 60 was conducted, except that 4-fluorobenzenaldehyde was used instead of 2-fluorobenzenaldehyde, to obtain the title compound (0.29 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.94 (d, J=6.8 Hz, 3H), 6.30˜6.38 (m, 1H), 6.57 (d, J=16 Hz, 1H), 6.85˜7.04 (m, 4H)

Preparation Example 80

Synthesis of 1-(4-fluorophenyl)-trans-1-butene

The substantially same method as described in Preparation Example 72 was conducted, except that 4-fluorobenzenaldehyde was used instead of 2-fluorobenzenaldehyde, to obtain the title compound (1.03 g, yield 10˜40%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (d, J=7.6 Hz, 3H), 2.29˜2.33 (m, 2H), 6.28 (dt, J=16 Hz, 6.4 Hz, 1H), 6.78 (d, J=15.6 Hz, 1H), 6.88.15˜7.05 (m, 4H)

Preparation Example 81

Synthesis of 1-(4-fluorophenyl)-3-methyl-trans-1-butene

The substantially same method as described in Preparation Example 73 was conducted, except that 4-fluorobenzenaldehyde was used instead of 2-fluorobenzenaldehyde, to obtain the title compound (1.41 g, yield 10˜40%)

¹H NMR (400 MHz, CDCl₃) δ1.14 (d, J=6.8 Hz, 6H), 2.25˜2.57 (m, 1H), 6.20 (dd, J=16 Hz, 7.2 Hz, 1H), 7.64 (d, J=16 Hz, 1H), 6.83˜7.09 (m, 4H)

Preparation Example 82

Synthesis of 1-(4-fluorophenyl)-trans-1-hexene

The substantially same method as described in Preparation Example 74 was conducted, except that 4-fluorobenzenaldehyde was used instead of 2-fluorobenzenaldehyde, to obtain the title compound (0.43 g, yield 10˜40%)

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=7.2 Hz, 3H), 1.33˜1.56 (m, 4H), 2.26˜2.32 (m, 4H), 6.24 (dt, J=15.6 Hz, 7 Hz, 1H), 6.78 (d, J=16 Hz, 1H), 6.84˜7.07 (m, 4H)

Preparation Example 83

Synthesis of 1-(2-iodophenyl)-3-methyl-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-iodophenyl)-3-methyl-trans-1-butene (Preparation Example 70) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.52 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.2 Hz, 6H), 1.83˜1.89 (m, 1H), 1.92 (d, J=5.6 Hz, 1H), 2.69 (d, J=6.4 Hz, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 7.04˜7.85 (m, 4H)

Preparation Example 84

Synthesis of 1-(2-iodophenyl)-3-methyl-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-iodophenyl)-trans-1-butene (Preparation Example 65) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.52 g, yield 60˜90%)

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.07 (br s, 1H), 2.74 (br s, 1H), 3.71˜3.76 (m, 1H), 4.87 (d, J=4.8 Hz, 1H), 7.01˜7.87 (m, 4H)

Preparation Example 85

Synthesis of 1-(2-iodophenyl)-(S,S)-1,2-hexanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2-iodophenyl)-trans-1-hexene (Preparation Example 71) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (1.21 g, yield 60˜90%)

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 2.08 (d, J=4.4 Hz, 1H), 2.71 (d, J=5.2 Hz, 1H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 7.02˜7.79 (m, 4H)

Preparation Example 86

Synthesis of 1-(2-iodophenyl)-(R,R)-1,2-hexanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2-iodophenyl)-trans-1-hexene (Preparation Example 71) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (0.74 g, yield 60˜90%)

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 2.08 (d, J=4.4 Hz, 1H), 2.71 (d, J=5.2 Hz, 1H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 7.02˜7.79 (m, 4H)

Preparation Example 87

Synthesis of 1-(3-iodophenyl)-(S,S)-1,2-propanediol

The substantially same method as described in Preparation Example 66 was conducted, except that 1-(3-iodophenyl)-trans-1-propene (Preparation Example 75) was used instead of 1-(2-iodophenyl)-trans-1-propene (Preparation Example 64), to obtain the title compound (2.03 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.27 (d, J=6.4 Hz, 3H), 2.26 (br s, 1H), 2.74 (br s, 1H), 3.99 (t, J=6.0 Hz, 1H), 4.81 (d, J=4.0 Hz, 1H), 6.98˜7.50 (m, 4H)

Preparation Example 88

Synthesis of 1-(3-iodophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 67 was conducted, except that 1-(3-iodophenyl)-trans-1-propene (Preparation Example 75) was used instead of 1-(2-iodophenyl)-trans-1-propene (Preparation Example 64), to obtain the title compound (1.12 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.27 (d, J=6.4 Hz, 3H), 2.26 (br s, 1H), 2.74 (br s, 1H), 3.99 (t, J=6.0 Hz, 1H), 4.81 (d, J=4.0 Hz, 1H), 6.98˜7.50 (m, 4H)

Preparation Example 89

Synthesis of 1-(3-iodophenyl)-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 68 was conducted, except that 1-(3-iodophenyl)-trans-1-butene (Preparation Example 76) was used instead of 1-(2-iodophenyl)-trans-1-propene (Preparation Example 64), to obtain the title compound (2.03 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.07 (br s, 1H), 2.74 (br s, 1H), 3.71˜3.76 (m, 1H), 4.87 (d, J=4.8 Hz, 1H), 6.99˜7.52 (m, 4H)

Preparation Example 90

Synthesis of 1-(3-iodophenyl)-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 84 was conducted, except that 1-(3-iodophenyl)-trans-1-butene (Preparation Example 76) was used instead of 1-(2-iodophenyl)-trans-1-propene (Preparation Example 64), to obtain the title compound (1.18 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.07 (br s, 1H), 2.74 (br s, 1H), 3.71˜3.76 (m, 1H), 4.87 (d, J=4.8 Hz, 1H), 6.99˜7.52 (m, 4H)

Preparation Example 91

Synthesis of 1-(3-iodophenyl)-3-methyl-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 83 was conducted, except that 1-(3-iodophenyl)-3-methyl-trans-1-butene (Preparation Example 77) was used instead of 1-(2-iodophenyl)-3-methyl-trans-1-butene (Preparation Example 70), to obtain the title compound (0.51 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.2 Hz, 6H), 1.83˜1.89 (m, 1H), 1.92 (d, J=5.6 Hz, 1H), 2.69 (d, J=6.4 Hz, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 6.92˜7.50 (m, 4H)

Preparation Example 92

Synthesis of 1-(3-iodophenyl)-3-methyl-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 90 was conducted, except that 1-(3-iodophenyl)-3-methyl-trans-1-butene (Preparation Example 77) was used instead of 1-(3-iodophenyl)-trans-1-butene (Preparation Example 76), to obtain the title compound (1.10 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.2 Hz, 6H), 1.83˜1.89 (m, 1H), 1.92 (d, J=5.6 Hz, 1H), 2.69 (d, J=6.4 Hz, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 6.92˜7.50 (m, 4H)

Preparation Example 93

Synthesis of 1-(3-iodophenyl)-(S,S)-1,2-hexanediol

The substantially same method as described in Preparation Example 85 was conducted, except that 1-(3-iodophenyl)-trans-1-hexene (Preparation Example 78) was used instead of 1-(2-iodophenyl)-trans-1-hexene (Preparation Example 71), to obtain the title compound (0.95 g, yield 60˜90%)

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 2.08 (d, J=4.4 Hz, 1H), 2.71 (d, J=5.2 Hz, 1H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 6.95˜7.49 (m, 4H)

Preparation Example 94

Synthesis of 1-(3-iodophenyl)-(R,R)-1,2-hexanediol

The substantially same method as described in Preparation Example 86 was conducted, except that 1-(3-iodophenyl)-trans-1-hexene (Preparation Example 78) was used instead of 1-(2-iodophenyl)-trans-1-hexene (Preparation Example 71), to obtain the title compound (0.41 g, yield 60˜90%)

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 2.08 (d, J=4.4 Hz, 1H), 2.71 (d, J=5.2 Hz, 1H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 6.95˜7.49 (m, 4H)

Preparation Example 95

Synthesis of 1-(4-fluorophenyl)-(S,S)-1,2-propanediol

The substantially same method as described in Preparation Example 87 was conducted, except that 1-(4-fluorophenyl)-trans-1-propene (Preparation Example 79) was used instead of 1-(3-iodophenyl)-trans-1-propene (Preparation Example 75), to obtain the title compound (2.01 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 2.43 (d, J=3.6 Hz, 1H), 2.69 (d, J=4.8 Hz, 1H), 3.90˜3.98 (m, 1H), 4.78 (dd, J=4.4, 7.2 Hz, 1H), 6.85˜7.04 (m, 4H)

Preparation Example 96

Synthesis of 1-(3-fluorophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 88 was conducted, except that 1-(4-fluorophenyl)-trans-1-propene (Preparation Example 79) was used instead of 1-(3-iodophenyl)-trans-1-propene (Preparation Example 75), to obtain the title compound (1.27 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 2.43 (d, J=3.6 Hz, 1H), 2.69 (d, J=4.8 Hz, 1H), 3.90˜3.98 (m, 1H), 4.78 (dd, J=4.4, 7.2 Hz, 1H), 6.85˜7.04 (m, 4H)

Preparation Example 97

Synthesis of 1-(4-fluorophenyl)-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 89 was conducted, except that 1-(4-fluorophenyl)-trans-1-butene (Preparation Example 80) was used instead of 1-(3-iodophenyl)-trans-1-butene (Preparation Example 76), to obtain the title compound (0.43 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.07 (br s, 1H), 2.74 (br s, 1H), 3.71˜3.76 (m, 1H), 4.87 (d, J=4.8 Hz, 1H), 6.88˜7.05 (m, 4H)

Preparation Example 98

Synthesis of 1-(3-fluorophenyl)-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 90 was conducted, except that 1-(4-fluorophenyl)-trans-1-butene (Preparation Example 80) was used instead of 1-(3-iodophenyl)-trans-1-butene (Preparation Example 76), to obtain the title compound (1.13 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.07 (br s, 1H), 2.74 (br s, 1H), 3.71˜3.76 (m, 1H), 4.87 (d, J=4.8 Hz, 1H), 6.88˜7.05 (m, 4H)

Preparation Example 99

Synthesis of 1-(4-fluorophenyl)-3-methyl-(S,S)-1,2-butanediol

The substantially same method as described in Preparation Example 91 was conducted, except that 1-(4-fluorophenyl)-3-methyl-trans-1-butene (Preparation Example 81) was used instead of 1-(3-iodophenyl)-3-methyl-trans-1-butene (Preparation Example 77), to obtain the title compound (0.71 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.2 Hz, 6H), 1.83˜1.89 (m, 1H), 1.92 (d, J=5.6 Hz, 1H), 2.69 (d, J=6.4 Hz, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 6.87˜7.02 (m, 4H)

Preparation Example 100

Synthesis of 1-(3-fluorophenyl)-3-methyl-(R,R)-1,2-butanediol

The substantially same method as described in Preparation Example 92 was conducted, except that 1-(4-fluorophenyl)-3-methyl-trans-1-butene (Preparation Example 81) was used instead of 1-(3-iodophenyl)-3-methyl-trans-1-butene (Preparation Example 77), to obtain the title compound (1.21 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.2 Hz, 6H), 1.83˜1.89 (m, 1H), 1.92 (d, J=5.6 Hz, 1H), 2.69 (d, J=6.4 Hz, 1H), 3.53˜3.56 (m, 1H), 5.22˜5.25 (m, 1H), 6.87˜7.02 (m, 4H)

Preparation Example 101

Synthesis of 1-(4-fluorophenyl)-(S,S)-1,2-hexanediol

The substantially same method as described in Preparation Example 93 was conducted, except that 1-(4-fluorophenyl)-trans-1-hexene (Preparation Example 82) was used instead of 1-(3-iodophenyl)-trans-1-hexene (Preparation Example 78), to obtain the title compound (1.13 g, yield 60˜90%)

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 2.08 (d, J=4.4 Hz, 1H), 2.71 (d, J=5.2 Hz, 1H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 6.88˜7.09 (m, 4H)

Preparation Example 102

Synthesis of 1-(3-fluorophenyl)-(R,R)-1,2-hexanediol

The substantially same method as described in Preparation Example 94 was conducted, except that 1-(4-fluorophenyl)-trans-1-hexene (Preparation Example 82) was used instead of 1-(3-iodophenyl)-trans-1-hexene (Preparation Example 78), to obtain the title compound (1.42 g, yield 60˜90%)

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.2 Hz, 3H), 1.35˜1.65 (m, 6H), 2.08 (d, J=4.4 Hz, 1H), 2.71 (d, J=5.2 Hz, 1H), 3.78˜3.83 (m, 1H), 5.04 (t, J=5.0 Hz, 1H), 6.88˜7.09 (m, 4H)

Preparation Example 103

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxypropyl-(S)-2-carbamate

1-(2-chlorophenyl)-(S,S)-1,2-propanediol (2.33 g) obtained in Preparation Example 14, tetrahydrofuran (THF, 12 ml), and carbonyldiimidazole (CDI, 3.04 g) were put into a flask and stirred at the room temperature. After approximately 3 hours, ammonia solution (NH₄OH, 4 ml) was added thereto. When the reaction was completed, the obtained product was washed with 1M HCl solution and ethylacetate (EA). The separated organic layer was dehydrated with anhydrous magnesium sulfate (MgSO₄), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography, to obtain the title compound (1.40 g, yield 49%).

M.P. 83˜84° C.

¹H NMR (400 MHz, CDCl₃) δ1.24 (d, J=6.4 Hz, 3H), 2.91 (d, J=4.8 Hz, 1H), 4.68 (br s, 2H), 5.06˜5.09 (m, 1H), 5.18˜5.21 (m, 1H), 7.23˜7.55 (m, 4H)

¹³C NMR (100 MHz, CDCl₃) δ16.4, 73.1, 75.0, 127.0, 128.4, 129.1, 129.5, 132.7, 138.0, 156.6

Preparation Example 104

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxypropyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 10303 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-propanediol obtained in Preparation Example 15 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.74 g, yield 50%).

M.P. 85˜86° C.

¹H NMR (400 MHz, CDCl₃) δ1.24 (d, J=6.4 Hz, 3H), 2.98 (d, J=4.0 Hz, 1H), 4.73 (br s, 2H), 5.04˜5.10 (m, 1H), 5.18˜5.20 (m, 1H), 7.24˜7.55 (m, 4H)

Preparation Example 105

Synthesis of 1-(2-chlorophenyl)-1-hydroxypropyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that the mixture of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol and 1-(2-chlorophenyl)-(R,R)-1,2-propanediol obtained in Preparation Example 16 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.41 g, yield 38%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (d, J=6.8 Hz, 3H), 3.34 (d, J=3.2 Hz, 1H), 5.06 (brs, 2H), 5.09˜5.15 (m, 1H), 5.31 (br t, J=2.4 Hz, 1H), 7.18˜7.59 (m, 4H)

Preparation Example 106

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxypropyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-(R,S)-1,2-propanediol obtained in Preparation Example 55 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.7 g, yield 50%).

¹H NMR (400 MHz, CDCl₃) δ1.20 (d, J=6.8, 3H), 2.68 (s, 1H), 4.67 (s, 2H), 5.16˜5.22 (m, 1H), 5.36 (t, J=3.2, 1H), 7.23˜7.61 (m, 4H)

Preparation Example 107

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxypropyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-(S,R)-1,2-propanediol obtained in Preparation Example 56 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.74 g, yield 50%).

¹H NMR (400 MHz, CDCl₃) δ1.20 (d, J=6.4, 3H), 2.83 (d, J=3.6, 1H), 4.78 (s, 2H), 5.15˜5.21 (m, 1H), 5.36 (t, J=3.2, 1H), 7.23˜7.63 (m, 4H)

Preparation Example 108

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxybutyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-(S,S)-1,2-butanediol obtained in Preparation Example 17 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.0 g, yield 45%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=7.4 Hz, 3H), 1.57˜1.73 (m, 2H), 3.01 (d, J=5.6 Hz, 1H), 4.74 (br s, 2H), 4.95 (dt, J=7.2, 8.8 Hz, 1H), 5.23 (t, J=5.6 Hz, 1H), 7.22˜7.54 (m, 4H)

Preparation Example 109

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxybtyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-butanediol obtained in Preparation Example 18 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.5 g, yield 25%).

¹H NMR (400 MHz, CDCl₃) δ 0.94 (t, J=7.4 Hz, 3H), 1.53˜1.73 (m, 2H), 2.92 (s, 1H), 4.78 (br s, 2H), 4.91˜4.96 (m, 1H), 5.22 (d, J=5.5 Hz, 1H), 7.20˜7.54 (m, 4H)

Preparation Example 110

Synthesis of 1-(2-chlorophenyl)-1-hydroxybutyl-2-carbamate(8)

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-1,2-butanediol obtained in Preparation Example 19 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.8 g, yield 30%).

¹H NMR (400 MHz, CDCl₃) δ 0.97 (t, J=7 Hz, 3H), 1.58˜1.74 (m, 2H), 2.94 (d, J=6 Hz, 1H), 4.69 (br s, 2H), 4.94˜4.99 (m, 1H), 5.24 (t, J=6 Hz, 1H), 7.23˜7.56 (m, 4H)

Preparation Example 111

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-3-methyl-(S,S)-1,2-butanediol obtained in Preparation Example 20 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.72 g, yield 48%).

¹H NMR (400 MHz, CDCl₃) δ1.01 (d, J=6.4 Hz, 3H), 1.09 (d, J=6.8 Hz, 3H), 2.06 (m, 1H), 2.75 (d, J=6.8 Hz, 1H), 4.58 (br s, 2H), 4.85˜4.88 (m, 1H), 5.34˜5.37 (m, 1H), 7.22˜7.33 (m, 2H), 7.35˜7.37 (m, 1H), 7.51˜7.53 (m, 1H)

Preparation Example 112

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxy-3-methyl-butyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-3-methyl-(R,R)-1,2-butanediol obtained in Preparation Example 21 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.56 g, yield 43%).

¹H NMR (400 MHz, CDCl₃) δ1.01 (d, J=6.8 Hz, 3H), 1.09 (d, J=6.8 Hz, 3H), 2.06 (m, 1H), 2.73 (d, J=6.8 Hz, 1H), 4.57 (br s, 2H), 4.85˜4.88 (m, 1H), 5.34˜5.37 (m, 1H), 7.24˜7.30 (m, 2H), 7.35˜7.37 (m, 1H), 7.51˜7.53 (m, 1H)

Preparation Example 113

Synthesis of 1-(2-chlorophenyl)-1-hydroxy-3-methyl-butyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-3-methyl-1,2-butanediol obtained in Preparation Example 22 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.5 g, yield 23%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (d, J=6.4 Hz, 3H), 1.09 (d, J=6.4 Hz, 3H), 2.08 (m, 1H), 2.76 (d, J=6.0 Hz, 1H), 4.59 (br s, 2H), 4.87 (dd, J=7.2 Hz, 4.4 Hz, 1H), 5.36 (t, J=4.6, 1H), 7.23˜7.54 (m, 4H)

Preparation Example 114

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxyhexyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-(S,S)-1,2-hexanediol obtained in Preparation Example 23 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.24 g, yield 49%).

¹H NMR (400 MHz, CDCl₃) δ0.88 (t, J=7 Hz, 3H), 1.33˜1.42 (m, 4H), 1.53˜1.71 (m, 2H), 2.89 (d, J=5.6 Hz, 1H) 4.64 (br s, 2H), 5.04 (dt, J=5.0, 9.0 Hz, 1H), 5.20 (t, J=5.6 Hz, 1H), 7.23˜7.55 (m, 4H)

Preparation Example 115

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxyhexyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-(R,R)-1,2-hexanediol obtained in Preparation Example 24 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (2.2 g, yield 44%).

¹H NMR (400 MHz, CDCl₃) δ 0.89 (dd, J=5 Hz, 3H), 1.28˜1.43 (m, 4H), 1.52˜1.58 (m, 1H), 1.65˜1.72 (m, 1H), 2.90 (d, J=6 Hz, 1H), 4.64 (br s, 2H), 5.01˜5.06 (m, 1H), 5.22 (t, J=6 Hz, 1H), 7.22˜7.56 (m, 4H)

Preparation Example 116

Synthesis of 1-(2-chlorophenyl)-1-hydroxyhexyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-1,2-hexanediol obtained in Preparation Example 25 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.6 g, yield 34%).

¹H NMR (400 MHz, CDCl₃) δ 0.88 (dd, J=5 Hz, 3H), 1.31˜1.43 (m, 4H), 1.63˜1.70 (m, 1H), 1.52˜1.60 (m, 1H), 3.06 (d, J=6 Hz, 1H), 4.75 (br s, 2H), 5.00˜5.05 (m, 1H), 5.21 (t, J=6 Hz, 1H), 7.22˜7.55 (m, 4H)

Preparation Example 117

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxypropyl-(S)-2-methylcarbamate

The substantially same method as described in Preparation Example 103 was conducted, except that methylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.6 g, yield 51%).

¹H NMR (400 MHz, CDCl₃) δ1.03˜1.25 (m, 3H), 2.76 (s, 3H), 3.34 (s, 1H), 4.80 (br s 1H), 5.04 (t, J=12.5 Hz, 1H), 5.14 (s, 1H), 7.20˜7.53 (m, 4H)

Preparation Example 118

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxypropyl-(S)-2-propylcarbamate

The substantially same method as described in Preparation Example 103 was conducted, except that propylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (0.79 g, yield 25%).

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.20 (d, J=5.96 Hz, 3H), 1.49 (dd, J=14.2 Hz, 2H), 3.11 (d, J=6.28 Hz, 2H), 3.34 (s, 1H), 4.84 (br s, 1H), 5.05 (t, J=5.88 Hz, 1H), 5.14 (s, 1H), 7.22˜7.53 (m, 4H)

Preparation Example 119

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxypropyl-(R)-2-isopropylcarbamate

The substantially same method as described in Preparation Example 103 was conducted, except that isopropylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.5 g, yield 41%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (dd, J=6.5 Hz, 6H), 1.19 (d, J=6.4 Hz, 3H), 3.21 (s, 1H), 3.73˜3.82 (m, 1H), 4.59 (br s, 1H), 5.01˜5.07 (m, 1H), 5.14 (t, J=5.8 Hz, 1H), 7.20˜7.53 (m, 4H)

Preparation Example 120

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxypropyl-(R)-2-cyclopropylcarbamate

The substantially same method as described in Preparation Example 103 was conducted, except that cyclopropylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (2.2 g, yield 43%).

¹H NMR (400 MHz, CDCl₃) δ0.50˜0.56 (m, 2H), 0.74 (d, J=7.21 Hz, 2H), 1.25 (s, 3H), 2.56˜2.61 (m, 1H), 3.72 (s, 1H), 4.98 (br s, 1H), 5.05˜5.11 (m, 1H), 7.16 (s, 1H), 7.23˜7.54 (m, 4H)

Preparation Example 121

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxypropyl-(R)-2-cyclohexyl carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that cyclohexylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.1 g, yield 26%).

¹H NMR (400 MHz, CDCl₃) δ1.06˜1.40 (m, 7H), 1.56˜1.61 (m, 2H), 1.69˜1.71 (m, 2H), 1.87˜1.94 (m, 2H), 3.19 (d, J=4.32 Hz, 1H), 3.45 (s, 1H), 4.64 (br s 1H), 5.02˜5.07 (m, 1H), 5.14 (t, J=6.08 Hz, 1H) 7.20˜7.53 (m, 4H)

Preparation Example 122

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxypropyl-(S)-2-benzyl carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that benzylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.2 g, yield 18%).

¹H NMR (400 MHz, CDCl₃) δ 1.27 (d, J=10 Hz, 3H), 3.12 (d, J=5 Hz, 1H), 4.37 (d, J=6 Hz, 2H), 5.12˜5.19 (m, 3H), 7.15˜7.56 (m, 9H)

Preparation Example 123

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxypropyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 2-aminonorbornane was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.7 g, yield 32%).

¹H NMR (400 MHz, CDCl₃) δ1.08˜1.35 (m, 9H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.22˜7.55 (m, 4H)

Preparation Example 124

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxypropyl-(R)-2-methylcarbamate

The substantially same method as described in Example 2 was conducted, except that methylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (3.36 g, yield 60%).

¹H NMR (400 MHz, CDCl₃) δ 1.20 (d, J=6.8 Hz, 3H), 2.80 (d, J=4.8 Hz, 3H), 3.20 (d, J=4.4 Hz, 1H), 4.75 (br s, 1H), 5.03˜5.09 (m, 1H), 5.14˜5.17 (m, 1H), 7.22˜7.55 (m, 4H)

Preparation Example 125

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxypropyl-(R)-2-propylcarbamate

The substantially same method as described in Preparation Example 104 was conducted, except that propylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (3.1 g, yield 53%).

¹H NMR (400 MHz, CDCl₃) δ0.92 (t, J=7.6 Hz, 3H), 1.21 (d, J=6.4 Hz, 3H), 1.51 (m, 2H), 3.09˜3.14 (m, 2H), 3.28 (d, J=4.4 Hz, 1H), 4.82 (br s, 1H), 5.03˜5.09 (m, 1H), 5.14˜5.17 (m, 1H), 7.22˜7.55 (m. 4H)

Preparation Example 126

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxypropyl-(R)-2-isopropylcarbamate

The substantially same method as described in Preparation Example 104 was conducted, except that isopropylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (0.16 g, yield 27%).

¹H NMR (400 MHz, CDCl₃) δ0.88˜1.16 (m, 6H), 1.19˜1.26 (m, 3H), 3.34 (s, 1H), 3.71˜3.78 (m, 1H), 4.62 (br s, 1H), 5.03 (t, J=5.8 Hz, 1H), 5.13 (d, J=4.9 Hz, 1H), 7.20˜7.53 (m, 4H)

Preparation Example 127

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxypropyl-(R)-2-cyclopropylcarbamate

The substantially same method as described in Preparation Example 104 was conducted, except that cyclopropylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (3.7 g, yield 60%).

¹H NMR (400 MHz, CDCl₃) δ0.49˜0.54 (m, 2H), 0.74 (d, J=7.2 Hz, 2H), 1.22 (s, 3H), 2.55˜2.60 (m, 1H), 3.16 (s, 1H), 5.00 (s, 1H), 5.04˜5.11 (m, 1H), 5.16 (s, 1H), 7.23˜7.54 (m, 4H)

Preparation Example 128

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxypropyl-(R)-2-cyclohexyl carbamate

The substantially same method as described in Preparation Example 104 was conducted, except that cyclohexylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.9 g, yield 28%).

¹H NMR (400 MHz, CDCl₃) δ1.05˜1.38 (m, 8H), 1.58˜1.70 (m, 3H), 1.85˜1.95 (m, 2H), 3.39˜3.47 (m, 1H), 3.56 (s, 1H), 4.79 (br s, 1H), 5.01˜5.07 (m, 1H), 5.14 (t, J=5.2 Hz, 1H), 7.20˜7.54 (m, 4H)

Preparation Example 129

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxypropyl-(R)-2-benzylcarbamate

The substantially same method as described in Preparation Example 104 was conducted, except that benzylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (0.52 g, yield 19%).

¹H NMR (400 MHz, CDCl₃) δ1.25 (d, J=6 Hz, 3H), 1.64 (s, 1H), 3.13 (d, J=4.4 Hz, 1H), 4.37 (d, J=5.6 Hz, 2H), 5.12˜5.19 (m, 2H), 7.23˜7.55 (m, 9H)

Preparation Example 130

Synthesis of 1-(2-chlorophenyl)-(R)-1-hydroxypropyl-(R)-2-bicyclo[2,2,1]heptanecarbamate

The substantially same method as described in Preparation Example 104 was conducted, except that 2-aminonorbornane was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.7 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.08˜1.35 (m, 9H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.22˜7.55 (m, 4H)

Preparation Example 131

Synthesis of 1-(2-chlorophenyl)-1-hydroxypropyl-2-methylcarbamate

The substantially same method as described in Preparation Example 105 was conducted, except that methylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (2.6 g, yield 45%).

¹H NMR (400 MHz, CDCl₃) δ 1.21 (d, J=6 Hz, 3H), 2.81 (d, J=5 Hz, 3H), 3.14 (d, J=4 Hz, 1H), 4.72 (br s, 1H), 5.07 (dd, J=6 Hz, 1H), 5.16 (t, J=6 Hz, 1H), 7.22˜7.56 (m, 4H)

Preparation Example 132

Synthesis of 1-(2-chlorophenyl)-1-hydroxypropyl-2-propylcarbamate

The substantially same method as described in Preparation Example 105 was conducted, except that propylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.0 g, yield 17%).

¹H NMR (400 MHz, CDCl₃) δ 0.92 (t, J=7 Hz, 3H), 1.21 (d, J=6 Hz, 3H), 1.53 (dd, J=7 Hz, 2H), 3.13 (dd, J=7 Hz, 2H), 3.28 (d, 1H), 4.82 (S, 1H), 5.06 (dd, J=7 Hz, 1H), 5.16 (t, J=5 Hz, 1H), 7.21˜7.56 (m, 4H)

Preparation Example 133

Synthesis of 1-(2-chlorophenyl)-1-hydroxypropyl-2-isopropylcarbamate

The substantially same method as described in Preparation Example 105 was conducted, except that isopropylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (0.54 g, yield 16%).

¹H NMR (400 MHz, CDCl₃) δ 1.16 (dd, J=6 Hz, 6H), 1.21 (d, J=6 Hz, 3H), 3.23 (d, J=6 Hz, 1H), 3.75˜3.84 (m, 1H), 4.61 (br s, 1H), 5.06 (t, J=6 Hz, 1H), 5.16 (t, J=6 Hz, 1H), 7.22˜7.56 (m, 4H)

Preparation Example 134

Synthesis of 1-(2-chlorophenyl)-1-hydroxypropyl-2-cyclopropylcarbamate

The substantially same method as described in Preparation Example 105 was conducted, except that cyclopropylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.0 g, yield 17%).

¹H NMR (400 MHz, CDCl₃) δ 0.50 (t, J=6 Hz, 2H), 0.77 (t, J=3 Hz, 2H), 1.12 (d, J=7 Hz, 3H), 2.53˜2.59 (m, 1H), 3.22 (d, J=4 Hz, 1H), 5.08 (dd, J=6 Hz, 1H), 5.15 (S, 1H), 7.22˜7.55 (m, 4H)

Preparation Example 135

Synthesis of 1-(2-chlorophenyl)-1-hydroxypropyl-2-cyclohexylcarbamate

The substantially same method as described in Preparation Example 105 was conducted, except that cyclohexylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (2.2 g, yield 33%).

¹H NMR (400 MHz, CDCl₃) δ 1.07˜1.17 (m, 3H), 1.21 (d, J=6 Hz, 3H), 1.29˜1.42 (m, 3H), 1.72 (dd, J=6 Hz, 2H), 1.92 (dd, J=6 Hz, 2H), 3.26 (d, J=4 Hz, 1H), 3.46 (t, J=4 Hz, 1H), 4.68 (d, J=6 Hz, 1H), 5.07 (dd, J=6 Hz, 1H), 5.16 (t, J=6 Hz, 1H), 7.22˜7.55 (m, 4H)

Preparation Example 136

Synthesis of 1-(2-chlorophenyl)-1-hydroxypropyl-2-benzylcarbamate

The substantially same method as described in Preparation Example 105 was conducted, except that benzylamine was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.3 g, yield 19%).

¹H NMR (400 MHz, CDCl₃) δ 1.25 (d, J=6 Hz, 3H), 3.16 (d, J=4 Hz, 1H), 4.36 (d, J=6 Hz, 2H), 5.14 (dd, J=6 Hz, 3H), 7.23˜7.56 (m, 9H), yield: 19% (1.3 g)

Preparation Example 137

Synthesis of 1-(2-chlorophenyl)-1-hydroxypropyl-2-bicyclo[2,2,1]heptanecarbamate

The substantially same method as described in Preparation Example 105 was conducted, except that 2-aminonorbornane was used instead of ammonia solution (NH₄OH), to obtain the title compound (1.7 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.08˜1.35 (m, 9H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.22˜7.55 (m, 4H)

Preparation Example 138

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-hydroxypropyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-propanediol obtained in Preparation Example 26 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.14 g, yield 34%).

¹H NMR (400 MHz, CDCl₃) δ1.22 (d, J=6.4 Hz, 3H), 4.16 (br t, 1H) 4.96 (br t, 3H), 5.07 (t, J=4.8 Hz, 1H), 7.23˜7.52 (m, 3H)

Preparation Example 139

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-hydroxypropyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-propanediol obtained in Preparation Example 38 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.22 g, yield 49%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),

Preparation Example 140

Synthesis of 1-(2,3-dichlorophenyl)-(S)-1-hydroxypropyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,3-dichlorophenyl)-(S,S)-1,2-propanediol obtained in Preparation Example 57 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.21 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),

Preparation Example 141

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-hydroxybutyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-butanediol obtained in Preparation Example 29 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.23 g, yield 52%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=7.4 Hz, 3H), 1.58˜1.74 (m, 2H), 2.98 (d, J=5.6 Hz, 1H) 4.68 (br s, 2H), 5.59 (dt, J=5.2, 8.8 Hz, 1H), 5.19 (t, J=5.4 Hz, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 142

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-hydroxybutyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-butanediol obtained in Preparation Example 41 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.49 g, yield 34%).

¹H NMR (400 MHz, CDCl₃) δ0.92 (t, J=7.4 Hz, 3H), 1.30˜1.38 (m, 1H), 1.57˜1.64 (m, 1H), 3.74 (d, J=9.2 Hz, 1H), 4.80 (br s, 2H), 5.40˜5.50 (m, 2H), 7.17˜7.34 (m, 3H)

Preparation Example 143

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-(S,S)-1,2-butanediol obtained in Preparation Example 32 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.13 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 144

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-(S,S)-1,2-butanediol obtained in Preparation Example 44 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.12 g, yield 20%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.16˜7.33 (m, 3H)

Preparation Example 145

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-hydroxyhexyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-(S,S)-1,2-hexanediol obtained in Preparation Example 35 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.94 g, yield 81%).

¹H NMR (400 MHz, CDCl₃) δ0.89 (t, J=3.6 Hz, 3H), 1.28˜1.42 (m, 4H), 1.52˜1.59 (m, 1H), 1.64˜1.71 (m, 1H), 2.98 (d, J=5.6 Hz, 1H), 4.67 (br s, 2H), 4.96˜5.00 (m, 1H), 5.17 (t, J=5.6 Hz, 1H), 7.30˜7.49 (m 3H)

Preparation Example 146

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-hydroxyhexyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-(S,S)-1,2-hexanediol obtained in Preparation Example 47 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.15 g, yield 31%).

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 147

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-hydroxypropyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-propanediol obtained in Preparation Example 27 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.14 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.22 (d, J=6.4 Hz, 3H), 4.16 (br t, 1H) 4.96 (br t, 3H), 5.07 (t, J=4.8 Hz, 1H), 7.23˜7.52 (m, 3H)

Preparation Example 148

Synthesis of 1-(2,6-dichlorophenyl)-(R)-1-hydroxypropyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-propanediol obtained in Preparation Example 39 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.21 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),

Preparation Example 149

Synthesis of 1-(2,3-dichlorophenyl)-(R)-1-hydroxypropyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,3-dichlorophenyl)-(R,R)-1,2-propanediol obtained in Preparation Example 58 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.08 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),

Preparation Example 150

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-hydroxybutyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-butanediol obtained in Preparation Example 30 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.23 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=7.4 Hz, 3H), 1.58˜1.74 (m, 2H), 2.98 (d, J=5.6 Hz, 1H) 4.68 (br s, 2H), 5.59 (dt, J=5.2, 8.8 Hz, 1H), 5.19 (t, J=5.4 Hz, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 151

Synthesis of 1-(2,6-dichlorophenyl)-(R)-1-hydroxybutyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-butanediol obtained in Preparation Example 42 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.49 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.92 (t, J=7.4 Hz, 3H), 1.30˜1.38 (m, 1H), 1.57˜1.64 (m, 1H), 3.74 (d, J=9.2 Hz, 1H), 4.80 (br s, 2H), 5.40˜5.50 (m, 2H), 7.17˜7.34 (m, 3H)

Preparation Example 152

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-hydroxy-3-methyl-butyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-(R,R)-1,2-butanediol obtained in Preparation Example 33 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.23 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 153

Synthesis of 1-(2,6-dichlorophenyl)-(R)-1-hydroxy-3-methyl-butyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-(R,R)-1,2-butanediol obtained in Preparation Example 45 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.14 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.16˜7.33 (m, 3H)

Preparation Example 154

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-hydroxyhexyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-(R,R)-1,2-hexanediol obtained in Preparation Example 36 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.84 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.89 (t, J=3.6 Hz, 3H), 1.28˜1.42 (m, 4H), 1.52˜1.59 (m, 1H), 1.64˜1.71 (m, 1H), 2.98 (d, J=5.6 Hz, 1H), 4.67 (br s, 2H), 4.96˜5.00 (m, 1H), 5.17 (t, J=5.6 Hz, 1H), 7.30˜7.49 (m, 3H)

Preparation Example 155

Synthesis of 1-(2,6-dichlorophenyl)-(R)-1-hydroxyhexyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-(R,R)-1,2-hexanediol obtained in Preparation Example 48 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.15 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 156

Synthesis of 1-(2,4-dichlorophenyl)-1-hydroxypropyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-propanediol obtained in Preparation Example 28 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.14 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.22 (d, J=6.4 Hz, 3H), 4.16 (br t, 1H) 4.96 (br t, 3H), 5.07 (t, J=4.8 Hz, 1H), 7.23˜7.52 (m, 3H)

Preparation Example 157

Synthesis of 1-(2,6-dichlorophenyl)-1-hydroxypropyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-propanediol obtained in Preparation Example 40 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.19 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H)

Preparation Example 158

Synthesis of 1-(2,3-dichlorophenyl)-1-hydroxypropyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,3-dichlorophenyl)-1,2-propanediol obtained in Preparation Example 59 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.21 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),

Preparation Example 159

Synthesis of 1-(2,4-dichlorophenyl)-1-hydroxybutyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-butanediol obtained in Preparation Example 31 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.23 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=7.4 Hz, 3H), 1.58˜1.74 (m, 2H), 2.98 (d, J=5.6 Hz, 1H) 4.68 (br s, 2H), 5.59 (dt, J=5.2, 8.8 Hz, 1H), 5.19 (t, J=5.4 Hz, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 160

Synthesis of 1-(2,6-dichlorophenyl)-1-hydroxybutyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-butanediol obtained in Preparation Example 43 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.49 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.92 (t, J=7.4 Hz, 3H), 1.30˜1.38 (m, 1H), 1.57˜1.64 (m, 1H), 3.74 (d, J=9.2 Hz, 1H), 4.80 (br s, 2H), 5.40˜5.50 (m, 2H), 7.17˜7.34 (m, 3H)

Preparation Example 161

Synthesis of 1-(2,4-dichlorophenyl)-1-hydroxy-3-methyl-butyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-3-methyl-1,2-butanediol obtained in Preparation Example 34 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.13 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 162

Synthesis of 1-(2,6-dichlorophenyl)-1-hydroxy-3-methyl-butyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-3-methyl-1,2-butanediol obtained in Preparation Example 46 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.13 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 7.16˜7.33 (m, 3H)

Preparation Example 163

Synthesis of 1-(2,4-dichlorophenyl)-1-hydroxyhexyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,4-dichlorophenyl)-1,2-hexanediol obtained in Preparation Example 37 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.94 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.89 (t, J=3.6 Hz, 3H), 1.28˜1.42 (m, 4H), 1.52˜1.59 (m, 1H), 1.64˜1.71 (m, 1H), 2.98 (d, J=5.6 Hz, 1H), 4.67 (br s, 2H), 4.96˜5.00 (m, 1H), 5.17 (t, J=5.6 Hz, 1H), 7.30˜7.49 (m, 3H)

Preparation Example 164

Synthesis of 1-(2,6-dichlorophenyl)-1-hydroxyhexyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-dichlorophenyl)-1,2-hexanediol obtained in Preparation Example 49 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (0.15 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 7.17˜7.35 (m, 3H)

Preparation Example 165

Synthesis of 1-(2-fluorophenyl)-(S)-1-hydroxypropyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-fluorophenyl)-(S,S)-1,2-propanediol (12.23 g) obtained in Preparation Example 61 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (6.11 g, yield 40%).

¹H NMR (400 MHz, CDCl₃) δ1.19 (d, J=5.2 Hz, 3H), 2.93 (d, J=4.4 Hz, 1H), 4.71 (br s, 2H), 4.99˜5.06 (m, H), 7.04˜7.48 (m, 4H)

Preparation Example 166

Synthesis of 1-(2-fluorophenyl)-(R)-1-hydroxypropyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-fluorophenyl)-(R,R)-1,2-propanediol (6.26 g) obtained in Preparation Example 62 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (3.13 g, yield 40%).

¹H NMR (400 MHz, CDCl₃) δ1.19 (d, J=5.2 Hz, 3H), 2.93 (d, J=4.4 Hz, 1H), 4.71 (br s, 2H), 4.99˜5.06 (m, H), 7.04˜7.48 (m, 4H)

Preparation Example 167

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxypropyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-propanediol obtained in Preparation Example 66 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (2.2 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.27 (d, J=6.4 Hz, 3H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 7.00˜7.76 (m, 4H)

Preparation Example 168

Synthesis of 1-(2-iodophenyl)-(R)-1-hydroxypropyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-iodophenyl)-(R,R)-1,2-propanediol obtained in Preparation Example 67 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (3.13 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.27 (d, J=6.4 Hz, 3H), 2.95 (d, J=3.6 Hz, 1H), 4.73 (br s, 2H), 5.01˜5.11 (m, 2H), 7.01˜7.86 (m, 4H)

Preparation Example 169

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxybutyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol obtained in Preparation Example 68 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (3.6 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.27 (d, J=6.4 Hz, 3H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 7.00˜7.76 (m, 4H)

Preparation Example 170

Synthesis of 1-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Preparation Example 103, to obtain the title compound (0.34 g, yield 10%).

¹H NMR (400 MHz, CDCl₃) δ1.24 (d, J=6.8 Hz, 3H), 2.13 (d, J=4.4 Hz, 1H), 4.12˜4.16 (m, 1H), 4.85 (br s, 2H), 5.98 (d, J=5.6 Hz, 1H), 7.24˜7.43 (m, 4H)

Preparation Example 171

Synthesis of 1-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 2, to obtain the title compound (0.77 g, yield 16%).

¹H NMR (400 MHz, CDCl₃) δ1.24 (d, J=6.4 Hz, 3H), 2.04 (d, J=4.8 Hz, 1H), 4.11˜4.18 (m, 1H), 4.74 (br s, 2H), 6.00 (d, J=5.6 Hz, 1H), 7.24˜7.43 (m, 4H)

Preparation Example 172

Synthesis of 1-(2-chlorophenyl)-2-hydroxypropyl-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 3, to obtain the title compound (0.16 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.24 (d, J=6.4 Hz, 3H), 2.04 (d, J=4.8 Hz, 1H), 4.11˜4.18 (m, 1H), 4.74 (br s, 2H), 6.00 (d, J=5.6 Hz, 1H), 7.24˜7.43 (m, 4H)

Preparation Example 173

Synthesis of 1-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-1-methylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 15, to obtain the title compound (0.70 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.21 (d, J=6.4 Hz, 3H), 2.80 (d, J=4.8 Hz, 3H), 3.12 (s, 1H), 4.09˜4.16 (m, 1H), 4.86 (br s, 1H), 5.99 (d, J=6.0 Hz, 1H), 7.23˜7.40 (m, 4H)

Preparation Example 174

Synthesis of 1-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-1-methylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 22, to obtain the title compound (0.69 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.21 (d, J=6.4 Hz, 3H), 2.80 (d, J=4.8 Hz, 3H), 3.12 (s, 1H), 4.09˜4.16 (m, 1H), 4.86 (br s, 1H), 5.99 (d, J=6.0 Hz, 1H), 7.23˜7.40 (m, 4H)

Preparation Example 175

Synthesis of 1-(2-chlorophenyl)-2-hydroxypropyl-1-methylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 29, to obtain the title compound (0.73 g, yield 10%).

¹H NMR (400 MHz, CDCl₃) δ 1.22 (d, J=6 Hz, 3H), 2.15 (d, J=4 Hz, 1H), 2.81 (d, J=5 Hz, 3H), 4.12 (dd, J=6 Hz, 1H), 4.83 (br s, 1H), 6.00 (d, J=6 Hz, 1H), 7.23˜7.41 (m, 4H)

Preparation Example 176

Synthesis of 1-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-1-propylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 16, to obtain the title compound (0.15 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ 0.91 (t, J=7 Hz, 3H), 1.22 (d, J=6 Hz, 3H), 1.52 (dd, J=7 Hz, 2H), 2.23 (d, J=4 Hz, 1H), 3.09˜3.21 (m, 2H), 4.09˜4.17 (m, 1H), 4.93 (s, 1H), 5.99 (d, J=6 Hz, 1H), 7.23˜7.47 (m, 4H)

Preparation Example 177

Synthesis of 1-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-1-propylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 23, to obtain the title compound (0.04 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ 0.91 (t, J=7 Hz, 3H), 1.22 (d, J=6 Hz, 3H), 1.52 (dd, J=7 Hz, 2H), 2.23 (d, J=4 Hz, 1H), 3.09˜3.21 (m, 2H), 4.09˜4.17 (m, 1H), 4.93 (s, 1H), 5.99 (d, J=6 Hz, 1H), 7.23˜7.47 (m, 4H)

Preparation Example 178

Synthesis of 1-(2-chlorophenyl)-2-hydroxypropyl-1-propylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 30, to obtain the title compound (0.15 g, yield 10%).

¹H NMR (400 MHz, CDCl₃) δ 0.91 (t, J=7 Hz, 3H), 1.22 (d, J=6 Hz, 3H), 1.52 (dd, J=7 Hz, 2H), 2.23 (d, J=4 Hz, 1H), 3.09˜3.21 (m, 2H), 4.09˜4.17 (m, 1H), 4.93 (s, 1H), 5.99 (d, J=6 Hz, 1H), 7.23˜7.47 (m, 4H)

Preparation Example 179

Synthesis of 1-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-1-isopropylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 17, to obtain the title compound (0.42 g, yield 28%).

¹H NMR (400 MHz, CDCl₃) δ1.10 (d, J=6.0 Hz, 3H), 1.15˜1.19 (m, 6H), 2.41 (s, 1H), 3.76˜4.08 (m, 1H), 4.34 (s, 1H), 4.83 (br s 1H), 5.95 (d, J=5.3 Hz, 1H), 7.19˜7.39 (m, 4H)

Preparation Example 180

Synthesis of 1-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-1-isopropylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 24, to obtain the title compound (0.5 g, yield 10%).

¹H NMR (400 MHz, CDCl₃) δ1.13 (d, J=6 Hz, 3H), 1.20 (dd, J=9.2 Hz, 6H), 2.23 (s, 1H), 3.77˜3.82 (m, 1H), 4.10 (s, 1H), 4.76 (br s, 1H), 5.98 (d, J=5.6 Hz, 1H), 7.23˜7.41 (m, 4H)

Preparation Example 181

Synthesis of 1-(2-chlorophenyl)-2-hydroxypropyl-1-isopropylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 31, to obtain the title compound (0.09 g, yield 40%).

¹H NMR (400 MHz, CDCl₃) δ 1.14 (d, J=6 Hz, 3H), 1.21 (dd, J=6 Hz, 6H), 2.16 (d, J=5 Hz, 1H), 3.81 (t, J=6 Hz, 1H), 4.11 (d, J=5 Hz, 1H), 4.73 (br s, 1H), 5.98 (d, J=5 Hz, 1H), 7.24˜7.41 (m, 4H)

Preparation Example 182

Synthesis of 1-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-1-cyclopropylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 18, to obtain the title compound (0.53 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ0.53˜0.60 (m, 2H), 0.74 (s, 2H), 1.21 (d, J=6.0 Hz, 3H), 2.19 (s, 1H), 2.59 (s, 1H), 4.11˜4.15 (m, 1H), 5.13 (br s, 1H), 5.99 (d, J=5.20 Hz, 1H), 7.23˜7.40 (m, 4H)

Preparation Example 183

Synthesis of 1-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-1-cyclopropylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 25, to obtain the title compound (0.58 g, yield 10%).

¹H NMR (400 MHz, CDCl₃) δ0.53˜0.60 (m, 2H), 0.74 (s, 2H), 1.21 (d, J=6.0 Hz, 3H), 2.19 (s, 1H), 2.59 (s, 1H), 4.11˜4.15 (m, 1H), 5.13 (br s, 1H), 5.99 (d, J=5.20 Hz, 1H), 7.23˜7.40 (m, 4H)

Preparation Example 184

Synthesis of 1-(2-chlorophenyl)-2-hydroxypropyl-1-cyclopropylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 32, to obtain the title compound (0.38 g, yield 14%).

¹H NMR (400 MHz, CDCl₃) δ 0.71 (s, 2H), 1.19 (d, J=6 Hz, 3H), 2.45 (S, 1H), 2.57 (S, 1H), 4.08˜4.12 (m, 1H), 5.26 (s, 1H), 5.97 (d, J=4 Hz, 1H), 7.22˜7.54 (m, 4H)

Preparation Example 185

Synthesis of 1-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-1-cyclohexylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 19, to obtain the title compound (0.24 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.10˜1.39 (m, 7H), 1.61 (s, 3H), 1.71˜1.74 (m, 2H), 1.87 (d, J=11.2 Hz, 1H), 2.48 (d, J=10.8 Hz, 1H), 3.46 (t, J=4 Hz, 1H), 4.10˜4.11 (m, 1H), 4.80 (br s 1H), 5.97 (d, J=5.6 Hz, 1H), 7.23˜7.41 (m, 4H)

Preparation Example 186

Synthesis of 1-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-1-cyclohexylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 26, to obtain the title compound (0.35 g, yield 10%).

¹H NMR (400 MHz, CDCl₃) δ1.10˜1.39 (m, 7H), 1.61 (s, 3H), 1.71˜1.74 (m, 2H), 1.87 (d, J=11.2 Hz, 1H), 2.48 (d, J=10.8 Hz, 1H), 3.46 (t, J=4 Hz, 1H), 4.10˜4.11 (m, 1H), 4.80 (br s 1H), 5.97 (d, J=5.6 Hz, 1H), 7.23˜7.41 (m, 4H)

Preparation Example 187

Synthesis of 1-(2-chlorophenyl)-2-hydroxypropyl-1-cyclohexylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 33, to obtain the title compound (0.26 g, yield 10%).

¹H NMR (400 MHz, CDCl₃) δ 1.12˜1.19 (m, 3H), 1.22 (d, J=6 Hz, 3H), 1.27˜1.37 (m, 1H), 1.71 (t, J=6 Hz, 2H), 1.86˜1.88 (m, 1H), 1.97˜2.00 (m, 1H), 2.18 (d, J=4 Hz, 1H), 3.47 (S, 1H), 4.12 (t, J=6 Hz, 1H), 4.78 (S, 1H), 5.97 (d, J=6 Hz, 1H), 7.23˜7.40 (m, 4H)

Preparation Example 188

Synthesis of 1-(2-chlorophenyl)-(S)-2-hydroxypropyl-(S)-1-benzylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 20, to obtain the title compound (0.19 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ 1.23 (d, J=6 Hz, 3H), 2.16 (d, J=4 Hz, 1H), 4.12 (t, J=6 Hz, 1H), 4.31˜4.44 (m, 2H), 5.22 (br S, 1H), 6.04 (d, J=6 Hz, 1H), 7.27˜7.42 (m, 9H)

Preparation Example 189

Synthesis of 1-(2-chlorophenyl)-(R)-2-hydroxypropyl-(R)-1-benzylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 27, to obtain the title compound (0.07 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ 1.23 (d, J=6 Hz, 3H), 2.16 (d, J=4 Hz, 1H), 4.12 (t, J=6 Hz, 1H), 4.31˜4.44 (m, 2H), 5.22 (br S, 1H), 6.04 (d, J=6 Hz, 1H), 7.27˜7.42 (m, 9H)

Preparation Example 190

Synthesis of 1-(2-chlorophenyl)-2-hydroxypropyl-1-benzylcarbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 34, to obtain the title compound (0.21 g, yield 14%).

¹H NMR (400 MHz, CDCl₃) δ 1.23 (d, J=6 Hz, 3H), 2.16 (d, J=4 Hz, 1H), 4.12 (t, J=6 Hz, 1H), 4.31˜4.44 (m, 2H), 5.22 (br S, 1H), 6.04 (d, J=6 Hz, 1H), 7.27˜7.42 (m, 9H)

Preparation Example 191

Synthesis of 1-(2,4-dichlorophenyl)-(S)-2-hydroxypropyl-(S)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 36, to obtain the title compound (0.05 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.30 (d, J=8.4 Hz, 1H), 7.39 (d, J=2.0 Hz, 2H), 7.50 (dd, J=8.4 Hz, 2.0 Hz, 1H)

Preparation Example 192

Synthesis of 1-(2,6-dichlorophenyl)-(S)-2-hydroxypropyl-(S)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 37, to obtain the title compound (0.07 g, yield 24%).

¹H NMR (400 MHz, CDCl₃) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.25˜7.40 (m, 3H)

Preparation Example 193

Synthesis of 1-(2,3-dichlorophenyl)-(S)-2-hydroxypropyl-(S)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 38, to obtain the title compound (0.08 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),

Preparation Example 194

Synthesis of 1-(2,4-dichlorophenyl)-(S)-2-hydroxybutyl-(S)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 39, to obtain the title compound (0.07 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.30˜7.50 (m, 3H)

Preparation Example 195

Synthesis of 1-(2,6-dichlorophenyl)-(S)-2-hydroxybutyl-(S)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 40, to obtain the title compound (0.11 g, yield 29%).

¹H NMR (400 MHz, CDCl₃) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.25˜7.40 (m, 3H)

Preparation Example 196

Synthesis of 1-(2,4-dichlorophenyl)-(S)-2-hydroxy-3-methyl-butyl-(S)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 41, to obtain the title compound (0.01 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.30˜7.50 (m, 3H)

Preparation Example 197

Synthesis of 1-(2,6-dichlorophenyl)-(S)-2-hydroxy-3-methyl-butyl-(S)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 42, to obtain the title compound (0.03 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.25˜7.40 (m, 3H)

Preparation Example 198

Synthesis of 1-(2,4-dichlorophenyl)-(S)-2-hydroxyhexyl-(S)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 43, to obtain the title compound (0.21 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 199

Synthesis of 1-(2,6-dichlorophenyl)-(S)-2-hydroxyhexyl-(S)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 44, to obtain the title compound (0.06 g, yield 29%).

¹H NMR (400 MHz, CDCl₃) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.16˜7.34 (m, 3H)

Preparation Example 200

Synthesis of 1-(2,4-dichlorophenyl)-(R)-2-hydroxypropyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 45, to obtain the title compound (0.04 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 201

Synthesis of 1-(2,6-dichlorophenyl)-(R)-2-hydroxypropyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 46, to obtain the title compound (0.09 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.25˜7.40 (m, 3H)

Preparation Example 202

Synthesis of 1-(2,3-dichlorophenyl)-(R)-2-hydroxypropyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 47, to obtain the title compound (0.25 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),

Preparation Example 203

Synthesis of 1-(2,4-dichlorophenyl)-(R)-2-hydroxybutyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 48, to obtain the title compound (0.08 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.30˜7.50 (m, 3H)

Preparation Example 204

Synthesis of 1-(2,6-dichlorophenyl)-(R)-2-hydroxybutyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 49, to obtain the title compound (0.09 g, yield 10˜30%). ¹H NMR (400 MHz, CDCl₃) 50.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.25˜7.40 (m, 3H)

Preparation Example 205

Synthesis of 1-(2,4-dichlorophenyl)-(R)-2-hydroxy-3-methyl-butyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 50, to obtain the title compound (0.01 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.30˜7.50 (m, 3H)

Preparation Example 206

Synthesis of 1-(2,6-dichlorophenyl)-(R)-2-hydroxy-3-methyl-butyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 51, to obtain the title compound (0.01 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.25˜7.40 (m, 3H)

Preparation Example 207

Synthesis of 1-(2,4-dichlorophenyl)-(R)-2-hydroxyhexyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 52, to obtain the title compound (0.21 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 208

Synthesis of 1-(2,6-dichlorophenyl)-(R)-2-hydroxyhexyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 53, to obtain the title compound (0.12 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.16˜7.34 (m, 3H)

Preparation Example 209

Synthesis of 1-(2,4-dichlorophenyl)-2-hydroxypropyl-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 54, to obtain the title compound (0.05 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 210

Synthesis of 1-(2,6-dichlorophenyl)-2-hydroxypropyl-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 55, to obtain the title compound (0.06 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.13 (d, J=6.8 Hz, 3H), 2.49 (d, J=4.0 Hz, 1H), 4.66˜4.74 (m, 1H), 4.76 (br s, 2H), 6.20 (d, J=8.8 Hz, 1H), 7.25˜7.40 (m, 3H)

Preparation Example 211

Synthesis of 1-(2,3-dichlorophenyl)-(R)-2-hydroxypropyl-(R)-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 56, to obtain the title compound (0.02 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),

Preparation Example 212

Synthesis of 1-(2,4-dichlorophenyl)-2-hydroxybutyl-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 57, to obtain the title compound (0.07 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.30˜7.50 (m, 3H)

Preparation Example 213

Synthesis of 1-(2,6-dichlorophenyl)-2-hydroxybutyl-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 58, to obtain the title compound (0.10 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ0.77 (t, J=7.4 Hz, 3H), 0.92˜1.01 (m, 1H), 1.18˜1.28 (m, 1H), 4.06˜4.13 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.4 (br s, 2H), 7.25˜7.40 (m, 3H)

Preparation Example 214

Synthesis of 1-(2,4-dichlorophenyl)-2-hydroxy-3-methyl-butyl-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 59, to obtain the title compound (0.04 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.30˜7.50 (m, 3H)

Preparation Example 215

Synthesis of 1-(2,6-dichlorophenyl)-2-hydroxy-3-methyl-butyl-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 60, to obtain the title compound (0.01 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.96 (d, J=6.0 Hz, 1H), 5.91 (d, J=8.8 Hz, 1H), 6.42 (br s, 2H), 7.25˜7.40 (m, 3H)

Preparation Example 216

Synthesis of 1-(2,4-dichlorophenyl)-2-hydroxyhexyl-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 61, to obtain the title compound (0.21 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.30˜7.50 (m, 3H)

Preparation Example 217

Synthesis of 1-(2,6-dichlorophenyl)-2-hydroxyhexyl-1-carbamate

A regioisomer of monocarbamate was separated and purified by conducting the silica gel column chromatography as described in Example 62, to obtain the title compound (0.12 g, yield 10˜30%).

¹H NMR (400 MHz, CDCl₃) δ0.85 (t, J=7.2 Hz, 3H), 1.18˜1.33 (m, 4H), 1.48˜1.55 (m, 2H), 2.35 (d, J=4.4 Hz, 1H), 4.45˜4.50 (m, 1H), 4.76 (br s, 2H), 6.21 (d, J=8.4 Hz, 1H), 7.16˜7.34 (m, 3H)

Preparation Example 218

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-carbamate

The substantially same method as described in Example 169 was conducted, except that 1-(2-iodophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 83) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation Example 68), to obtain the title compound (1.92 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (d, J=6.4 Hz, 6H), 2.36˜2.52 (m, 1H), 3.34 (s, 1H), 4.80 (br s 2H), 5.04 (t, J=12.5 Hz, 1H), 5.14 (s, 1H), 7.01˜7.63 (m, 4H)

Preparation Example 219

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxyhexyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-hexanediol obtained in Preparation Example 85 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.68 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 6.96˜7.57 (m, 4H)

Preparation Example 220

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxypropyl-(S)-2-methylcarbamate

The substantially same method as described in Example 117 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.01 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.03˜1.25 (m, 3H), 2.76 (s, 3H), 3.34 (s, 1H), 4.80 (br s 1H), 5.04 (t, J=12.5 Hz, 1H), 5.14 (s, 1H), 7.01˜7.63 (m, 4H)

Preparation Example 221

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxypropyl-(S)-2-propylcarbamate

The substantially same method as described in Example 118 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (0.72 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.20 (d, J=5.96 Hz, 3H), 1.49 (dd, J=14.2 Hz, 2H), 3.11 (d, J=6.28 Hz, 2H), 3.34 (s, 1H), 4.84 (br s, 1H), 5.05 (t, J=5.88 Hz, 1H), 5.14 (s, 1H), 7.02˜7.63 (m, 4H)

Preparation Example 222

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxypropyl-(S)-2-isopropylcarbamate

The substantially same method as described in Example 119 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.08 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (dd, J=6.5 Hz, 6H), 1.19 (d, J=6.4 Hz, 3H), 3.21 (s, 1H), 3.73˜3.82 (m, 1H), 4.59 (br s, 1H), 5.01˜5.07 (m, 1H), 5.14 (t, J=5.8 Hz, 1H), 7.01˜7.65 (m, 4H)

Preparation Example 223

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxypropyl-(S)-2-cyclopropylcarbamate

The substantially same method as described in Example 120 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.02 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.50˜0.56 (m, 2H), 0.74 (d, J=7.21 Hz, 2H), 1.25 (s, 3H), 2.56˜2.61 (m, 1H), 3.72 (s, 1H), 4.98 (br s, 1H), 5.05˜5.11 (m, 1H), 7.16 (s, 1H), 7.03˜7.64 (m, 4H)

Preparation Example 224

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxypropyl-(S)-2-cyclohexyl carbamate

The substantially same method as described in Example 121 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.84 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.06˜1.40 (m, 7H), 1.56˜1.61 (m, 2H), 1.69˜1.71 (m, 2H), 1.87˜1.94 (m, 2H), 3.19 (d, J=4.32 Hz, 1H), 3.45 (s, 1H), 4.64 (br s 1H), 5.02˜5.07 (m, 1H), 5.14 (t, J=6.08 Hz, 1H) 7.02˜7.63 (m, 4H)

Preparation Example 225

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxypropyl-(S)-2-benzyl carbamate

The substantially same method as described in Example 122 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (0.72 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ 1.27 (d, J=10 Hz, 3H), 3.12 (d, J=5 Hz, 1H), 4.37 (d, J=6 Hz, 2H), 5.12˜5.19 (m, 3H), 7.05˜7.66 (m, 9H)

Preparation Example 226

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxypropyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

The substantially same method as described in Example 123 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (0.82 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.08˜1.35 (m, 9H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.02˜7.65 (m, 4H)

Preparation Example 227

Synthesis of 1-(2-fluorophenyl)-(S)-1-hydroxypropyl-(S)-2-methylcarbamate

The substantially same method as described in Example 220 was conducted, except that 1-(2-fluorophenyl)-(S,S)-1,2-propandiol (Preparation example 61) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (1.19 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.03˜1.25 (m, 3H), 2.76 (s, 3H), 3.34 (s, 1H), 4.80 (br s 1H), 5.04 (t, J=12.5 Hz, 1H), 5.14 (s, 1H), 6.90˜7.50 (m, 4H)

Preparation Example 228

Synthesis of 1-(2-fluorophenyl)-(S)-1-hydroxypropyl-(S)-2-propylcarbamate

The substantially same method as described in Example 221 was conducted, except that 1-(2-fluorophenyl)-(S,S)-1,2-propandiol (Preparation example 61) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (0.86 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.20 (d, J=5.96 Hz, 3H), 1.49 (dd, J=14.2 Hz, 2H), 3.11 (d, J=6.28 Hz, 2H), 3.34 (s, 1H), 4.84 (br s, 1H), 5.05 (t, J=5.88 Hz, 1H), 5.14 (s, 1H), 6.99˜7.53 (m, 4H)

Preparation Example 229

Synthesis of 1-(2-fulorophenyl)-(S)-1-hydroxypropyl-(S)-2-isopropylcarbamate

The substantially same method as described in Example 222 was conducted, except that 1-(2-fluorophenyl)-(S,S)-1,2-propandiol (Preparation example 61) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (0.48 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.14 (dd, J=6.5 Hz, 6H), 1.19 (d, J=6.4 Hz, 3H), 3.21 (s, 1H), 3.73˜3.82 (m, 1H), 4.59 (br s, 1H), 5.01˜5.07 (m, 1H), 5.14 (t, J=5.8 Hz, 1H), 7.01˜7.62 (m, 4H)

Preparation Example 230

Synthesis of 1-(2-fluorophenyl)-(S)-1-hydroxypropyl-(S)-2-cyclopropylcarbamate

The substantially same method as described in Example 223 was conducted, except that 1-(2-fluorophenyl)-(S,S)-1,2-propandiol (Preparation example 61) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (0.39 g, yield 20˜50%)

¹H NMR (400 MHz, CDCl₃) δ0.50˜0.56 (m, 2H), 0.74 (d, J=7.21 Hz, 2H), 1.25 (s, 3H), 2.56˜2.61 (m, 1H), 3.72 (s, 1H), 4.98 (br s, 1H), 5.05˜5.11 (m, 1H), 7.16 (s, 1H), 7.01˜7.65 (m, 4H)

Preparation Example 231

Synthesis of 1-(2-fluorophenyl)-(S)-1-hydroxypropyl-(S)-2-cyclohexyl carbamate

The substantially same method as described in Example 225 was conducted, except that 1-(2-fluorophenyl)-(S,S)-1,2-propandiol (Preparation example 61) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (0.54 g, yield 20˜50%)

¹H NMR (400 MHz, CDCl₃) δ1.06˜1.40 (m, 7H), 1.56˜1.61 (m, 2H), 1.69˜1.71 (m, 2H), 1.87˜1.94 (m, 2H), 3.19 (d, J=4.32 Hz, 1H), 3.45 (s, 1H), 4.64 (br s 1H), 5.02˜5.07 (m, 1H), 5.14 (t, J=6.08 Hz, 1H) 7.00˜7.65 (m, 4H)

Preparation Example 232

Synthesis of 1-(2-fluorophenyl)-(S)-1-hydroxypropyl-(S)-2-benzyl carbamate

The substantially same method as described in Example 226 was conducted, except that 1-(2-fluorophenyl)-(S,S)-1,2-propandiol (Preparation example 61) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (0.39 g, yield 20˜50%)

¹H NMR (400 MHz, CDCl₃) δ 1.27 (d, J=10 Hz, 3H), 3.12 (d, J=5 Hz, 1H), 4.37 (d, J=6 Hz, 2H), 5.12˜5.19 (m, 3H), 7.01˜7.67 (m, 9H)

Preparation Example 233

Synthesis of 1-(2-fluorophenyl)-(S)-1-hydroxypropyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

The substantially same method as described in Example 227 was conducted, except that 1-(2-fluorophenyl)-(S,S)-1,2-propandiol (Preparation example 61) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (0.57 g, yield 20˜50%)

¹H NMR (400 MHz, CDCl₃) δ1.08˜1.35 (m, 9H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.01˜7.66 (m, 4H)

Preparation Example 234

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxybutyl-(S)-2-methylcarbamate

The substantially same method as described in Example 117 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (1.81 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (d, J=6.4 Hz, 3H), 1.56 (m, 2H), 2.76 (s, 3H), 3.34 (s, 1H), 4.80 (br s 1H), 5.04 (t, J=12.5 Hz, 1H), 5.14 (s, 1H), 7.01˜7.63 (m, 4H)

Preparation Example 235

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxybutyl-(S)-2-propylcarbamate

The substantially same method as described in Example 118 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (0.92 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.20 (d, J=5.96 Hz, 3H), 1.49 (dd, J=14.2 Hz, 2H), 1.57 (m, 2H), 3.11 (d, J=6.28 Hz, 2H), 3.34 (s, 1H), 4.84 (br s, 1H), 5.05 (t, J=5.88 Hz, 1H), 5.14 (s, 1H), 7.02˜7.63 (m, 4H)

Preparation Example 236

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxybutyl-(S)-2-isopropylcarbamate

The substantially same method as described in Example 119 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.28 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=6.8 Hz, 3H), 1.14 (dd, J=6.5 Hz, 6H), 1.57 (m, 2H), 3.21 (s, 1H), 3.73˜3.82 (m, 1H), 4.59 (br s, 1H), 5.01˜5.07 (m, 1H), 5.14 (t, J=5.8 Hz, 1H), 7.01˜7.65 (m, 4H)

Preparation Example 237

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxybutyl-(S)-2-cyclopropylcarbamate

The substantially same method as described in Example 120 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.51 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.50˜0.56 (m, 2H), 0.74 (d, J=7.21 Hz, 2H), 0.96 (t, J=6.8 Hz, 3H), 1.25 (m, 2H), 2.56˜2.61 (m, 1H), 3.72 (s, 1H), 4.98 (br s, 1H), 5.05˜5.11 (m, 1H), 7.16 (s, 1H), 6.96˜7.57 (m, 4H)

Preparation Example 238

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxybutyl-(S)-2-cyclohexyl carbamate

The substantially same method as described in Example 121 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.92 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=6.8 Hz, 3H), 1.06˜1.40 (m, 7H), 1.56˜1.61 (m, 2H), 1.69˜1.71 (m, 2H), 1.87˜1.94 (m, 2H), 3.19 (d, J=4.32 Hz, 1H), 3.45 (s, 1H), 4.64 (br s 1H), 5.02˜5.07 (m, 1H), 5.14 (t, J=6.08 Hz, 1H) 7.02˜7.63 (m, 4H)

Preparation Example 239

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxybutyl-(S)-2-benzyl carbamate

The substantially same method as described in Example 122 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.52 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ 0.96 (t, J=6.8 Hz, 3H), 1.55˜1.62 (m, 2H), 3.12 (d, J=5 Hz, 1H), 4.37 (d, J=6 Hz, 2H), 5.12˜5.19 (m, 3H), 7.05˜7.66 (m, 9H)

Preparation Example 240

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxybutyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

The substantially same method as described in Example 123 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.08 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=6.8 Hz, 3H), 1.08˜1.35 (m, 6H), 1.55˜1.62 (m, 2H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.02˜7.65 (m, 4H)

Preparation Example 241

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-methylcarbamate

The substantially same method as described in Example 117 was conducted, except that 1-(2-iodophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 83) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (1.92 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (d, J=6.4 Hz, 6H), 2.36˜2.52 (m, 1H), 2.76 (s, 3H), 3.34 (s, 1H), 4.80 (br s 1H), 5.04 (t, J=12.5 Hz, 1H), 5.14 (s, 1H), 7.01˜7.63 (m, 4H)

Preparation Example 242

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-propylcarbamate

The substantially same method as described in Example 118 was conducted, except that 1-(2-iodophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 83) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (1.82 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=6.8 Hz, 3H), 1.10 (d, J=6.4 Hz, 6H), 1.49 (dd, J=14.2 Hz, 2H), 2.38˜2.42 (m, 1H), 3.11 (d, J=6.28 Hz, 2H), 3.34 (s, 1H), 4.84 (br s, 1H), 5.05 (t, J=5.88 Hz, 1H), 5.14 (s, 1H), 7.02˜7.63 (m, 4H)

Preparation Example 243

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-isopropylcarbamate

The substantially same method as described in Example 119 was conducted, except that 1-(2-iodophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 83) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.77 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.01 (d, J=6.8 Hz, 6H), 1.14 (d, J=6.5 Hz, 6H), 2.39˜2.47 (m, 1H), 3.90˜3.98 (m, 1H), 3.73˜3.82 (m, 1H), 4.59 (br s, 1H), 5.01˜5.07 (m, 1H), 5.14 (t, J=5.8 Hz, 1H), 7.01˜7.65 (m, 4H)

Preparation Example 244

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-cyclopropylcarbamate

The substantially same method as described in Example 120 was conducted, except that 1-(2-iodophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 83) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.81 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.50˜0.56 (m, 2H), 0.74 (d, J=7.21 Hz, 2H), 1.01 (d, J=6.8 Hz, 6H), 2.38˜2.44 (m, 1H), 2.56˜2.61 (m, 1H), 3.72 (s, 1H), 4.98 (br s, 1H), 5.05˜5.11 (m, 1H), 7.16 (s, 1H), 6.96˜7.57 (m, 4H)

Preparation Example 245

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-cyclohexyl carbamate

The substantially same method as described in Example 121 was conducted, except that 1-(2-iodophenyl)-3-methyl-(S,S)-1,2-butanediol (Preparation example 83) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.29 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.01 (d, J=6.8 Hz, 6H), 1.11˜1.21 (m, 4H), 1.47˜1.49 (m, 4H), 1.69˜1.71 (m, 2H), 2.38˜2.44 (m, 1H), 3.19 (d, J=4.32 Hz, 1H), 3.45 (s, 1H), 4.64 (br s 1H), 5.02˜5.07 (m, 1H), 5.14 (t, J=6.08 Hz, 1H) 7.02˜7.63 (m, 4H)

Preparation Example 246

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-benzyl carbamate

The substantially same method as described in Example 122 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.91 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ 1.10 (d, J=6.8 Hz, 3H), 2.42 (m, 1H), 3.12 (d, J=5 Hz, 1H), 4.37 (d, J=6 Hz, 2H), 5.12˜5.19 (m, 3H), 7.05˜7.66 (m, 9H)

Preparation Example 247

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

The substantially same method as described in Example 123 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.68 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ1.01 (d, J=6.8 Hz, 6H), 1.08˜1.35 (m, 6H), 1.55˜1.62 (m, 2H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.42 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.02˜7.65 (m, 4H)

Preparation Example 248

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxyhexyl-(S)-2-methylcarbamate

The substantially same method as described in Example 117 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-hexanediol (Preparation example 85) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (1.58 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (t, J=6.4 Hz, 3H), 1.29˜1.33 (m, 4H), 1.53 (m, 2H), 2.76 (s, 3H), 3.34 (s, 1H), 4.80 (br s 1H), 5.04 (t, J=12.5 Hz, 1H), 5.14 (s, 1H), 7.01˜7.63 (m, 4H)

Preparation Example 249

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxyhexyl-(S)-2-propylcarbamate

The substantially same method as described in Example 118 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-hexanediol (Preparation example 85) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-propandiol (Preparation example 66), to obtain the title compound (1.38 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=6.8 Hz, 3H), 0.97 (t, J=6.4 Hz, 3H), 1.29˜1.33 (m, 4H), 1.53 (m, 2H), 1.55˜1.60 (m, 2H), 2.96 (t, J=6.0, 2H), 3.34 (s, 1H), 4.84 (br s, 1H), 5.05 (t, J=5.88 Hz, 1H), 5.14 (s, 1H), 7.02˜7.63 (m, 4H)

Preparation Example 250

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxyhexyl-(S)-2-isopropylcarbamate

The substantially same method as described in Example 119 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-hexanediol (Preparation example 85) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.73 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (t, J=6.4 Hz, 3H), 1.14 (d, J=6.5 Hz, 6H), 1.29˜1.33 (m, 4H), 1.53 (m, 2H), 3.90˜3.98 (m, 1H), 3.73˜3.82 (m, 1H), 4.59 (br s, 1H), 5.01˜5.07 (m, 1H), 5.14 (t, J=5.8 Hz, 1H), 7.01˜7.65 (m, 4H)

Preparation Example 251

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxyhexyl-(S)-2-cyclopropylcarbamate

The substantially same method as described in Example 120 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-hexanediol (Preparation example 85) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.81 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.50˜0.56 (m, 2H), 0.74 (d, J=7.21 Hz, 2H), 0.97 (t, J=6.4 Hz, 3H), 1.29˜1.33 (m, 4H), 1.53 (m, 2H), 2.38˜2.44 (m, 1H), 3.72 (s, 1H), 4.98 (br s, 1H), 5.05˜5.11 (m, 1H), 7.16 (s, 1H), 6.96˜7.57 (m, 4H)

Preparation Example 252

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxyhexyl-(S)-2-cyclohexyl carbamate

The substantially same method as described in Example 121 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-hexanediol (Preparation example 85) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.79 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (t, J=6.4 Hz, 3H), 1.11˜1.21 (m, 4H), 1.29˜1.33 (m, 4H), 1.47˜1.49 (m, 4H), 1.53 (m, 2H), 1.69˜1.71 (m, 2H), 3.19 (d, J=4.32 Hz, 1H), 3.45 (s, 1H), 4.64 (br s 1H), 5.02˜5.07 (m, 1H), 5.14 (t, J=6.08 Hz, 1H) 7.02˜7.63 (m, 4H)

Preparation Example 253

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxyhexyl-(S)-2-benzyl carbamate

The substantially same method as described in Example 122 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-hexanediol (Preparation example 85) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.51 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (t, J=6.4 Hz, 3H), 1.29˜1.33 (m, 4H), 1.53 (m, 2H), 3.12 (d, J=5 Hz, 1H), 4.37 (d, J=6 Hz, 2H), 5.12˜5.19 (m, 3H), 7.05˜7.66 (m, 9H)

Preparation Example 254

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxyhexyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

The substantially same method as described in Example 123 was conducted, except that 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation example 68) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propandiol (Preparation example 14), to obtain the title compound (1.68 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (t, J=6.4 Hz, 3H), 1.08˜1.35 (m, 6H), 1.29˜1.33 (m, 4H), 1.53 (m, 2H), 1.55˜1.62 (m, 2H), 1.65 (br s, 1H), 1.75˜1.71 (m, 1H), 2.14˜2.24 (m, 1H), 2.27˜2.30 (m, 1H), 3.23˜3.29 (m, 1H), 3.47˜3.52 (m, 1H), 4.67 (br s, 1H), 5.01˜5.09 (m, 1H), 5.12˜5.18 (m, 1H), 7.02˜7.65 (m, 4H)

Preparation Example 255

Synthesis of 1-(3-iodophenyl)-(S)-1-hydroxypropyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(3-iodophenyl)-(S,S)-1,2-butanediol obtained in Preparation Example 87 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (2.04 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t. J=7.4 Hz, 3H), 1.53˜1.73 (m, 2H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 6.96˜7.57 (m, 4H)

Preparation Example 256

Synthesis of 1-(3-iodophenyl)-(S)-1-hydroxybutyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(3-iodophenyl)-(S,S)-1,2-butanediol obtained in Preparation Example 89 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.49 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t. J=7.4 Hz, 3H), 1.53˜1.73 (m, 2H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 6.92˜7.51 (m, 4H)

Preparation Example 257

Synthesis of 1-(3-iodophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(3-iodophenyl)-3-methyl-(S,S)-1,2-butanediol obtained in Preparation Example 91 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.82 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ 81.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 6.97˜7.53 (m, 4H)

Preparation Example 258

Synthesis of 1-(3-iodophenyl)-(S)-1-hydroxyhexyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(3-iodophenyl)-(S,S)-1,2-hexanediol obtained in Preparation Example 93 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.92 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 7.01˜7.55 (m, 4H)

Preparation Example 259

Synthesis of 1-(4-fluorophenyl)-(S)-1-hydroxypropyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(4-fluorophenyl)-(S,S)-1,2-propanediol obtained in Preparation Example 95 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.61 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.27 (d, J=6.4 Hz, 3H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 6.89˜7.05 (m, 4H)

Preparation Example 260

Synthesis of 1-(4-fluorophenyl)-(S)-1-hydroxybutyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(4-fluorophenyl)-(S,S)-1,2-butanediol obtained in Preparation Example 97 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.55 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t. J=7.4 Hz, 3H), 1.53˜1.73 (m, 2H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 6.92˜7.09 (m, 4H)

Preparation Example 261

Synthesis of 1-(4-fluorophenyl)-(S)-1-hydroxy-3-methyl-butyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(4-fluorophenyl)-3-methyl-(S,S)-1,2-butanediol obtained in Preparation Example 99 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.97 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ 81.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 6.94˜7.03 (m, 4H)

Preparation Example 262

Synthesis of 1-(4-fluorophenyl)-(S)-1-hydroxyhexyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(4-fluorophenyl)-(S,S)-1,2-hexanediol obtained in Preparation Example 101 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.86 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 6.95˜7.17 (m, 4H)

Preparation Example 263

Synthesis of 1-(2-iodophenyl)-(R)-1-hydroxybutyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-iodophenyl)-(R,R)-1,2-butanediol obtained in Preparation Example 69 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.98 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.27 (d, J=6.4 Hz, 3H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 7.00˜7.76 (m, 4H)

Preparation Example 264

Synthesis of 1-(2-iodophenyl)-(R)-1-hydroxy-3-methyl-butyl-(R)-2-carbamate

The substantially same method as described in Example 169 was conducted, except that 1-(2-iodophenyl)-3-methyl-(R,R)-1,2-butanediol (Preparation example 84) was used instead of 1-(2-iodophenyl)-(S,S)-1,2-butanediol (Preparation Example 68), to obtain the title compound (1.88 g, yield 20˜50%).

¹H NMR (400 MHz, CDCl₃) δ0.97 (d, J=6.4 Hz, 6H), 2.36˜2.52 (m, 1H), 3.34 (s, 1H), 4.80 (br s 2H), 5.04 (t, J=12.5 Hz, 1H), 5.14 (s, 1H), 7.01˜7.63 (m, 4H)

Preparation Example 265

Synthesis of 1-(2-iodophenyl)-(R)-1-hydroxyhexyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-iodophenyl)-(R,R)-1,2-hexanediol obtained in Preparation Example 86 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.68 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 6.99˜7.55 (m, 4H)

Preparation Example 266

Synthesis of 1-(4-fluorophenyl)-(R)-1-hydroxypropyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(4-fluorophenyl)-(R,R)-1,2-propanediol obtained in Preparation Example 96 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.49 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.27 (d, J=6.4 Hz, 3H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 7.00˜7.22 (m, 4H)

Preparation Example 267

Synthesis of 1-(4-fluorophenyl)-(R)-1-hydroxybutyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(4-fluorophenyl)-(R,R)-1,2-butanediol obtained in Preparation Example 98 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (2.25 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t. J=7.4 Hz, 3H), 1.53˜1.73 (m, 2H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 6.92˜7.20 (m, 4H)

Preparation Example 268

Synthesis of 1-(4-fluorophenyl)-(R)-1-hydroxy-3-methyl-butyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(4-fluorophenyl)-3-methyl-(R,R)-1,2-butanediol obtained in Preparation Example 100 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.74 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ 81.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 6.92˜7.20 (m, 4H)

Preparation Example 269

Synthesis of 1-(4-fluorophenyl)-(R)-1-hydroxyhexyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(4-fluorophenyl)-(R,R)-1,2-hexanediol obtained in Preparation Example 102 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.59 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 6.95˜7.21 (m, 4H)

Preparation Example 270

Synthesis of 1-(3-iodophenyl)-(R)-1-hydroxypropyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(3-iodophenyl)-(R,R)-1,2-butanediol obtained in Preparation Example 88 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.54 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t. J=7.4 Hz, 3H), 1.53˜1.73 (m, 2H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 6.96˜7.57 (m, 4H)

Preparation Example 271

Synthesis of 1-(3-iodophenyl)-(R)-1-hydroxybutyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(3-iodophenyl)-(R,R)-1,2-butanediol obtained in Preparation Example 90 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.44 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.96 (t. J=7.4 Hz, 3H), 1.53˜1.73 (m, 2H), 3.09 (br s, 1H), 4.83 (br s, 2H), 5.00˜5.10 (m, 2H), 6.92˜7.51 (m, 4H)

Preparation Example 272

Synthesis of 1-(3-iodophenyl)-(R)-1-hydroxy-3-methyl-butyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(3-iodophenyl)-3-methyl-(R,R)-1,2-butanediol obtained in Preparation Example 92 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.65 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ δ1.00 (t, J=7.2 Hz, 6H), 1.73˜1.79 (m, 1H), 3.67˜3.69 (m, 1H), 4.85 (br s, 2H), 5.40˜5.43 (m, 1H), 5.49˜5.54 (m, 1H), 6.97˜7.53 (m, 4H)

Preparation Example 273

Synthesis of 1-(3-iodophenyl)-(R)-1-hydroxyhexyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(3-iodophenyl)-(R,R)-1,2-hexanediol obtained in Preparation Example 94 was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.71 g, yield 30˜60%).

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.71 (d, J=10.0 Hz, 1H), 4.74 (br s, 2H), 5.40˜5.44 (m, 1H), 5.52˜5.57 (m, 1H), 7.01˜7.55 (m, 4H)

Preparation Example 274

Synthesis of 1-(2,6-difluorophenyl)-trans-1-propene

The substantially same method as described in Preparation Example 1 was conducted, except that 2,6-difluorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (3.4 g, yield 52%).

¹H NMR (400 MHz, CDCl₃) δ1.95 (dd, J=6.8 Hz, 1.6 Hz, 3H), 6.24 (m, 1H), 6.72 (d, J=15.6 Hz, 1H), 7.18˜7.44 (m, 3H)

Preparation Example 275

Synthesis of 1-(2,6-difluorophenyl)-(S,S)-1,2-propanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,6-difluorophenyl)-trans-1-propene (Preparation Example 275) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (1.5 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.18˜7.36 (m, 3H)

Preparation Example 276

Synthesis of 1-(2,6-difluorophenyl)-(S)-1-hydroxypropyl-(S)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,6-difluorophenyl)-1,2-propanediol (Preparation Example 275) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (2.4 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H),

Preparation Example 277

Synthesis of 1-(2,5-dichlorophenyl)-trans-1-propene

The substantially same method as described in Preparation Example 1 was conducted, except that 2,5-dichlorobenzenaldehyde was used instead of 2-chlorobenzenaldehyde, to obtain the title compound (3.1 g, yield 52%).

¹H NMR (400 MHz, CDCl₃) δ1.95 (dd, J=6.8 Hz, 1.6 Hz, 3H), 6.24 (m, 1H), 6.72 (d, J=15.6 Hz, 1H), 7.09˜7.25 (m, 3H)

Preparation Example 278

Synthesis of 1-(2,5-dichlorophenyl)-(S,S)-1,2-propanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 1-(2,5-dichlorophenyl)-trans-1-propene (Preparation Example 277) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (1.9 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.14˜7.26 (m, 3H)

Preparation Example 279

Synthesis of 1-(2,5-dichlorophenyl)-1-hydroxypropyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,5-dichlorophenyl)-1,2-propanediol (Preparation Example 278) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (2.29 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.18˜7.22 (m, 3H)

Preparation Example 280

Synthesis of 1-(2,5-dichlorophenyl)-(R,R)-1,2-propanediol

The substantially same method as described in Preparation Example 15 was conducted, except that 1-(2,5-dichlorophenyl)-trans-1-propene (Preparation Example 277) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (2.3 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ1.10 (d, J=6.4 Hz, 3H), 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 5.24 (t, J=8.8 Hz, 1H), 7.14˜7.26 (m, 3H)

Preparation Example 281

Synthesis of 1-(2,5-dichlorophenyl)-(R)-1-hydroxypropyl-(R)-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2,5-dichlorophenyl)-1,2-propanediol (Preparation Example 278) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (2.25 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ1.15 (d, J=6.4 Hz, 3H), 3.66 (d, J=9.2 Hz, 1H), 4.73 (br s, 2H), 5.43 (t, J=9.0 Hz, 1H), 5.62˜5.69 (m, 1H), 7.13˜7.25 (m, 3H)

Preparation Example 282

Synthesis of 1-(2-chlorophenyl)-1-(S)-1,2-ethanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 2-chlorostyrene (Aldrich No. 160679) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (2.29 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ 2.72 (d, J=2.4 Hz, 1H), 3.10 (d, J=8.4 Hz, 1H), 4.47˜4.54 (m, 1H), 4.91 (t, J=8.8 Hz, 1H), 7.09˜7.26 (m, 4H)

Preparation Example 283

Synthesis of 1-(2-chlorophenyl)-(S)-1-hydroxyethyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-1-(S)-1,2-ethanediol (Preparation Example 282) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.92 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ 1.72 (br s, 1H), 4.26 (dd, J=12.0, 7.8 Hz, 1H), 4.39 (dd, J=12.0, 2.7 Hz, 1H), 4.41 (dd, J=7.8, 2.7 Hz, 1H), 4.77 (br 2H), 7.26˜7.68 (m, 4H)

Preparation Example 284

Synthesis of 2-iodostyrene

The substantially same method as described in Preparation Example 64 was conducted, except that 2-propanone was used instead of 3-pentanone, to obtain the title compound (2.1 g, yield 20˜40%).

¹H NMR (400 MHz, CDCl₃) δ5.34 (dd, J=10.8, 0.8 Hz, 1H), 5.65 (dd, J=17.2, 0.8 Hz, 1H), 6.89˜7.92 (m, 5H)

Preparation Example 285

Synthesis of 1-(2-iodophenyl)-1-(S)-1,2-ethanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 2-iodostyrene (Preparation Example 284) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (2.52 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ 2.07˜2.13 (m, 1H), 3.52˜3.58 (m, 1H), 3.89˜3.94 (m, 1H), 5.04˜5.08 (m, 1H), 7.01˜7.85 (m, 4H)

Preparation Example 286

Synthesis of 1-(2-iodophenyl)-(S)-1-hydroxyethyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-chlorophenyl)-1-(S)-1,2-ethanediol (Preparation Example 282) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.92 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ 1.72 (br s, 1H), 4.26 (dd, J=12.0, 7.8 Hz, 1H), 4.39 (dd, J=12.0, 2.7 Hz, 1H), 4.41 (dd, J=7.8, 2.7 Hz, 1H), 4.77 (br 2H), 7.06˜7.29 (m, 4H)

Preparation Example 287

Synthesis of 2-fluorostyrene

The substantially same method as described in Preparation Example 284 was conducted, except that 2-fluorobenzaldehyde (Aldrich No. F4807) was used instead of 2-iodobenzaldehyde (Preparation Example 63) to obtain the title compound (1.82 g, yield 20˜40%).

¹H NMR (400 MHz, CDCl₃) δ5.34 (dd, J=10.8, 0.8 Hz, 1H), 5.65 (dd, J=17.2, 0.8 Hz, 1H), 6.92˜7.89 (m, 5H)

Preparation Example 285

Synthesis of 1-(2-fluorophenyl)-1-(S)-1,2-ethanediol

The substantially same method as described in Preparation Example 14 was conducted, except that 2-fluorostyrene (Preparation Example 287) was used instead of 1-(2-chlorophenyl)-trans-1-propene (Preparation Example 1), to obtain the title compound (2.32 g, yield 60˜90%).

¹H NMR (400 MHz, CDCl₃) δ 2.07˜2.13 (m, 1H), 3.52˜3.58 (m, 1H), 3.89˜3.94 (m, 1H), 5.04˜5.08 (m, 1H), 6.90˜7.17 (m, 4H)

Preparation Example 286

Synthesis of 1-(2-fluorophenyl)-(S)-1-hydroxyethyl-2-carbamate

The substantially same method as described in Preparation Example 103 was conducted, except that 1-(2-fluorophenyl)-1-(S)-1,2-ethanediol (Preparation Example 285) was used instead of 1-(2-chlorophenyl)-(S,S)-1,2-propanediol, to obtain the title compound (1.59 g, yield 20˜60%).

¹H NMR (400 MHz, CDCl₃) δ 1.72 (br s, 1H), 4.26 (dd, J=12.0, 7.8 Hz, 1H), 4.39 (dd, J=12.0, 2.7 Hz, 1H), 4.41 (dd, J=7.8, 2.7 Hz, 1H), 4.77 (br 2H), 7.01˜7.27 (m, 4H)

Example Scheme I

Synthesis of 1-(n-halophenyl)-1-methoxymethoxyalkyl-2-alkylcarbamate (Examples 1 to 123, 271 to 274 and 276 to 278)

To a stirred solution of 1-(n-halophenyl)-1-hydrorxyalkyl-2-alkylcarbamate in MC(Methylenechloloride) was added DIPEA(Diisopropylethylamine) at 0° C. under N₂ condition. The mixture was added MOM-Cl(MOMchloride) at 0° C. then slowly warm to R.T. When the reaction was completed, the obtained product was washed with H₂O and MC. The separated organic layer was dehydrated with anhydrous MgSO₄(Magnesium sulfate), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silicagel aolumn chromatography, to obtain title compound (Yield 40˜60%)

Example Scheme II

Synthesis of 1-(n-halophenyl)-1-methoxyalkyl-2-alkylcarbamate (Examples 124 to 246, 275 and 279 to 281)

1-(n-halophenyl)-1-hydrorxyalkyl-2-alkylcarbamate, THF(Tetrahydrofuran), MeI(Methyliodide) and t-BuOH(Potassium tert-butoxide) were put into a flask and stirred at the 0° C. When the reaction was completed, the obtained product was washed with 1M HCl solution and EA(Ethylacetate). The separated organic layer was dehydrated with anhydrous MgSO4(Magnesium sulfate), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silicagel aolumn chromatography, to obtain title compound (Yield 20˜40%)

Example scheme III

Synthesis of 1-(n-halophenyl)-1-carbamoyloxyalkyl-2-alkylcarbamate (Examples 247 to 270)

1-(n-halophenyl)-1-hydroxypropyl-1-carbamate, tetrahydrofuran (THF), and carbonyldiimidazole (CDI) were put into a flask and stirred at the room temperature. After approximately 3 hours, ammonia solution (NH₄OH) was added thereto. When the reaction was completed, the obtained product was washed with 1M HCl solution and ethylacetate (EA). The separated organic layer was dehydrated with anhydrous MgSO₄(Magnesium sulfate), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography, to obtain the title compound (yield 75˜95%).

According to the above described methods, the compounds as defined in following Tables 1 and 2 were prepared.

TABLE 1
Carbamate derivetives (B is not a carbamoyl derivative)
Example	X	Position	A	B	R1	R2	Chiral-1	Chiral-2
1	Cl	2	Carbamoyl	MOM	Me	H	S	S
2	Cl	2	Carbamoyl	MOM	Me	Me	S	S
3	Cl	2	Carbamoyl	MOM	Me	Propyl	S	S
4	Cl	2	Carbamoyl	MOM	Me	Isopropyl	S	S
5	Cl	2	Carbamoyl	MOM	Me	Cyclopropyl	S	S
6	Cl	2	Carbamoyl	MOM	Me	Cyclohexyl	S	S
7	Cl	2	Carbamoyl	MOM	Me	Benzyl	S	S
8	Cl	2	Carbamoyl	MOM	Me	Bicycloheptyl	S	S
9	Cl	2	Carbamoyl	MOM	Et	H	S	S
10	Cl	2	Carbamoyl	MOM	Isopropyl	H	S	S
11	Cl	2	Carbamoyl	MOM	Butyl	H	S	S
12	F	2	Carbamoyl	MOM	Me	H	S	S
13	F	2	Carbamoyl	MOM	Me	Me	S	S
14	F	2	Carbamoyl	MOM	Me	Propyl	S	S
15	F	2	Carbamoyl	MOM	Me	Isopropyl	S	S
16	F	2	Carbamoyl	MOM	Me	Cyclopropyl	S	S
17	F	2	Carbamoyl	MOM	Me	Cyclohexyl	S	S
18	F	2	Carbamoyl	MOM	Me	Benzyl	S	S
19	F	2	Carbamoyl	MOM	Me	Bicycloheptyl	S	S
20	I	2	Carbamoyl	MOM	Me	H	S	S
21	I	2	Carbamoyl	MOM	Me	Me	S	S
22	I	2	Carbamoyl	MOM	Me	Propyl	S	S
23	I	2	Carbamoyl	MOM	Me	Isopropyl	S	S
24	I	2	Carbamoyl	MOM	Me	Cyclopropyl	S	S
25	I	2	Carbamoyl	MOM	Me	Cyclohexyl	S	S
26	I	2	Carbamoyl	MOM	Me	Benzyl	S	S
27	I	2	Carbamoyl	MOM	Me	Bicycloheptyl	S	S
28	I	2	Carbamoyl	MOM	Et	H	S	S
29	I	2	Carbamoyl	MOM	Et	Me	S	S
30	I	2	Carbamoyl	MOM	Et	Propyl	S	S
31	I	2	Carbamoyl	MOM	Et	Isopropyl	S	S
32	I	2	Carbamoyl	MOM	Et	Cyclopropyl	S	S
33	I	2	Carbamoyl	MOM	Et	Cyclohexyl	S	S
34	I	2	Carbamoyl	MOM	Et	Benzyl	S	S
35	I	2	Carbamoyl	MOM	Et	Bicycloheptyl	S	S
36	I	2	Carbamoyl	MOM	Isopropyl	H	S	S
37	I	2	Carbamoyl	MOM	Isopropyl	Me	S	S
38	I	2	Carbamoyl	MOM	Isopropyl	Propyl	S	S
39	I	2	Carbamoyl	MOM	Isopropyl	Isopropyl	S	S
40	I	2	Carbamoyl	MOM	Isopropyl	Cyclopropyl	S	S
41	I	2	Carbamoyl	MOM	Isopropyl	Cyclohexyl	S	S
42	I	2	Carbamoyl	MOM	Isopropyl	Benzyl	S	S
43	I	2	Carbamoyl	MOM	Isopropyl	Bicycloheptyl	S	S
44	I	2	Carbamoyl	MOM	Butyl	H	S	S
45	I	2	Carbamoyl	MOM	Butyl	Me	S	S
46	I	2	Carbamoyl	MOM	Butyl	Propyl	S	S
47	I	2	Carbamoyl	MOM	Butyl	Isopropyl	S	S
48	I	2	Carbamoyl	MOM	Butyl	Cuclopropyl	S	S
49	I	2	Carbamoyl	MOM	Butyl	Cyclohexyl	S	S
50	I	2	Carbamoyl	MOM	Butyl	Benzyl	S	S
51	I	2	Carbamoyl	MOM	Butyl	Bicycloheptyl	S	S
52	I	3	Carbamoyl	MOM	Me	H	S	S
53	I	3	Carbamoyl	MOM	Et	H	S	S
54	I	3	Carbamoyl	MOM	Isopropyl	H	S	S
55	I	3	Carbamoyl	MOM	Butyl	H	S	S
56	F	4	Carbamoyl	MOM	Me	H	S	S
57	F	4	Carbamoyl	MOM	Et	H	S	S
58	F	4	Carbamoyl	MOM	Isopropyl	H	S	S
59	F	4	Carbamoyl	MOM	Butyl	H	S	S
60	Cl	2,4	Carbamoyl	MOM	Me	H	S	S
61	Cl	2,4	Carbamoyl	MOM	Et	H	S	S
62	Cl	2,4	Carbamoyl	MOM	Isopropyl	H	S	S
63	Cl	2,4	Carbamoyl	MOM	Butyl	H	S	S
64	Cl	2,6	Carbamoyl	MOM	Me	H	S	S
65	Cl	2,6	Carbamoyl	MOM	Et	H	S	S
66	Cl	2,6	Carbamoyl	MOM	Isopropyl	H	S	S
67	Cl	2,6	Carbamoyl	MOM	Butyl	H	S	S
68	Cl	2,3	Carbamoyl	MOM	Me	H	S	S
69	Cl	2	Carbamoyl	MOM	Me	H	R	R
70	Cl	2	Carbamoyl	MOM	Me	H	rac	rac
71	Cl	2	Carbamoyl	MOM	Me	H	R	S
72	Cl	2	Carbamoyl	MOM	Me	H	S	R
73	Cl	2	Carbamoyl	MOM	Et	H	R	R
74	Cl	2	Carbamoyl	MOM	Et	H	rac	rac
75	Cl	2	Carbamoyl	MOM	Isopropyl	H	R	R
76	Cl	2	Carbamoyl	MOM	Isopropyl	H	rac	rac
77	Cl	2	Carbamoyl	MOM	Butyl	H	R	R
78	Cl	2	Carbamoyl	MOM	Butyl	H	rac	rac
79	Cl	2	Carbamoyl	MOM	Me	Me	R	R
80	Cl	2	Carbamoyl	MOM	Me	Propyl	R	R
81	Cl	2	Carbamoyl	MOM	Me	Isopropyl	R	R
82	Cl	2	Carbamoyl	MOM	Me	Cyclopropyl	R	R
83	Cl	2	Carbamoyl	MOM	Me	Cyclohexyl	R	R
84	Cl	2	Carbamoyl	MOM	Me	Benzyl	R	R
85	Cl	2	Carbamoyl	MOM	Me	Bicycloheptyl	R	R
86	F	2	Carbamoyl	MOM	Me	H	R	R
87	F	4	Carbamoyl	MOM	Me	H	R	R
88	F	4	Carbamoyl	MOM	Et	H	R	R
89	F	4	Carbamoyl	MOM	Isopropyl	H	R	R
90	F	4	Carbamoyl	MOM	Butyl	H	R	R
91	I	2	Carbamoyl	MOM	Me	H	R	R
92	I	2	Carbamoyl	MOM	Et	H	R	R
93	I	2	Carbamoyl	MOM	Isopropyl	H	R	R
94	I	2	Carbamoyl	MOM	Butyl	H	R	R
95	I	3	Carbamoyl	MOM	Me	H	R	R
96	I	3	Carbamoyl	MOM	Et	H	R	R
97	I	3	Carbamoyl	MOM	Isopropyl	H	R	R
98	I	3	Carbamoyl	MOM	Butyl	H	R	R
99	Cl	2	Carbamoyl	MOM	Me	Me	rac	rac
100	Cl	2	Carbamoyl	MOM	Me	Propyl	rac	rac
101	Cl	2	Carbamoyl	MOM	Me	Isopropyl	rac	rac
102	Cl	2	Carbamoyl	MOM	Me	Cyclopropyl	rac	rac
103	Cl	2	Carbamoyl	MOM	Me	Cyclohexyl	rac	rac
104	Cl	2	Carbamoyl	MOM	Me	Benzyl	rac	rac
105	Cl	2	Carbamoyl	MOM	Me	Bicycloheptyl	rac	rac
106	Cl	2,4	Carbamoyl	MOM	Me	H	R	R
107	Cl	2,6	Carbamoyl	MOM	Me	H	R	R
108	Cl	2,3	Carbamoyl	MOM	Me	H	R	R
109	Cl	2,4	Carbamoyl	MOM	Et	H	R	R
110	Cl	2,6	Carbamoyl	MOM	Et	H	R	R
111	Cl	2,4	Carbamoyl	MOM	Isopropyl	H	R	R
112	Cl	2,6	Carbamoyl	MOM	Isopropyl	H	R	R
113	Cl	2,4	Carbamoyl	MOM	Butyl	H	R	R
114	Cl	2,6	Carbamoyl	MOM	Butyl	H	R	R
115	Cl	2,4	Carbamoyl	MOM	Me	H	rac	rac
116	Cl	2,6	Carbamoyl	MOM	Me	H	rac	rac
117	Cl	2,3	Carbamoyl	MOM	Me	H	rac	rac
118	Cl	2,4	Carbamoyl	MOM	Et	H	rac	rac
119	Cl	2,6	Carbamoyl	MOM	Et	H	rac	rac
120	Cl	2,4	Carbamoyl	MOM	Isopropyl	H	rac	rac
121	Cl	2,6	Carbamoyl	MOM	Isopropyl	H	rac	rac
122	Cl	2,4	Carbamoyl	MOM	Butyl	H	rac	rac
123	Cl	2,6	Carbamoyl	MOM	Butyl	H	rac	rac
124	Cl	2	Carbamoyl	Methyl	Me	H	S	S
125	Cl	2	Carbamoyl	Methyl	Me	Me	S	S
126	Cl	2	Carbamoyl	Methyl	Me	Propyl	S	S
127	Cl	2	Carbamoyl	Methyl	Me	Isopropyl	S	S
128	Cl	2	Carbamoyl	Methyl	Me	Cuclopropyl	S	S
129	Cl	2	Carbamoyl	Methyl	Me	Cyclohexyl	S	S
130	Cl	2	Carbamoyl	Methyl	Me	Benzyl	S	S
131	Cl	2	Carbamoyl	Methyl	Me	Bicycloheptyl	S	S
132	Cl	2	Carbamoyl	Methyl	Et	H	S	S
133	Cl	2	Carbamoyl	Methyl	Isopropyl	H	S	S
134	Cl	2	Carbamoyl	Methyl	Butyl	H	S	S
135	F	2	Carbamoyl	Methyl	Me	H	S	S
136	F	2	Carbamoyl	Methyl	Me	Me	S	S
137	F	2	Carbamoyl	Methyl	Me	Propyl	S	S
138	F	2	Carbamoyl	Methyl	Me	Isopropyl	S	S
139	F	2	Carbamoyl	Methyl	Me	Cuclopropyl	S	S
140	F	2	Carbamoyl	Methyl	Me	Cyclohexyl	S	S
141	F	2	Carbamoyl	Methyl	Me	Benzyl	S	S
142	F	2	Carbamoyl	Methyl	Me	Bicycloheptyl	S	S
143	I	2	Carbamoyl	Methyl	Me	H	S	S
144	I	2	Carbamoyl	Methyl	Me	Me	S	S
145	I	2	Carbamoyl	Methyl	Me	Propyl	S	S
146	I	2	Carbamoyl	Methyl	Me	Isopropyl	S	S
147	I	2	Carbamoyl	Methyl	Me	Cuclopropyl	S	S
148	I	2	Carbamoyl	Methyl	Me	Cyclohexyl	S	S
149	I	2	Carbamoyl	Methyl	Me	Benzyl	S	S
150	I	2	Carbamoyl	Methyl	Me	Bicycloheptyl	S	S
151	I	2	Carbamoyl	Methyl	Et	H	S	S
152	I	2	Carbamoyl	Methyl	Et	Me	S	S
153	I	2	Carbamoyl	Methyl	Et	Propyl	S	S
154	I	2	Carbamoyl	Methyl	Et	Isopropyl	S	S
155	I	2	Carbamoyl	Methyl	Et	Cyclopropyl	S	S
156	I	2	Carbamoyl	Methyl	Et	Cyclohexyl	S	S
157	I	2	Carbamoyl	Methyl	Et	Benzyl	S	S
158	I	2	Carbamoyl	Methyl	Et	Bicycloheptyl	S	S
159	I	2	Carbamoyl	Methyl	Isopropyl	H	S	S
160	I	2	Carbamoyl	Methyl	Isopropyl	Me	S	S
161	I	2	Carbamoyl	Methyl	Isopropyl	Propyl	S	S
162	I	2	Carbamoyl	Methyl	Isopropyl	Isopropyl	S	S
163	I	2	Carbamoyl	Methyl	Isopropyl	Cyclopropyl	S	S
164	I	2	Carbamoyl	Methyl	Isopropyl	Cyclohexyl	S	S
165	I	2	Carbamoyl	Methyl	Isopropyl	Benzyl	S	S
166	I	2	Carbamoyl	Methyl	Isopropyl	Bicycloheptyl	S	S
167	I	2	Carbamoyl	Methyl	Butyl	H	S	S
168	I	2	Carbamoyl	Methyl	Butyl	Me	S	S
169	I	2	Carbamoyl	Methyl	Butyl	Propyl	S	S
170	I	2	Carbamoyl	Methyl	Butyl	Isopropyl	S	S
171	I	2	Carbamoyl	Methyl	Butyl	Cuclopropyl	S	S
172	I	2	Carbamoyl	Methyl	Butyl	Cyclohexyl	S	S
173	I	2	Carbamoyl	Methyl	Butyl	Benzyl	S	S
174	I	2	Carbamoyl	Methyl	Butyl	Bicycloheptyl	S	S
175	I	3	Carbamoyl	Methyl	Me	H	S	S
176	I	3	Carbamoyl	Methyl	Et	H	S	S
177	I	3	Carbamoyl	Methyl	Isopropyl	H	S	S
178	I	3	Carbamoyl	Methyl	Butyl	H	S	S
179	F	4	Carbamoyl	Methyl	Me	H	S	S
180	F	4	Carbamoyl	Methyl	Et	H	S	S
181	F	4	Carbamoyl	Methyl	Isopropyl	H	S	S
182	F	4	Carbamoyl	Methyl	Butyl	H	S	S
183	Cl	2,4	Carbamoyl	Methyl	Me	H	S	S
184	Cl	2,4	Carbamoyl	Methyl	Et	H	S	S
185	Cl	2,4	Carbamoyl	Methyl	Isopropyl	H	S	S
186	Cl	2,4	Carbamoyl	Methyl	Butyl	H	S	S
187	Cl	2,6	Carbamoyl	Methyl	Me	H	S	S
188	Cl	2,6	Carbamoyl	Methyl	Et	H	S	S
189	Cl	2,6	Carbamoyl	Methyl	Isopropyl	H	S	S
190	Cl	2,6	Carbamoyl	Methyl	Butyl	H	S	S
191	Cl	2,3	Carbamoyl	Methyl	Me	H	S	S
192	Cl	2	Carbamoyl	Methyl	Me	H	R	R
193	Cl	2	Carbamoyl	Methyl	Me	H	rac	rac
194	Cl	2	Carbamoyl	Methyl	Me	H	R	S
195	Cl	2	Carbamoyl	Methyl	Me	H	S	R
196	Cl	2	Carbamoyl	Methyl	Et	H	R	R
197	Cl	2	Carbamoyl	Methyl	Et	H	rac	rac
198	Cl	2	Carbamoyl	Methyl	Isopropyl	H	R	R
199	Cl	2	Carbamoyl	Methyl	Isopropyl	H	rac	rac
200	Cl	2	Carbamoyl	Methyl	Butyl	H	R	R
201	Cl	2	Carbamoyl	Methyl	Butyl	H	rac	rac
202	Cl	2	Carbamoyl	Methyl	Me	Me	R	R
203	Cl	2	Carbamoyl	Methyl	Me	Propyl	R	R
204	Cl	2	Carbamoyl	Methyl	Me	Isopropyl	R	R
205	Cl	2	Carbamoyl	Methyl	Me	Cyclopropyl	R	R
206	Cl	2	Carbamoyl	Methyl	Me	Cyclohexyl	R	R
207	Cl	2	Carbamoyl	Methyl	Me	Benzyl	R	R
208	Cl	2	Carbamoyl	Methyl	Me	Bicycloheptyl	R	R
209	F	2	Carbamoyl	Methyl	Me	H	R	R
210	F	4	Carbamoyl	Methyl	Me	H	R	R
211	F	4	Carbamoyl	Methyl	Et	H	R	R
212	F	4	Carbamoyl	Methyl	Isopropyl	H	R	R
213	F	4	Carbamoyl	Methyl	Butyl	H	R	R
214	I	2	Carbamoyl	Methyl	Me	H	R	R
215	I	2	Carbamoyl	Methyl	Et	H	R	R
216	I	2	Carbamoyl	Methyl	Isopropyl	H	R	R
217	I	2	Carbamoyl	Methyl	Butyl	H	R	R
218	I	3	Carbamoyl	Methyl	Me	H	R	R
219	I	3	Carbamoyl	Methyl	Et	H	R	R
220	I	3	Carbamoyl	Methyl	Isopropyl	H	R	R
221	I	3	Carbamoyl	Methyl	Butyl	H	R	R
222	Cl	2	Carbamoyl	Methyl	Me	Me	rac	rac
223	Cl	2	Carbamoyl	Methyl	Me	Propyl	rac	rac
224	Cl	2	Carbamoyl	Methyl	Me	Isopropyl	rac	rac
225	Cl	2	Carbamoyl	Methyl	Me	Cyclopropyl	rac	rac
226	Cl	2	Carbamoyl	Methyl	Me	Cyclohexyl	rac	rac
227	Cl	2	Carbamoyl	Methyl	Me	Benzyl	rac	rac
228	Cl	2	Carbamoyl	Methyl	Me	Bicycloheptyl	rac	rac
229	Cl	2,4	Carbamoyl	Methyl	Me	H	R	R
230	Cl	2,6	Carbamoyl	Methyl	Me	H	R	R
231	Cl	2,3	Carbamoyl	Methyl	Me	H	R	R
232	Cl	2,4	Carbamoyl	Methyl	Et	H	R	R
233	Cl	2,6	Carbamoyl	Methyl	Et	H	R	R
234	Cl	2,4	Carbamoyl	Methyl	Isopropyl	H	R	R
235	Cl	2,6	Carbamoyl	Methyl	Isopropyl	H	R	R
236	Cl	2,4	Carbamoyl	Methyl	Butyl	H	R	R
237	Cl	2,6	Carbamoyl	Methyl	Butyl	H	R	R
238	Cl	2,4	Carbamoyl	Methyl	Me	H	rac	rac
239	Cl	2,6	Carbamoyl	Methyl	Me	H	rac	rac
240	Cl	2,3	Carbamoyl	Methyl	Me	H	rac	rac
241	Cl	2,4	Carbamoyl	Methyl	Et	H	rac	rac
242	Cl	2,6	Carbamoyl	Methyl	Et	H	rac	rac
243	Cl	2,4	Carbamoyl	Methyl	Isopropyl	H	rac	rac
244	Cl	2,6	Carbamoyl	Methyl	Isopropyl	H	rac	rac
245	Cl	2,4	Carbamoyl	Methyl	Butyl	H	rac	rac
246	Cl	2,6	Carbamoyl	Methyl	Butyl	H	rac	rac
271	F	2,6	Carbamoyl	MOM	Me	H	S	S
272	Cl	2,5	Carbamoyl	MOM	Me	H	S	S
273	Cl	2,5	Carbamoyl	MOM	Me	H	R	R
276	Cl	2	Carbamoyl	MOM	H	H	S	S
277	F	2	Carbamoyl	MOM	H	H	S	S
278	I	2	Carbamoyl	MOM	H	H	S	S
279	Cl	2	Carbamoyl	Methyl	H	H	S	S
280	F	2	Carbamoyl	Methyl	H	H	S	S
281	I	2	Carbamoyl	Methyl	H	H	S	S

TABLE 2
Carbamate derivertives (B is a carbamoyl derivative)
				B
Example	X	Position	A	—	R3	R1	R2	Chiral-1	Chiral-2
247	Cl	2	Carbamoyl	Carbamoyl	H	Me	H	S	S
248	Cl	2	Carbamoyl	Carbamoyl	H	Me	Me	S	S
249	Cl	2	Carbamoyl	Carbamoyl	H	Me	Propyl	S	S
250	Cl	2	Carbamoyl	Carbamoyl	H	Me	H	R	R
251	Cl	2	Carbamoyl	Carbamoyl	H	Me	H	rac	rac
252	Cl	2	Carbamoyl	Carbamoyl	H	Et	H	S	S
253	Cl	2	Carbamoyl	Carbamoyl	H	Isopropyl	H	S	S
254	Cl	2	Carbamoyl	Carbamoyl	H	Butyl	H	S	S
255	F	2	Carbamoyl	Carbamoyl	H	Me	H	S	S
256	F	2	Carbamoyl	Carbamoyl	H	Et	H	S	S
257	F	2	Carbamoyl	Carbamoyl	H	Isopropyl	H	S	S
258	F	2	Carbamoyl	Carbamoyl	H	Butyl	H	S	S
259	I	2	Carbamoyl	Carbamoyl	H	Me	H	S	S
260	I	2	Carbamoyl	Carbamoyl	H	Et	H	S	S
261	I	2	Carbamoyl	Carbamoyl	H	Isopropyl	H	S	S
262	I	2	Carbamoyl	Carbamoyl	H	Butyl	H	S	S
263	Cl	2,4	Carbamoyl	Carbamoyl	H	Me	H	S	S
264	Cl	2,4	Carbamoyl	Carbamoyl	H	Et	H	S	S
265	Cl	2,4	Carbamoyl	Carbamoyl	H	Isopropyl	H	S	S
266	Cl	2,4	Carbamoyl	Carbamoyl	H	Butyl	H	S	S
267	Cl	2,4	Carbamoyl	Carbamoyl	H	Me	H	S	S
268	Cl	2,4	Carbamoyl	Carbamoyl	H	Et	H	S	S
269	Cl	2,4	Carbamoyl	Carbamoyl	H	Isopropyl	H	S	S
270	Cl	2,4	Carbamoyl	Carbamoyl	H	Butyl	H	S	S
274	Cl	2	MOM	Carbamoyl	H	Me	H	S	S
275	Cl	2	Methyl	Carbamoyl	H	Me	H	S	S

Example 1

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-carbamate

To a stirred solution of 1-(2-chlorophenyl)-1-hydrorxyalkyl-2-carbamate (Preparation Example 103, 1.7 g) in MC(Methylenechloloride) was added DIPEA(Diisopropylethylamine, 5 eq, 5.1 ml) at WC under N₂ condition. The mixture was added MOM-Cl(MOMchloride, 5 eq, 2.3 ml) at WC then slowly warm to R.T. When the reaction was completed, the obtained product was washed with H₂O and MC. The separated organic layer was dehydrated with anhydrous MgSO₄(Magnesium sulfate), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silicagel aolumn chromatography, to obtain title compound.

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

According to the method described in Example 1, the following compounds of Examples 2 to 123 were prepared:

Example 2

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 2.58 (s, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 3

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.37 (d, J=6.8 Hz, 3H), 1.60 (m, 2H), 3.18 (t, J=7.1 Hz, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 4

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ, 1.27 (d, J=6.8 Hz, 6H), 1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 5

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.37 (d, J=6.8 Hz, 3H), 2.75 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 6

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.11˜1.21 (m, 4H), 1.37 (d, J=6.8 Hz, 3H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 3.30 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 7

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 8

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.33˜1.58 (m, 9H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.30 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 9

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 10

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 11

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 12

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.68 (m, 4H)

Example 13

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 2.58 (s, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.68 (m, 4H)

Example 14

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.37 (d, J=6.8 Hz, 3H), 1.60 (m, 2H), 3.18 (t, J=7.1 Hz, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.68 (m, 4H)

Example 15

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ, 1.27 (d, J=6.8 Hz, 6H), 1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.69 (m, 4H)

Example 16

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.37 (d, J=6.8 Hz, 3H), 2.75 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.16˜7.70 (m, 4H)

Example 17

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.11˜1.21 (m, 4H), 1.37 (d, J=6.8 Hz, 3H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 3.30 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.66 (m, 4H)

Example 18

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.68 (m, 4H), 7.72˜7.88 (m, 5H)

Example 19

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.33˜1.58 (m, 9H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.30 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.68 (m, 4H), 7.37˜7.88 (m, 5H)

Example 20

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.88 (m, 4H)

Example 21

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 2.58 (s, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.898 (m, 4H)

Example 22

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.37 (d, J=6.8 Hz, 3H), 1.60 (m, 2H), 3.18 (t, J=7.1 Hz, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.14˜7.87 (m, 4H)

Example 23

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ, 1.27 (d, J=6.8 Hz, 6H), 1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.89 (m, 4H)

Example 24

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.37 (d, J=6.8 Hz, 3H), 2.75 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.16˜7.87 (m, 4H)

Example 25

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.11˜1.21 (m, 4H), 1.37 (d, J=6.8 Hz, 3H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 3.30 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.18˜7.91 (m, 4H)

Example 26

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.68 (m, 4H), 7.72˜7.88 (m, 5H)

Example 27

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.33˜1.58 (m, 9H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.30 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.68 (m, 4H), 7.37˜7.88 (m, 5H)

Example 28

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 29

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.58 (s, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.88 (m, 4H)

Example 30

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.04 (t, J=7.6 Hz, 3H), 1.58˜1.71 (m, 4H), 3.18 (t, J=7.1 Hz, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.14˜7.89 (m, 4H)

Example 31

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.27 (d, J=6.8 Hz, 6H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.90 (m, 4H)

Example 32

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.75 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.16˜7.90 (m, 4H)

Example 33

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.11˜1.21 (m, 4H), 1.47˜1.49 (m, 4H), 1.60˜1.71 (m, 2H), 1.74 (m, 2H), 3.30 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.14˜7.87 (m, 4H)

Example 34

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.14˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 35

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.33˜1.58 (m, 6H), 1.60˜1.71 (m, 2H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.30 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 36

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (d, J=7.6 Hz, 3H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 37

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (d, J=7.6 Hz, 6H), 1.60˜1.71 (m, 1H), 2.58 (s, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.88 (m, 4H)

Example 38

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.04 (d, J=7.6 Hz, 6H), 1.58˜1.71 (m, 5H), 3.18 (t, J=7.1 Hz, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.14˜7.89 (m, 4H)

Example 39

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 6H), 1.27 (d, J=6.8 Hz, 6H), 1.60˜1.71 (m, 1H), 3.30 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.90 (m, 4H)

Example 40

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.04 (d, J=7.6 Hz, 6H), 1.60˜1.71 (m, 1H), 2.75 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.16˜7.90 (m, 4H)

Example 41

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (d, J=7.6 Hz, 6H), 1.11˜1.21 (m, 4H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 1.84˜1.90 (m, 1H), 3.30 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.14˜7.87 (m, 4H)

Example 42

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (d, J=7.6 Hz, 6H), 1.87˜1.90 (m, 1H), 3.30 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.14˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 43

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (d, J=7.6 Hz, 6H), 1.33˜1.58 (m, 6H), 1.75˜1.88 (m, 2H), 1.88˜1.93 (m, 1H), 2.06˜2.13 (m, 2H), 3.30 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 44

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.30 (s, 3H), 4.47 (br s, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 45

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.89 (t, J=7.2 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 2.58 (s, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.88 (m, 4H)

Example 46

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.87 (t, J=6.8 Hz, 3H), 0.90 (t, J=6.8 Hz, 3H), 1.21˜1.35 (m, 4H), 1.36˜1.40 (m, 1H), 1.58˜1.62 (m, 1H), 3.18 (t, J=7.1 Hz, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.14˜7.89 (m, 4H)

Example 47

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.6 Hz, 3H), 1.22˜1.35 (m, 4H), 1.27 (d, J=6.8 Hz, 6H), 1.36˜1.40 (m, 1H), 1.58˜1.62 (m, 1H), 3.30 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.90 (m, 4H)

Example 48

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 0.88 (t, J=7.6 Hz, 3H), 1.22˜1.35 (m, 4H), 1.36˜1.40 (m, 1H), 1.58˜1.62 (m, 1H), 2.75 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.16˜7.90 (m, 4H)

Example 49

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.98 (t, J=7.6 Hz, 3H), 1.11˜1.21 (m, 4H), 1.26˜1.33 (m, 4H), 1.47˜1.49 (m, 2H), 1.52˜1.54 (m, 2H), 1.74 (m, 2H), 1.84˜1.90 (m, 1H), 3.30 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.14˜7.87 (m, 4H)

Example 50

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.94 (t, J=7.6 Hz, 3H), 1.26˜1.33 (m, 4H), 1.51˜1.55 (m, 2H), 3.30 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.14˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 51

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ0.97 (t, J=7.0 Hz, 3H), 1.25˜1.32 (m, 4H), 1.33˜1.58 (m, 8H), 1.60˜1.71 (m, 2H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.30 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 52

Synthesis of 1-(3-iodophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.16 (d, J=6.4 Hz, 3H), 3.39 (s, 3H), 4.54˜4.63 (m, 6H), 5.04˜5.10 (m, 1H), 7.09˜7.73 (m, 4H)

Example 53

Synthesis of 1-(3-iodophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 6.96˜7.57 (m, 4H)

Example 54

Synthesis of 1-(3-iodophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.00˜7.58 (m, 4H)

Example 55

Synthesis of 1-(3-iodophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.01˜7.59 (m, 4H)

Example 56

Synthesis of 1-(4-fluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 6.96˜7.17 (m, 4H)

Example 57

Synthesis of 1-(4-fluorophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 6.90˜7.20 (m, 4H)

Example 58

Synthesis of 1-(4-fluorophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 6.92˜7.17 (m, 4H)

Example 59

Synthesis of 1-(4-fluorophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 6.96˜7.19 (m, 4H)

Example 60

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 61

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 62

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 63

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 64

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.57˜7.58 (m, 3H)

Example 65

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-methoxymethoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.54˜7.57 (m, 3H)

Example 66

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-methoxymethoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.55˜7.57 (m, 3H)

Example 67

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-methoxymethoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.54˜7.59 (m, 3H)

Example 68

Synthesis of 1-(2,3-dichlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.01˜7.14 (m, 3H)

Example 69

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 70

Synthesis of 1-(2-chlorophenyl)-1-methoxymethoxypropyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 71

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 72

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 73

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 74

Synthesis of 1-(2-chlorophenyl)-1-methoxymethoxybutyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 75

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 76

Synthesis of 1-(2-chlorophenyl)-1-methoxymethoxy-3-methyl-butyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 77

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 78

Synthesis of 1-(2-chlorophenyl)-1-methoxymethoxyhexyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 79

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 2.58 (s, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 80

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.37 (d, J=6.8 Hz, 3H), 1.60 (m, 2H), 3.18 (t, J=7.1 Hz, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 81

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ, 1.27 (d, J=6.8 Hz, 6H), 1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 82

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.37 (d, J=6.8 Hz, 3H), 2.75 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 83

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.11˜1.21 (m, 4H), 1.37 (d, J=6.8 Hz, 3H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 3.30 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 84

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 85

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.33˜1.58 (m, 9H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.30 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 86

Synthesis of 1-(2-fluorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.68 (m, 4H)

Example 87

Synthesis of 1-(4-fluorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 6.96˜7.17 (m, 4H)

Example 88

Synthesis of 1-(4-fluorophenyl)-(R)-1-methoxymethoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 6.90˜7.20 (m, 4H)

Example 89

Synthesis of 1-(4-fluorophenyl)-(R)-1-methoxymethoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 6.92˜7.17 (m, 4H)

Example 90

Synthesis of 1-(4-fluorophenyl)-(R)-1-methoxymethoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 6.96˜7.19 (m, 4H)

Example 91

Synthesis of 1-(2-iodophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.88 (m, 4H)

Example 92

Synthesis of 1-(2-iodophenyl)-(R)-1-methoxymethoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 93

Synthesis of 1-(2-iodophenyl)-(R)-1-methoxymethoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (d, J=7.6 Hz, 3H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 94

Synthesis of 1-(2-iodophenyl)-(R)-1-methoxymethoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.30 (s, 3H), 4.47 (br s, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 95

Synthesis of 1-(3-iodophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.16 (d, J=6.4 Hz, 3H), 3.39 (s, 3H), 4.54˜4.63 (m, 6H), 5.04˜5.10 (m, 1H), 7.09˜7.73 (m, 4H)

Example 96

Synthesis of 1-(3-iodophenyl)-(R)-1-methoxymethoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 97

Synthesis of 1-(3-iodophenyl)-(R)-1-methoxymethoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (d, J=7.6 Hz, 3H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 98

Synthesis of 1-(3-iodophenyl)-(R)-1-methoxymethoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.30 (s, 3H), 4.47 (br s, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 99

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 2.58 (s, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 100

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.37 (d, J=6.8 Hz, 3H), 1.60 (m, 2H), 3.18 (t, J=7.1 Hz, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 101

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ, 1.27 (d, J=6.8 Hz, 6H), 1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 102

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.37 (d, J=6.8 Hz, 3H), 2.75 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 103

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.11˜1.21 (m, 4H), 1.37 (d, J=6.8 Hz, 3H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 3.30 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 104

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 105

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.33˜1.58 (m, 9H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.30 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 106

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 107

Synthesis of 1-(2,6-dichlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.57˜7.58 (m, 3H)

Example 108

Synthesis of 1-(2,3-dichlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.01˜7.14 (m, 3H)

Example 109

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-methoxymethoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 110

Synthesis of 1-(2,6-dichlorophenyl)-(R)-1-methoxymethoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.54˜7.57 (m, 3H)

Example 111

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-methoxymethoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 112

Synthesis of 1-(2,6-dichlorophenyl)-(R)-1-methoxymethoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.55˜7.57 (m, 3H)

Example 113

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-methoxymethoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 114

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-methoxymethoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.54˜7.59 (m, 3H)

Example 115

Synthesis of 1-(2,4-dichlorophenyl)-1-methoxymethoxypropyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 116

Synthesis of 1-(2,6-dichlorophenyl)-1-methoxymethoxypropyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.57˜7.58 (m, 3H)

Example 117

Synthesis of 1-(2,3-dichlorophenyl)-1-methoxymethoxypropyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.01˜7.14 (m, 3H)

Example 118

Synthesis of 1-(2,4-dichlorophenyl)-1-methoxymethoxybutyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 119

Synthesis of 1-(2,6-dichlorophenyl)-1-methoxymethoxybutyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.54˜7.57 (m, 3H)

Example 120

Synthesis of 1-(2,4-dichlorophenyl)-1-methoxymethoxy-3-methyl-butyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 121

Synthesis of 1-(2,6-dichlorophenyl)-1-methoxymethoxy-3-methyl-butyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.55˜7.57 (m, 3H)

Example 122

Synthesis of 1-(2,4-dichlorophenyl)-1-methoxymethoxyhexyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 123

Synthesis of 1-(2,4-dichlorophenyl)-1-methoxymethoxyhexyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.54˜7.59 (m, 3H)

Example 124

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxypropyl-(S)-2-carbamate

1-(2-chlorophenyl)-1-hydrorxyalkyl-2-alkylcarbamate (Preparation Example 103, 0.5 g), THF(Tetrahydrofuran), MeI(Methyliodide, 5 eq, 0.5 ml) and t-BuOH(Potassium tert-butoxide, 1.5 eq, 0.26 g) were put into a flask and stirred at the 0° C. When the reaction was completed, the obtained product was washed with 1M HCl solution and EA(Ethylacetate). The separated organic layer was dehydrated with anhydrous MgSO₄(Magnesium sulfate), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silicagel aolumn chromatography, to obtain title compound.

¹H NMR (400 MHz, CDCl₃) δ1.40 (d, J=6.0 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.4 Hz, 1H), 4.80˜4.85 (m, 1H), 7.01 (br s, 1H), 7.07˜7.20 (m, 4H)

According to the method described in Example 124, the following compounds of Examples 124 to 123246 were prepared:

Example 125

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxypropyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.40 (d, J=6.0 Hz, 3H), 2.74 (s, 3H), 3.24 (s, 3H), 4.71 (d, J=6.4 Hz, 1H), 4.80˜4.85 (m, 1H), 7.01 (br s, 1H), 7.07˜7.20 (m, 4H)

Example 126

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxypropyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=6.4 Hz, 3H), 1.40 (d, J=6.0 Hz, 3H), 1.55˜1.60 (m, 2H), 2.96 (t, J=6.0 Hz, 2H), 3.24 (s, 3H), 4.71 (d, J=6.0 Hz, 1H), 4.82˜4.88 (m, 1H), 6.76 (br s, 2H), 7.07˜7.21 (m, 4H)

Example 127

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxypropyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ, 1.15 (d, J=6.0 Hz, 3H), 1.35 (d, J=6.4 Hz, 3H), 1.50 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 3.75 (br s, 1H), 4.48 (br s, 1H), 4.50 (d, J=4.8 Hz, 1H), 5.09˜5.20 (m, 1H), 7.07˜7.20 (m, 4H)

Example 128

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxypropyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.30˜0.34 (m, 2H), 0.54˜0.58 (m, 2H), 1.30 (d, J=6.8 Hz, 3H), 2.55 (m, 1H), 3.24 (s, 3H), 4.55 (d, J=4.8 Hz, 1H), 4.90 (br m, 1H), 5.09˜5.15 (br s, 1H), 7.06˜7.21 (m, 4H)

Example 129

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.11˜1.21 (m, 4H), 1.37 (d, J=6.8 Hz, 3H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 3.30 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 130

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.40 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.19 (m, 4H), 7.32˜7.46 (m, 5H)

Example 131

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxypropyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.40 (d, J=6.4 Hz, 3H), 1.44˜1.50 (m, 7H), 1.70˜1.73 (m, 1H), 2.03˜2.07 (m, 1H), 3.24 (s, 3H), 3.50˜3.55 (m, 2H), 4.71 (d, J=6.4 Hz, 1H), 4.80˜4.87 (m, 1H), 7.07˜7.19 (m, 4H)

Example 132

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.22 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 133

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.26 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 134

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 135

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.68 (m, 4H)

Example 136

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxypropyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 2.58 (s, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.68 (m, 4H)

Example 137

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxypropyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.37 (d, J=6.8 Hz, 3H), 1.60 (m, 2H), 3.18 (t, J=7.1 Hz, 2H), 3.22 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.68 (m, 4H)

Example 138

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxypropyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ, 1.27 (d, J=6.8 Hz, 6H), 1.37 (d, J=6.8 Hz, 3H), 3.25 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.69 (m, 4H)

Example 139

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxypropyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.37 (d, J=6.8 Hz, 3H), 2.75 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.16˜7.70 (m, 4H)

Example 140

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.11˜1.21 (m, 4H), 1.37 (d, J=6.8 Hz, 3H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 3.26 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.66 (m, 4H)

Example 141

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.68 (m, 4H), 7.72˜7.88 (m, 5H)

Example 142

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxypropyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.33˜1.58 (m, 9H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.23 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.68 (m, 4H), 7.37˜7.88 (m, 5H)

Example 143

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.21 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.88 (m, 4H)

Example 144

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxypropyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 2.58 (s, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.898 (m, 4H)

Example 145

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxypropyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.37 (d, J=6.8 Hz, 3H), 1.60 (m, 2H), 3.18 (t, J=7.1 Hz, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.14˜7.87 (m, 4H)

Example 146

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxypropyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ, 1.27 (d, J=6.8 Hz, 6H), 1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.15˜7.89 (m, 4H)

Example 147

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxypropyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.37 (d, J=6.8 Hz, 3H), 2.75 (m, 1H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.16˜7.87 (m, 4H)

Example 148

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.11˜1.21 (m, 4H), 1.37 (d, J=6.8 Hz, 3H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 3.30 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.18˜7.91 (m, 4H)

Example 149

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxypropyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.68 (m, 4H), 7.72˜7.88 (m, 5H)

Example 150

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxypropyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.33˜1.58 (m, 9H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.22 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.68 (m, 4H), 7.37˜7.88 (m, 5H)

Example 151

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 152

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxybutyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.58 (s, 3H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.88 (m, 4H)

Example 153

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxybutyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.04 (t, J=7.6 Hz, 3H), 1.58˜1.71 (m, 4H), 3.18 (t, J=7.1 Hz, 2H), 3.22 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.14˜7.89 (m, 4H)

Example 154

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxybutyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.27 (d, J=6.8 Hz, 6H), 1.60˜1.71 (m, 2H), 3.23 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.90 (m, 4H)

Example 155

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxybutyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 2.75 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.16˜7.90 (m, 4H)

Example 156

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxybutyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.11˜1.21 (m, 4H), 1.47˜1.49 (m, 4H), 1.60˜1.71 (m, 2H), 1.74 (m, 2H), 3.23 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.14˜7.87 (m, 4H)

Example 157

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxybutyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.23 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.14˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 158

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxybutyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.33˜1.58 (m, 6H), 1.60˜1.71 (m, 2H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.24 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 159

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (d, J=7.6 Hz, 3H), 1.83˜1.89 (m, 1H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 160

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (d, J=7.6 Hz, 6H), 1.60˜1.71 (m, 1H), 2.58 (s, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.88 (m, 4H)

Example 161

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.04 (d, J=7.6 Hz, 6H), 1.58˜1.71 (m, 5H), 3.18 (t, J=7.1 Hz, 2H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.14˜7.89 (m, 4H)

Example 162

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 6H), 1.27 (d, J=6.8 Hz, 6H), 1.60˜1.71 (m, 1H), 3.24 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.90 (m, 4H)

Example 163

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.04 (d, J=7.6 Hz, 6H), 1.60˜1.71 (m, 1H), 2.75 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.16˜7.90 (m, 4H)

Example 164

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (d, J=7.6 Hz, 6H), 1.11˜1.21 (m, 4H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 1.84˜1.90 (m, 1H), 3.23 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.14˜7.87 (m, 4H)

Example 165

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (d, J=7.6 Hz, 6H), 1.87˜1.90 (m, 1H), 3.24 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.14˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 166

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (d, J=7.6 Hz, 6H), 1.33˜1.58 (m, 6H), 1.75˜1.88 (m, 2H), 1.88˜1.93 (m, 1H), 2.06˜2.13 (m, 2H), 3.22 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 167

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.23 (s, 3H), 4.47 (br s, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 168

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxyhexyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.89 (t, J=7.2 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 2.58 (s, 3H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.88 (m, 4H)

Example 169

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxyhexyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.87 (t, J=6.8 Hz, 3H), 0.90 (t, J=6.8 Hz, 3H), 1.21˜1.35 (m, 4H), 1.36˜1.40 (m, 1H), 1.58˜1.62 (m, 1H), 3.18 (t, J=7.1 Hz, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.14˜7.89 (m, 4H)

Example 170

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxyhexyl-(S)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.6 Hz, 3H), 1.22˜1.35 (m, 4H), 1.27 (d, J=6.8 Hz, 6H), 1.36˜1.40 (m, 1H), 1.58˜1.62 (m, 1H), 3.23 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.90 (m, 4H)

Example 171

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxyhexyl-(S)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 0.88 (t, J=7.6 Hz, 3H), 1.22˜1.35 (m, 4H), 1.36˜1.40 (m, 1H), 1.58˜1.62 (m, 1H), 2.75 (m, 1H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.16˜7.90 (m, 4H)

Example 172

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxyhexyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.98 (t, J=7.6 Hz, 3H), 1.11˜1.21 (m, 4H), 1.26˜1.33 (m, 4H), 1.47˜1.49 (m, 2H), 1.52˜1.54 (m, 2H), 1.74 (m, 2H), 1.84˜1.90 (m, 1H), 3.23 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.14˜7.87 (m, 4H)

Example 173

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxyhexyl-(S)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.94 (t, J=7.6 Hz, 3H), 1.26˜1.33 (m, 4H), 1.51˜1.55 (m, 2H), 3.23 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.14˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 174

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxyhexyl-(S)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ0.97 (t, J=7.0 Hz, 3H), 1.25˜1.32 (m, 4H), 1.33˜1.58 (m, 8H), 1.60˜1.71 (m, 2H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.24 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 175

Synthesis of 1-(3-iodophenyl)-(S)-1-methoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.16 (d, J=6.4 Hz, 3H), 3.24 (s, 3H), 4.54˜4.63 (m, 4H), 5.04˜5.10 (m, 1H), 7.09˜7.73 (m, 4H)

Example 176

Synthesis of 1-(3-iodophenyl)-(S)-1-methoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 6.96˜7.57 (m, 4H)

Example 177

Synthesis of 1-(3-iodophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.00˜7.58 (m, 4H)

Example 178

Synthesis of 1-(3-iodophenyl)-(S)-1-methoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.01˜7.59 (m, 4H)

Example 179

Synthesis of 1-(4-fluorophenyl)-(S)-1-methoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 6.96˜7.17 (m, 4H)

Example 180

Synthesis of 1-(4-fluorophenyl)-(S)-1-methoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 6.90˜7.20 (m, 4H)

Example 181

Synthesis of 1-(4-fluorophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 6.92˜7.17 (m, 4H)

Example 182

Synthesis of 1-(4-fluorophenyl)-(S)-1-methoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 6.96˜7.19 (m, 4H)

Example 183

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-methoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 184

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-methoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 185

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 186

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-methoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 187

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-methoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.57˜7.58 (m, 3H)

Example 188

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-methoxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.54˜7.57 (m, 3H)

Example 189

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-methoxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.55˜7.57 (m, 3H)

Example 190

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-methoxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.54˜7.59 (m, 3H)

Example 191

Synthesis of 1-(2,3-dichlorophenyl)-(S)-1-methoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.01˜7.14 (m, 3H)

Example 192

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 193

Synthesis of 1-(2-chlorophenyl)-1-methoxypropyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 194

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 195

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 196

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 197

Synthesis of 1-(2-chlorophenyl)-1-methoxybutyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 198

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 199

Synthesis of 1-(2-chlorophenyl)-1-methoxy-3-methyl-butyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 200

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 201

Synthesis of 1-(2-chlorophenyl)-1-methoxyhexyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 202

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 2.58 (s, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 203

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.37 (d, J=6.8 Hz, 3H), 1.60 (m, 2H), 3.18 (t, J=7.1 Hz, 2H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 204

Synthesis of 1-(2-chlorophenyl)-(R)-1-thoxypropyl-(R)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ, 1.27 (d, J=6.8 Hz, 6H), 1.37 (d, J=6.8 Hz, 3H), 3.23 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1HH), 7.26˜7.70 (m, 4H)

Example 205

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.37 (d, J=6.8 Hz, 3H), 2.75 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 206

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.11˜1.21 (m, 4H), 1.37 (d, J=6.8 Hz, 3H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 3.24 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 207

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 208

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.33˜1.58 (m, 9H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.22 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 209

Synthesis of 1-(2-fluorophenyl)-(R)-1-methoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.15˜7.68 (m, 4H)

Example 210

Synthesis of 1-(4-fluorophenyl)-(R)-1-methoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 6.96˜7.17 (m, 4H)

Example 211

Synthesis of 1-(4-fluorophenyl)-(R)-1-methoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 6.90˜7.20 (m, 4H)

Example 212

Synthesis of 1-(4-fluorophenyl)-(R)-1-methoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 6.92˜7.17 (m, 4H)

Example 213

Synthesis of 1-(4-fluorophenyl)-(R)-1-methoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 6.96˜7.19 (m, 4H)

Example 214

Synthesis of 1-(2-iodophenyl)-(R)-1-methoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.88 (m, 4H)

Example 215

Synthesis of 1-(2-iodophenyl)-(R)-1-methoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 216

Synthesis of 1-(2-iodophenyl)-(R)-1-methoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (d, J=7.6 Hz, 3H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 217

Synthesis of 1-(2-iodophenyl)-(R)-1-methoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.30 (s, 3H), 4.47 (br s, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 218

Synthesis of 1-(3-iodophenyl)-(R)-1-methoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.16 (d, J=6.4 Hz, 3H), 3.23 (s, 3H), 4.54˜4.63 (m, 4H), 5.04˜5.10 (m, 1H), 7.09˜7.73 (m, 4H)

Example 219

Synthesis of 1-(3-iodophenyl)-(R)-1-methoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 220

Synthesis of 1-(3-iodophenyl)-(R)-1-methoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (d, J=7.6 Hz, 3H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 221

Synthesis of 1-(3-iodophenyl)-(R)-1-methoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.84 (t, J=7.0 Hz, 3H), 1.20˜1.35 (m, 4H), 1.36˜1.41 (m, 1H), 1.59˜1.63 (m, 1H), 3.30 (s, 3H), 4.47 (br s, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 222

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 2.58 (s, 3H), 2.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 223

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=6.8 Hz, 3H), 1.37 (d, J=6.8 Hz, 3H), 1.60 (m, 2H), 3.18 (t, J=7.1 Hz, 2H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 224

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-isopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ, 1.27 (d, J=6.8 Hz, 6H), 1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.17 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 225

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-cyclopropylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.57 (m, 2H), 0.82 (m, 2H), 1.37 (d, J=6.8 Hz, 3H), 2.75 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 226

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.11˜1.21 (m, 4H), 1.37 (d, J=6.8 Hz, 3H), 1.47˜1.49 (m, 4H), 1.74 (m, 2H), 3.24 (s, 3H), 3.54 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 227

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-cyclohexylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.20 (m, 2H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 228

Synthesis of 1-(2-chlorophenyl)-(R)-1-methoxypropyl-(R)-2-bicyclo[2,2,1]heptanescarbamate

¹H NMR (400 MHz, CDCl₃) δ1.33˜1.58 (m, 9H), 1.75˜1.88 (m, 2H), 2.06˜2.13 (m, 2H), 3.24 (s, 3H), 3.53 (m, 1H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.19 (m, 4H), 7.37˜7.88 (m, 5H)

Example 229

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-methoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 230

Synthesis of 1-(2,6-dichlorophenyl)-(R)-1-methoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.57˜7.58 (m, 3H)

Example 231

Synthesis of 1-(2,3-dichlorophenyl)-(R)-1-methoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.01˜7.14 (m, 3H)

Example 232

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-methoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 233

Synthesis of 1-(2,6-dichlorophenyl)-(R)-1-methoxybutyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.54˜7.57 (m, 3H)

Example 234

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-methoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 235

Synthesis of 1-(2,6-dichlorophenyl)-(R)-1-methoxy-3-methyl-butyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.55˜7.57 (m, 3H)

Example 236

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-methoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 237

Synthesis of 1-(2,4-dichlorophenyl)-(R)-1-methoxyhexyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.54˜7.59 (m, 3H)

Example 238

Synthesis of 1-(2,4-dichlorophenyl)-1-methoxypropyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 239

Synthesis of 1-(2,6-dichlorophenyl)-1-methoxypropyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.57˜7.58 (m, 3H)

Example 240

Synthesis of 1-(2,3-dichlorophenyl)-1-methoxypropyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.01˜7.14 (m, 3H)

Example 241

Synthesis of 1-(2,4-dichlorophenyl)-1-methoxybutyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.23 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 242

Synthesis of 1-(2,6-dichlorophenyl)-1-methoxybutyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.54˜7.57 (m, 3H)

Example 243

Synthesis of 1-(2,4-dichlorophenyl)-1-methoxy-3-methyl-butyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 244

Synthesis of 1-(2,6-dichlorophenyl)-1-methoxy-3-methyl-butyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.55˜7.57 (m, 3H)

Example 245

Synthesis of 1-(2,4-dichlorophenyl)-1-methoxyhexyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.24˜7.30 (m, 2H), 7.73 (d, J=1.5 Hz, 1H)

Example 246

Synthesis of 1-(2,4-dichlorophenyl)-1-methoxyhexyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 3.24 (s, 3H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 4.82˜4.88 (m, 1H), 7.54˜7.59 (m, 3H)

Example 247

Synthesis of 1-(2-chlorophenyl)-(S)-1-carbamoyloxypropyl-(S)-2-carbamate

1-(2-chlorophenyl)-1-hydroxypropyl-1-carbamate (Preparation Example 103, 8 g), tetrahydrofuran (THF), and carbonyldiimidazole (CDI, 1.5 eq, 9.1 g) were put into a flask and stirred at the room temperature. After approximately 3 hours, ammonia solution (NH₄OH, 3 eq, 4.4 ml) was added thereto. When the reaction was completed, the obtained product was washed with 1M HCl solution and ethylacetate (EA). The separated organic layer was dehydrated with anhydrous MgSO₄(Magnesium sulfate), filtrated, and concented under reduced pressure. The concentrated residue was purified by a silica gel column chromatography, to obtain the title compound.

¹H NMR (400 MHz, DMSO-d₆) δ1.12 (d, J=6.4 Hz, 3H), 4.97˜5.03 (m, 1H), 5.91 (d, J=5.2 Hz, 1H), 6.31˜6.92 (m, 4H), 7.30˜7.42 (m, 4H)

According to the method described in Example 247, the following compounds of Examples 248 to 256 were prepared:

Example 248

Synthesis of 1-(2-chlorophenyl)-(S)-1-carbamoyloxypropyl-(S)-2-methylcarbamate

¹H NMR (400 MHz, CDCl₃) δ1.40 (d, J=6.0 Hz, 3H), 2.74 (s, 3H), 4.71 (d, J=6.4 Hz, 1H), 4.80˜4.85 (m, 1H), 6.30˜6.90 (br s, 3H), 7.28˜7.43 (m, 4H)

Example 249

Synthesis of 1-(2-chlorophenyl)-(S)-1-carbamoyloxypropyl-(S)-2-propylcarbamate

¹H NMR (400 MHz, CDCl₃) δ0.96 (t, J=6.4 Hz, 3H), 1.40 (d, J=6.0 Hz, 3H), 1.55˜1.60 (m, 2H), 2.96 (t, J=6.0 Hz, 2H), 4.71 (d, J=6.0 Hz, 1H), 4.82˜4.88 (m, 1H), 6.76 (br s, 3H), 7.07˜7.21 (m, 4H)

Example 250

Synthesis of 1-(2-chlorophenyl)-(R)-2-carbamoyloxypropyl-(R)-1-carbamate(2)

¹H NMR (400 MHz, DMSO-d₆) δ1.12 (d, J=6.4 Hz, 3H), 4.97˜5.04 (m, 1H), 5.92 (d, J=5.2 Hz, 1H), 6.25˜6.83 (m, 4H), 7.30˜7.44 (m, 4H)

Example 251

Synthesis of 1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-carbamate(3)

¹H NMR (400 MHz, DMSO-d₆) δ1.12 (d, J=6.4 Hz, 3H), 4.97˜5.03 (m, 1H), 5.91 (d, J=5.2 Hz, 1H), 6.31˜6.92 (m, 4H), 7.30˜7.42 (m, 4H)

Example 252

Synthesis of 1-(2-chlorophenyl)-(S)-1-carbamoyloxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.04 (t, J=7.6 Hz, 3H), 1.60˜1.71 (m, 2H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 5.82˜5.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 253

Synthesis of 1-(2-chlorophenyl)-(S)-1-carbamoyloxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 5.80˜5.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 254

Synthesis of 1-(2-chlorophenyl)-(S)-1-carbamoyloxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 4.71 (d, J=6.8, 1H), 4.73 (br s, 2H), 5.82˜5.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 255

Synthesis of 1-(2-fluorophenyl)-(S)-1-carbamoyloxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, DMSO-d₆) δ1.37 (d, J=6.8 Hz, 3H), 4.71 (d, J=6.8, 1H), 5.82˜5.88 (m, 1H), 7.15˜7.68 (m, 4H)

Example 256

Synthesis of 1-(2-fluorophenyl)-(S)-1-carbamoyloxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.02 (t, J=7.2 Hz, 3H), 1.60˜1.71 (m, 2H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.82˜5.88 (m, 1H), 6.09˜7.17 (m, 4H)

Example 257

Synthesis of 1-(2-fluorophenyl)-(S)-1-carbamoyloxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.80˜5.88 (m, 1H), 6.10˜7.20 (m, 4H)

Example 258

Synthesis of 1-(2-fluorophenyl)-(S)-1-carbamoyloxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.82˜5.88 (m, 1H), 7.16˜7.69 (m, 4H)

Example 259

Synthesis of 1-(2-iodophenyl)-(S)-1-carbamoyloxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, DMSO-d₆) δ1.37 (d, J=6.8 Hz, 3H), 4.71 (d, J=6.8 Hz, 1H), 4.82˜4.88 (m, 1H), 7.13˜7.88 (m, 4H)

Example 260

Synthesis of 1-(2-iodophenyl)-(S)-1-carbamoyloxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.02 (t, J=7.2 Hz, 3H), 1.60˜1.71 (m, 2H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.82˜5.88 (m, 1H), 6.96˜7.57 (m, 4H)

Example 261

Synthesis of 1-(2-iodophenyl)-(S)-1-carbamoyloxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.80˜5.88 (m, 1H), 6.98˜7.61 (m, 4H)

Example 262

Synthesis of 1-(2-iodophenyl)-(S)-1-carbamoyloxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.82˜5.88 (m, 1H), 6.95˜7.61 (m, 4H)

Example 263

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-carbamoyloxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, DMSO-d₆) δ1.37 (d, J=6.8 Hz, 3H), 4.71 (d, J=6.8 Hz, 1H), 4.82˜4.88 (m, 1H), 7.07˜7.21 (m, 3H)

Example 264

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-carbamoyloxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.02 (t, J=7.2 Hz, 3H), 1.60˜1.71 (m, 2H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.82˜5.88 (m, 1H), 7.05˜7.19 (m, 3H)

Example 265

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-carbamoyloxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.80˜5.88 (m, 1H), 7.02˜7.17 (m, 3H)

Example 266

Synthesis of 1-(2,4-dichlorophenyl)-(S)-1-carbamoyloxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.82˜5.88 (m, 1H), 7.08˜7.22 (m, 3H)

Example 267

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-carbamoyloxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, DMSO-d₆) δ1.37 (d, J=6.8 Hz, 3H), 4.71 (d, J=6.8 Hz, 1H), 4.82˜4.88 (m, 1H), 7.07˜7.11 (m, 3H)

Example 268

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-carbamoyloxybutyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.02 (t, J=7.2 Hz, 3H), 1.60˜1.71 (m, 2H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.82˜5.88 (m, 1H), 7.05˜7.10 (m, 3H)

Example 269

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-carbamoyloxy-3-methyl-butyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.07 (t, J=7.6 Hz, 6H), 1.83˜1.89 (m, 1H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.80˜5.88 (m, 1H), 7.02˜7.08 (m, 3H)

Example 270

Synthesis of 1-(2,6-dichlorophenyl)-(S)-1-carbamoyloxyhexyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ0.90 (t, J=7.6 Hz, 3H), 1.35˜1.65 (m, 6H), 4.71 (d, J=6.8 Hz, 1H), 4.73 (br s, 2H), 5.82˜5.88 (m, 1H), 7.05˜7.12 (m, 3H)

Example 271

Synthesis of 1-(2,6-difluorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 6.67˜7.15 (m, 3H)

Example 272

Synthesis of 1-(2,5-dichlorophenyl)-(S)-1-methoxymethoxypropyl-(S)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.26 (m, 3H)

Example 273

Synthesis of 1-(2,5-dichlorophenyl)-(R)-1-methoxymethoxypropyl-(R)-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.37 (d, J=6.8 Hz, 3H), 3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.13˜7.26 (m, 3H)

Example 274

Synthesis of 1-(2-chlorophenyl)-(S)-2-methoxymethoxypropyl-(S)-1-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.21 (d, J=6.8 Hz, 3H), 3.24 (s, 3H), 3.94˜4.05 (m, 1H), 5.45 (s, 2H), 5.56 (d, J=6.8 Hz, 1H), 7.07˜7.20 (m, 4H)

Example 275

Synthesis of 1-(2-chlorophenyl)-(S)-2-methoxypropyl-(S)-1-carbamate

¹H NMR (400 MHz, CDCl₃) δ1.23 (d, J=6.4 Hz, 3H), 3.22 (s, 3H), 3.99 (m, 1H), 5.52 (d, J=6.4 Hz, 1H), 7.07˜7.21 (m, 4H)

Example 276

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxymethoxyethyl-2-carbamate

¹H NMR (400 MHz, DMSO-d₆) δ3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 277

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxymethoxyethyl-2-carbamate

¹H NMR (400 MHz, CDCl₃) δ3.30 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 5.45 (s, 2H), 7.26˜7.70 (m, 4H)

Example 278

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxymethoxyethyl-2-carbamate

¹H NMR (400 MHz, DMSO-d₆) δ3.26 (s, 3H), 3.94˜4.09 (m, 1H), 4.47 (d, J=6.8 Hz, 1H), 4.60 (d, J=6.8 Hz, 1H), 4.97 (m, 1H), 6.55 (br 2H), 7.07˜7.87 (m, 4H)

Example 279

Synthesis of 1-(2-chlorophenyl)-(S)-1-methoxyethyl-2-carbamate

¹H NMR (400 MHz, DMSO-d₆) δ3.27 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 6.47˜6.63 (br 2H), 7.26˜7.70 (m, 4H)

Example 280

Synthesis of 1-(2-fluorophenyl)-(S)-1-methoxyethyl-2-carbamate

¹H NMR (400 MHz, DMSO-d₆) δ3.29 (s, 3H), 4.71 (d, J=6.8, 1H), 4.82˜4.88 (m, 1H), 7.26˜7.70 (m, 4H)

Example 281

Synthesis of 1-(2-iodophenyl)-(S)-1-methoxethyl-2-carbamate

¹H NMR (400 MHz, DMSO-d₆) δ3.28 (s, 3H), 3.94˜4.09 (m, 1H), 4.97 (m, 1H), 7.07˜7.87 (m, 4H)

[Animal Testing Examples]

For testing, male mice (ICR) were purchased from ORIENT BIO INC. (Korea), divided into several groups with 6 mice in each group, and were adapted for 4-5 days. The mice having the weight ranging from 19 g to 26 g were employed for the test. The pharmacological effect of the test compounds on muscle relaxation was evaluated by Rotarod test, grip strength test, and muscular force (wire hang) test. All mice were adapted to the test environment at one hour before starting the tests. The pharmacological effects of all the test compounds were evaluated by administration through peritoneal cavity of the mice (10 ul/g, bw).

Experimental Example 1

Measurement of Muscle Relaxation Activity by Residence Time on a Rotarod Rotating at a Fixed Speed

All the mice to be tested were preliminarily trained for 5 minutes on a rod rotating at the rate of 15 revolutions per a minute. The mice that could not remain on the rod without falling off therefrom for a minimum of 2 minutes were excluded from this testing. After the training, all the mice were allowed to rest for 45-60 minutes. Before the administration of the test compounds, the mice were subjected to a further training for one minute on the rod rotating under the same condition, where the mice falling off from the rod were excluded from this experimentation. All the test compounds were intraperitoneally administered (10 ul/g, bw) to the mice at 15 minutes, 30 minutes, 1 hour, and 2 hours prior to the testing, and the median effective concentration (ED50) was determined at the time (generally 15 min, 30 min or 60 min) that the compounds exhibit their maximum pharmacological effect. In case a mouse stays on the rod until the test is finished, the time was recorded as 10 minutes. As test time for evaluation, a maximum of 10 minutes was applied. The obtained results were shown in following Table 2. This experimentation was conducted according to the method described in the reference, ‘Yasuda et al. (2005) Antipyretic, analgesic and muscle relaxant activities of Pueraria isoflavonoids and their metabolites from Pueraria lobata Ohwi—a traditional Chinese drug. Biol. Pharm. Bull. 28: 1224-1228’.

Experimental Example 2

Measurement of Muscle Relaxation Activity by Grip Strength

A grip strength test using the test animals' forelimbs was performed using an instrument equipped with triangle ring and designed so as to easily grip with the forelimbs of experimental animals, manufactured from Ugo Basile Inc. (Ugo Basile, Model 47106, Italy). The test was conducted before and after administration of the compounds to evaluate the effects thereof. All the test compounds were intraperitoneally administered (10 ul/g, bw) at 15 minutes, 30 minutes, 1 hour, and 2 hours before test, and the median effective concentration (ED50) was determined at the time (generally 15 min, 30 min or 60 min) that the compounds exhibits their maximum pharmacological effect. The mouse was made to grip the rod with its forelimbs, and its tail was pulled, where the force at which the mouse detached from the rod was recorded. The instrument indicated the force in grams. All of the mice were given 3 opportunities for test, and the 3 highest values among the test opportunities were selected and the mean value was used as the test result. The obtained results are shown in Table 2. This experimentation was conducted according to the method described in the reference, ‘Nevins et al. (1993) Quantitative grip strength assessment as a means of evaluating muscle relaxation in mice. Psychopharmacol. 110: 92-96’.

Experimental Example 3

Measurement of Muscle Relaxation Activity by Wire Hang

This experimentation was conducted using a metal wire of 30 cm in length, which was suspended between two pillars at a height of about 40 cm from the bottom covered with a soft pad. All the test compounds were administered to the mice through peritoneal cavity (10 ul/g, bw) at 15 minutes, 30 minutes, 1 hour, and 2 hours prior to the testing, and the median effective concentration (ED50) was determined at the time that the compound exhibits the maximum pharmacological effect. Each mouse was made to grip the wire using two forelimbs, and the elapse time before the mouse fell off from the wire to the pad on the bottom was recorded in seconds. Each mouse was given 5 opportunities for this test at an interval of 2 minutes period. The highest 3 records among the test opportunities were selected and the mean value was used as the test result. The obtained results are shown in Table 2. This experimentation was conducted according to the method described in the reference, ‘Jacqueline N. Crawley (1999) Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. 835: 18-26’.

[Results]

The results of muscle relaxation activity of the phenyl alkyl carbamate derivative compounds measured in above Experimental Examples 1 to 3 are shown in following Table 3. In the Table 3, the ED50 was represented by the concentration where the compound shows the 50% of muscle relaxation activity compared to the vehicle only (100%).

TABLE 3
Results of the measurements of muscle relaxation activity of
the phenyl alkyl carbamate derivatives
		MR test (ED50; mg/kg, bw)
	No.	I	II	III
	1	55.0	115.2	37.0
	12		a 50(82.2/0.5 hr)
	28		a 50(84.4/1 hr)
	64		a 50(93.3/0.5 hr)
	91	30.1	a 50(92.6/0.5 hr)	24.4
	95		a 50(79.1/0.5 hr)
	107		a 50(75.2/1 hr)
	124	35.9	66.4	34.8
	135	60.0	145.6	26.2
	143	13.0	61.0	33.5
	146		a 50(24.5/0.5 hr)
	147		a 50(77.2/0.5 hr)
	151		a 50(82.8/0.5 hr)
	159		a 50(81.1/0.5 hr)
	247		264.3
	250		225.6
	257		a 50(86.2/0.5 hr)
	258		a 50(79.3/0.5 hr)
	261		a 50(84.9/0.5 hr)
	278		a 50(68.0/0.5 hr)
I = Fixed 15 r.p.m. Rotarod (constantly rotating ratarod test; Experimental Example 1),
II = Grip strength (Experimental Example 2),
III = Wire hang (Experimental Example 3)
a = the concentration administered and effect (%, peak time (hr)) compared to that of control treated with vehicle only
Control: administered with vehicle only (Vehicle: 20% Tween 80)

Claims

1. A compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof:

2. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein X is chlorine, fluorine, iodine, or bromine,n is 1 or 2,R1 is hydrogen, methyl group, ethyl group, isopropyl group, or butyl group,A is selected from the group consisting of hydrogen, a methyl group, a methoxy methyl group, and a carbamoyl derivative represented by

3. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is in the form of racemate, enantiomer, diastereomer, a mixture of enantiomer, or a mixture of diastereomer.

4. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is selected from the group consisting of: 1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-N-methylcarbamate,1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-N-propylcarbamate1-(2-chlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-chlorophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(3-iodophenyl)-1-(methoxy)-propyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-fluorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-proyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-chlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2,3-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-chlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,3-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,5-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-fluorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,6-difluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(3-iodophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-2-(methoxymethoxy)-propyl-1-carbamate, and1-(2-chlorophenyl)-2-(methoxy)-propyl-1-carbamate, orin the form of racemate, enantiomer, diastereomer, a mixture of enantiomer, or a mixture of diastereomer of the compound.

5. A pharmaceutical composition for muscle relaxation or treating or preventing a muscle spasm associated disease, containing the compound represented by the following Chemical Formula 1, a pharmaceutically acceptable salt thereof, a racemate thereof, an enantiomer thereof, a diastereomer thereof, a mixture of enantiomer thereof, or a mixture of diastereomer thereof, as an active ingredient:

6. The pharmaceutical composition according to claim 5, wherein X is chlorine, fluorine, iodine, or bromine,n is 1 or 2,R1 is hydrogen, methyl group, ethyl group, isopropyl group, or butyl group,A is selected from the group consisting of hydrogen, a methyl group, a methoxy methyl group, and a carbamoyl derivative represented by

7. The pharmaceutical composition according to claim 5, wherein the compound is selected from the group consisting of: 1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-N-methylcarbamate,1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-N-propylcarbamate1-(2-chlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-chlorophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(3-iodophenyl)-1-(methoxy)-propyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-fluorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-proyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-chlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2,3-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-chlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,3-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,5-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-fluorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,6-difluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-prop ylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(3-iodophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-2-(methoxymethoxy)-propyl-1-carbamate, and1-(2-chlorophenyl)-2-(methoxy)-propyl-1-carbamate.

8. The pharmaceutical composition according to claim 5, wherein the muscle spasm associated disease is selected from the group consisting of vascular disorders of the spinal cord, spastic spinal paralysis, cervical spondylosis, cerebral palsy, sequelae of injuries, and spinocerebellar degeneration.

9. A method of muscle relaxation comprising administering a therapeutically effective amount of the compound represented by the following Chemical Formula 1, a pharmaceutically acceptable salt thereof, a racemate thereof, an enantiomer thereof, a diastereomer thereof, a mixture of enantiomer thereof, or a mixture of diastereomer thereof, to a subject in need of muscle relaxation or treating or preventing a muscle spasm associated disease:

10. The method according to claim 9, wherein X is chlorine, fluorine, iodine, or bromine,n is 1 or 2,R1 is hydrogen, methyl group, ethyl group, isopropyl group, or butyl group,A is selected from the group consisting of hydrogen, a methyl group, a methoxy methyl group, and a carbamoyl derivative represented by

11. The method according to claim 9, wherein the compound is selected from the group consisting of: 1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-N-methylcarbamate,1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-N-propylcarbamate1-(2-chlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-chlorophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(3-iodophenyl)-1-(methoxy)-propyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-fluorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-proyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-chlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2,3-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-chlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,3-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,5-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-fluorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,6-difluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-prop ylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(3-iodophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-2-(methoxymethoxy)-propyl-1-carbamate, and1-(2-chlorophenyl)-2-(methoxy)-propyl-1-carbamate.

12. A method of treating or preventing a muscle spasm associated disease, comprising administering a therapeutically effective amount of the compound represented by the following Chemical Formula 1, a pharmaceutically acceptable salt thereof, a racemate thereof, an enantiomer thereof, a diastereomer thereof, a mixture of enantiomer thereof, or a mixture of diastereomer thereof, to a subject in need of muscle relaxation or treating or preventing a muscle spasm associated disease:

13. The method according to claim 12, wherein X is chlorine, fluorine, iodine, or bromine,n is 1 or 2,R1 is hydrogen, methyl group, ethyl group, isopropyl group, or butyl group,A is selected from the group consisting of hydrogen, a methyl group, a methoxy methyl group, and a carbamoyl derivative represented by

14. The method according to claim 12, wherein the compound is selected from the group consisting of: 1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-N-methylcarbamate,1-(2-chlorophenyl)-2-carbamoyloxypropyl-1-N-propylcarbamate1-(2-chlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-chlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-iodophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2-fluorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2,4-dichlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxypropyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxybutyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxy-3-methyl-butyl-1-carbamate,1-(2,6-dichlorophenyl)-2-carbamoyloxyhexyl-1-carbamate,1-(2-chlorophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxy)-hexyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(3-iodophenyl)-1-(methoxy)-propyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-fluorophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-fluorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-proyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-methylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-propylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-isopropylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-benzylcarbamate,1-(2-chlorophenyl)-1-(methoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-chlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2,3-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-3-methyl-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-ethyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-chlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-chlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,3-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2,4-dichlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,5-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2,6-dichlorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-fluorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-fluorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(4-fluorophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2,6-difluorophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-propyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-butyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-prop ylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-N-bicyclo[2,2,1]heptanecarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-methylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-propylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-isopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-cyclopropylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-cyclohexylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-benzylcarbamate,1-(2-iodophenyl)-1-(methoxymethoxy)-hexyl-2-N-bicyclo[2,2,1]heptanecarbamate1-(3-iodophenyl)-1-(methoxymethoxy)-propyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-3-methyl-butyl-2-carbamate,1-(3-iodophenyl)-1-(methoxymethoxy)-hexyl-2-carbamate,1-(2-chlorophenyl)-2-(methoxymethoxy)-propyl-1-carbamate, and1-(2-chlorophenyl)-2-(methoxy)-propyl-1-carbamate.

15. The method according to claim 12, wherein the muscle spasm associated disease is selected from the group consisting of vascular disorders of the spinal cord, spastic spinal paralysis, cervical spondylosis, cerebral palsy, sequelae of injuries, and spinocerebellar degeneration.